OID|Version|Source|Type|Definition|MUType|MeasureTitle|QDM|NQF|CMSId
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Intervention|0142|CMS100v3|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Intervention|0435|CMS104v3|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Intervention||CMS109v3|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Intervention|0639|CMS30v4|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Stroke Education|Intervention||CMS107v3|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Discharged on Statin Medication|Intervention|0439|CMS105v3|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Intervention|0436|CMS71v4|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Intervention|0372|CMS190v3|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Assessed for Rehabilitation|Intervention|0441|CMS102v3|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Intervention|0438|CMS72v3|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Intervention|0371|CMS108v3|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Intervention||CMS114v3|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Intervention|0147|CMS188v4|
1.3.6.1.4.1.33895.1.3.0.45|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Intervention|0373|CMS73v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Individual Characteristic|0435|CMS104v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Individual Characteristic||CMS110v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Discharged on Statin Medication|Individual Characteristic|0439|CMS105v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Thrombolytic Therapy|Individual Characteristic|0437|CMS91v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Individual Characteristic|0163|CMS53v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Individual Characteristic|0147|CMS188v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Individual Characteristic|0453|CMS178v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Individual Characteristic||CMS114v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Individual Characteristic|0372|CMS190v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Admitted ED Patients|Individual Characteristic|0495|CMS55v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Stroke Education|Individual Characteristic||CMS107v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver|Individual Characteristic||CMS26v2|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Individual Characteristic||CMS109v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Healthy Term Newborn|Individual Characteristic|0716|CMS185v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Elective Delivery|Individual Characteristic|0469|CMS113v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Assessed for Rehabilitation|Individual Characteristic|0441|CMS102v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Median Admit Decision Time to ED Departure Time for Admitted Patients|Individual Characteristic|0497|CMS111v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Individual Characteristic|0527|CMS171v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Hearing Screening Prior To Hospital Discharge|Individual Characteristic|1354|CMS31v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Individual Characteristic|0164|CMS60v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Dementia: Cognitive Assessment|Individual Characteristic|Not Applicable|CMS149v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Individual Characteristic|0712|CMS160v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Controlling High Blood Pressure|Individual Characteristic|0018|CMS165v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Individual Characteristic|Not Applicable|CMS22v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|Individual Characteristic|0405|CMS52v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|HIV/AIDS: RNA Control for Patients with HIV|Individual Characteristic|Not Applicable|CMS77v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Functional Status Assessment for Complex Chronic Conditions|Individual Characteristic|Not Applicable|CMS90v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Childhood Immunization Status|Individual Characteristic|0038|CMS117v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Individual Characteristic|0389|CMS129v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Colorectal Cancer Screening|Individual Characteristic|0034|CMS130v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Individual Characteristic|0564|CMS132v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Individual Characteristic|0086|CMS143v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Individual Characteristic|0024|CMS155v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Chlamydia Screening for Women|Individual Characteristic|0033|CMS153v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Individual Characteristic|0387|CMS140v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Individual Characteristic|0070|CMS145v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Individual Characteristic|0104|CMS161v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Individual Characteristic|1365|CMS177v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Individual Characteristic|0075|CMS182v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Hypertension: Improvement in Blood Pressure|Individual Characteristic|Not Applicable|CMS65v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Individual Characteristic|0064|CMS163v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Individual Characteristic|0088|CMS167v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Individual Characteristic|0418|CMS2v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Individual Characteristic|Not Applicable|CMS61v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Functional Status Assessment for Knee Replacement|Individual Characteristic|Not Applicable|CMS66v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Maternal Depression Screening|Individual Characteristic|1401|CMS82v2|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Documentation of Current Medications in the Medical Record|Individual Characteristic|0419|CMS68v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Individual Characteristic|0421|CMS69v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Individual Characteristic|0059|CMS122v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Breast Cancer Screening|Individual Characteristic|Not Applicable|CMS125v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Cervical Cancer Screening|Individual Characteristic|0032|CMS124v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Individual Characteristic|0043|CMS127v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Anti-depressant Medication Management|Individual Characteristic|0105|CMS128v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Use of High-Risk Medications in the Elderly|Individual Characteristic|0022|CMS156v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Use of Imaging Studies for Low Back Pain|Individual Characteristic|0052|CMS166v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Diabetes: Urine Protein Screening|Individual Characteristic|0062|CMS134v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Individual Characteristic|0004|CMS137v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Individual Characteristic|0565|CMS133v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Individual Characteristic|0081|CMS135v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Falls: Screening for Future Fall Risk|Individual Characteristic|0101|CMS139v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Individual Characteristic|0385|CMS141v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Individual Characteristic|0041|CMS147v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Appropriate Testing for Children with Pharyngitis|Individual Characteristic|0002|CMS146v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Pregnant women that had HBsAg testing|Individual Characteristic|Not Applicable|CMS158v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Individual Characteristic|0028|CMS138v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Oncology: Medical and Radiation – Pain Intensity Quantified|Individual Characteristic|0384|CMS157v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Individual Characteristic|0068|CMS164v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Individual Characteristic|0110|CMS169v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Individual Characteristic|0069|CMS154v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Depression Remission at Twelve Months|Individual Characteristic|0710|CMS159v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range|Individual Characteristic|NA|CMS179v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Functional Status Assessment for Hip Replacement|Individual Characteristic|Not Applicable|CMS56v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|HIV/AIDS: Medical Visit|Individual Characteristic|Not Applicable|CMS62v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Individual Characteristic|Not Applicable|CMS64v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Children Who Have Dental Decay or Cavities|Individual Characteristic|Not Applicable|CMS75v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Closing the Referral Loop: Receipt of Specialist Report|Individual Characteristic|Not Applicable|CMS50v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Individual Characteristic|Not Applicable|CMS74v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Diabetes: Foot Exam|Individual Characteristic|0056|CMS123v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Use of Appropriate Medications for Asthma|Individual Characteristic|0036|CMS126v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Diabetes: Eye Exam|Individual Characteristic|0055|CMS131v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Individual Characteristic|0108|CMS136v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Individual Characteristic|0089|CMS142v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Hemoglobin A1c Test for Pediatric Patients|Individual Characteristic|0060|CMS148v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Individual Characteristic|0083|CMS144v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Discharged ED Patients|Individual Characteristic|0496|CMS32v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Individual Characteristic|0142|CMS100v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Individual Characteristic|0528|CMS172v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Individual Characteristic|0639|CMS30v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Individual Characteristic|0436|CMS71v4|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Individual Characteristic|0371|CMS108v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Individual Characteristic|0373|CMS73v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Individual Characteristic|0438|CMS72v3|
2.16.840.1.113762.1.4.1|20140701|National Library of Medicine|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Individual Characteristic|0480|CMS9v3|
2.16.840.1.113762.1.4.1021.10|20140401|MD Partners|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Medication|0371|CMS108v3|
2.16.840.1.113762.1.4.1021.10|20140401|MD Partners|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Medication|0372|CMS190v3|
2.16.840.1.113762.1.4.1021.11|20140401|MD Partners|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Medication|0371|CMS108v3|
2.16.840.1.113762.1.4.1021.11|20140401|MD Partners|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Medication|0372|CMS190v3|
2.16.840.1.113762.1.4.1021.12|20140401|MD Partners|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Medication|0371|CMS108v3|
2.16.840.1.113762.1.4.1021.12|20140401|MD Partners|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Medication|0372|CMS190v3|
2.16.840.1.113762.1.4.1021.13|20140401|MD Partners|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Medication|0371|CMS108v3|
2.16.840.1.113762.1.4.1021.13|20140401|MD Partners|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Medication|0372|CMS190v3|
2.16.840.1.113762.1.4.1021.3|20140401|MD Partners|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Medication|0142|CMS100v3|
2.16.840.1.113762.1.4.1021.4|20140401|MD Partners|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Medication|0373|CMS73v3|
2.16.840.1.113762.1.4.1021.6|20140401|MD Partners|Extensional||FY 2014 EH|Thrombolytic Therapy|Medication|0437|CMS91v4|
2.16.840.1.113762.1.4.1021.7|20140401|MD Partners|Extensional||FY 2014 EH|Discharged on Statin Medication|Medication|0439|CMS105v3|
2.16.840.1.113762.1.4.1021.7|20140401|MD Partners|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Medication|0639|CMS30v4|
2.16.840.1.113762.1.4.1021.8|20140401|MD Partners|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Medication|0435|CMS104v3|
2.16.840.1.113762.1.4.1021.8|20140401|MD Partners|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Medication|0438|CMS72v3|
2.16.840.1.113762.1.4.1021.9|20140401|MD Partners|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Medication|0436|CMS71v4|
2.16.840.1.113762.1.4.1045.14|20140401|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Physical Exam|0437|CMS91v4|
2.16.840.1.113762.1.4.1045.15|20140401|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Procedure|0437|CMS91v4|
2.16.840.1.113762.1.4.1045.18|20140401|Joint Commission|Extensional||FY 2014 EH|Assessed for Rehabilitation|Procedure|0441|CMS102v3|
2.16.840.1.113762.1.4.1045.19|20140401|Joint Commission|Extensional||FY 2014 EH|Assessed for Rehabilitation|Procedure|0441|CMS102v3|
2.16.840.1.113762.1.4.1045.21|20140401|Joint Commission|Grouping|(2.16.840.1.113762.1.4.1045.16:Intra-arterial Thrombolytic (t-PA) Therapy),(2.16.840.1.113762.1.4.1045.15:Intravenous Thrombolytic (t-PA) Therapy)|FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Procedure|0438|CMS72v3|
2.16.840.1.113762.1.4.1045.24|20140401|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Laboratory Test|0437|CMS91v4|
2.16.840.1.113762.1.4.1045.25|20140401|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Laboratory Test|0437|CMS91v4|
2.16.840.1.113762.1.4.1045.26|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Physical Exam|0469|CMS113v3|
2.16.840.1.113762.1.4.1045.27|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Condition/Diagnosis/Problem|0469|CMS113v3|
2.16.840.1.113762.1.4.1045.28|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Physical Exam|0469|CMS113v3|
2.16.840.1.113762.1.4.1045.29|20140401|Joint Commission|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Communication|0480|CMS9v3|
2.16.840.1.113762.1.4.1045.3|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113762.1.4.1045.31|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Medication|0142|CMS100v3|
2.16.840.1.113762.1.4.1045.32|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Attribute|0453|CMS178v4|
2.16.840.1.113762.1.4.1045.36|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113762.1.4.1045.34:NSTEMI),(2.16.840.1.113762.1.4.1045.33:NSTEMI),(2.16.840.1.113762.1.4.1045.35:NSTEMI)|FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Attribute|0163|CMS53v3|
2.16.840.1.113762.1.4.1045.36|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113762.1.4.1045.34:NSTEMI),(2.16.840.1.113762.1.4.1045.33:NSTEMI),(2.16.840.1.113762.1.4.1045.35:NSTEMI)|FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Attribute|0164|CMS60v3|
2.16.840.1.113762.1.4.1045.39|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Medication||CMS114v3|
2.16.840.1.113762.1.4.1045.39|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Medication|0372|CMS190v3|
2.16.840.1.113762.1.4.1045.39|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Medication|0371|CMS108v3|
2.16.840.1.113762.1.4.1045.41|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Medication|0371|CMS108v3|
2.16.840.1.113762.1.4.1045.41|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Medication|0372|CMS190v3|
2.16.840.1.113762.1.4.1045.45|20140401|Joint Commission|Grouping|(2.16.840.1.113762.1.4.1045.43:Thrombocytopenia),(2.16.840.1.113762.1.4.1045.42:Thrombocytopenia),(2.16.840.1.113762.1.4.1045.44:Thrombocytopenia)|FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Condition/Diagnosis/Problem|0373|CMS73v3|
2.16.840.1.113762.1.4.1045.47|20140401|Joint Commission|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Physical Exam|0480|CMS9v3|
2.16.840.1.113762.1.4.1045.5|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113762.1.4.1045.52|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113762.1.4.1045.50:Laparoscopic Procedures),(2.16.840.1.113762.1.4.1045.51:Laparoscopic Procedures),(2.16.840.1.113762.1.4.1045.4:Laparoscopic Procedures)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113762.1.4.1045.55|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Medication|0469|CMS113v3|
2.16.840.1.113762.1.4.1045.56|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Medication|0469|CMS113v3|
2.16.840.1.113762.1.4.1045.57|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Procedure|0469|CMS113v3|
2.16.840.1.113762.1.4.1045.6|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Attribute|0528|CMS172v4|
2.16.840.1.113762.1.4.1045.67|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113762.1.4.1045.86:PCI),(2.16.840.1.113762.1.4.1045.66:PCI),(2.16.840.1.113883.3.666.5.737:Hospital Measures-PCI)|FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Procedure|0163|CMS53v3|
2.16.840.1.113762.1.4.1045.67|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113762.1.4.1045.86:PCI),(2.16.840.1.113762.1.4.1045.66:PCI),(2.16.840.1.113883.3.666.5.737:Hospital Measures-PCI)|FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Procedure|0164|CMS60v3|
2.16.840.1.113762.1.4.1045.69|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.747:Hospital Measures-Endotrachael intubation),(2.16.840.1.113762.1.4.1045.68:Endotracheal Intubation)|FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Procedure|0163|CMS53v3|
2.16.840.1.113762.1.4.1045.69|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.747:Hospital Measures-Endotrachael intubation),(2.16.840.1.113762.1.4.1045.68:Endotracheal Intubation)|FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Procedure|0164|CMS60v3|
2.16.840.1.113762.1.4.1045.7|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113762.1.4.1045.74|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113762.1.4.1045.73:Indwelling urinary catheter),(2.16.840.1.113762.1.4.1045.71:Indwelling urinary catheter),(2.16.840.1.113762.1.4.1045.72:Indwelling urinary catheter)|FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Procedure|0453|CMS178v4|
2.16.840.1.113762.1.4.1045.77|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.781:Hospital Measures-Tracheostomy care),(2.16.840.1.113762.1.4.1045.76:Tracheostomy care)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Intervention|0147|CMS188v4|
2.16.840.1.113762.1.4.1045.8|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113762.1.4.1045.84|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2320:Hospital Measures-Respiratory failure acute or chronic I10),(2.16.840.1.113883.3.666.5.673:Hospital Measures-Respiratory failure acute or chronic),(2.16.840.1.113883.3.666.5.2086:Tachycardia),(2.16.840.1.113762.1.4.1045.81:Hypoxemia),(2.16.840.1.113762.1.4.1045.83:Respiratory Distress),(2.16.840.1.113762.1.4.1045.80:Hypotension),(2.16.840.1.113883.3.666.5.2321:Hospital Measures-Respiratory failure acute or chronic I9),(2.16.840.1.113883.3.666.5.2602:Septic Shock),(2.16.840.1.113762.1.4.1045.79:Need for ventilator),(2.16.840.1.113762.1.4.1045.78:Need for Ventilator)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113762.1.4.1046.6|20140401|CDC National Center on Birth Defects and Developmental Disabilities|Grouping|(2.16.840.1.113762.1.4.1046.4:Liveborn Newborn Born in Hospital),(2.16.840.1.113762.1.4.1046.5:Liveborn Newborn Born in Hospital)|FY 2014 EH|Hearing Screening Prior To Hospital Discharge|Condition/Diagnosis/Problem|1354|CMS31v3|
2.16.840.1.113762.1.4.1078.5|20140701|OptumInsight|Grouping|(2.16.840.1.113883.3.67.1.101.1.277:Delivery),(2.16.840.1.113883.3.67.1.101.1.2433:Delivery),(2.16.840.1.113883.3.464.1003.111.11.1027:Delivery Live Births),(2.16.840.1.113762.1.4.1078.4:Delivery ICD9Px)|CY 2014 EP|Pregnant women that had HBsAg testing|Procedure|Not Applicable|CMS158v3|
2.16.840.1.113762.1.4.1080.2|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113762.1.4.1080.1:Face to Face Interaction - No ED)|CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Encounter|0712|CMS160v3|
2.16.840.1.113762.1.4.1080.2|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113762.1.4.1080.1:Face to Face Interaction - No ED)|CY 2014 EP|Depression Remission at Twelve Months|Encounter|0710|CMS159v3|
2.16.840.1.113883.3.117.1.7.1.131|20140401|Joint Commission|Extensional||FY 2014 EH|Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver|Communication||CMS26v2|
2.16.840.1.113883.3.117.1.7.1.132|20140401|Joint Commission|Extensional||FY 2014 EH|Assessed for Rehabilitation|Attribute|0441|CMS102v3|
2.16.840.1.113883.3.117.1.7.1.134|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Medication|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.134|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Medication|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.134|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Medication||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.134|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Medication|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.136|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Condition/Diagnosis/Problem|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.137|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Condition/Diagnosis/Problem|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.138|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Condition/Diagnosis/Problem|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.139|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Medication|0142|CMS100v3|
2.16.840.1.113883.3.117.1.7.1.14|20140701|Oklahoma Foundation for Medical Quality|Extensional||CY 2014 EP|Depression Remission at Twelve Months|Attribute|0710|CMS159v3|
2.16.840.1.113883.3.117.1.7.1.14|20140701|Oklahoma Foundation for Medical Quality|Extensional||CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Attribute|0712|CMS160v3|
2.16.840.1.113883.3.117.1.7.1.14|20140701|Oklahoma Foundation for Medical Quality|Extensional||CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Attribute|0108|CMS136v4|
2.16.840.1.113883.3.117.1.7.1.2|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.117.1.7.1.1:SCIP Major Surgical Procedure ICD-10),(2.16.840.1.113883.3.666.5.817:SCIP Major Surgical Procedure ICD-9),(2.16.840.1.113883.3.666.5.1250:SCIP Major Surgery)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113883.3.117.1.7.1.2|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.117.1.7.1.1:SCIP Major Surgical Procedure ICD-10),(2.16.840.1.113883.3.666.5.817:SCIP Major Surgical Procedure ICD-9),(2.16.840.1.113883.3.666.5.1250:SCIP Major Surgery)|FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Procedure|0453|CMS178v4|
2.16.840.1.113883.3.117.1.7.1.2|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.117.1.7.1.1:SCIP Major Surgical Procedure ICD-10),(2.16.840.1.113883.3.666.5.817:SCIP Major Surgical Procedure ICD-9),(2.16.840.1.113883.3.666.5.1250:SCIP Major Surgery)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.117.1.7.1.200|20140401|Joint Commission|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Medication|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.201|20140401|Joint Commission|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Medication|0438|CMS72v3|
2.16.840.1.113883.3.117.1.7.1.201|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Medication|0435|CMS104v3|
2.16.840.1.113883.3.117.1.7.1.202|20140701|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.246:Atrial Fibrillation/Flutter),(2.16.840.1.113883.3.117.1.7.1.245:Atrial Fibrillation/Flutter),(2.16.840.1.113883.3.117.1.7.1.244:Atrial Fibrillation/Flutter)|CY 2014 EP|ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range|Condition/Diagnosis/Problem|NA|CMS179v3|
2.16.840.1.113883.3.117.1.7.1.203|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.243:Atrial Ablation),(2.16.840.1.113883.3.117.1.7.1.242:Atrial Ablation)|FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Procedure|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.205|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Medication|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.205|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Medication|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.207|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Statin Medication|Attribute|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.207|20140401|Joint Commission|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Attribute|0142|CMS100v3|
2.16.840.1.113883.3.117.1.7.1.207|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Attribute|0435|CMS104v3|
2.16.840.1.113883.3.117.1.7.1.207|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Attribute||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.207|20140401|Joint Commission|Extensional||FY 2014 EH|Assessed for Rehabilitation|Attribute|0441|CMS102v3|
2.16.840.1.113883.3.117.1.7.1.207|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Attribute|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.207|20140401|Joint Commission|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Attribute|0639|CMS30v4|
2.16.840.1.113883.3.117.1.7.1.207|20140401|Joint Commission|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Attribute|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.209|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Attribute|0435|CMS104v3|
2.16.840.1.113883.3.117.1.7.1.209|20140401|Joint Commission|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Attribute|0142|CMS100v3|
2.16.840.1.113883.3.117.1.7.1.209|20140401|Joint Commission|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Attribute|0639|CMS30v4|
2.16.840.1.113883.3.117.1.7.1.209|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Attribute||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.209|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Attribute|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.209|20140401|Joint Commission|Extensional||FY 2014 EH|Assessed for Rehabilitation|Attribute|0441|CMS102v3|
2.16.840.1.113883.3.117.1.7.1.209|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Statin Medication|Attribute|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.209|20140401|Joint Commission|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Attribute|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.209|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Attribute||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.211|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Medication|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.211|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Medication||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.211|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Medication|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.212|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.233:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.235:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.234:Hemorrhagic Stroke)|FY 2014 EH|Stroke Education|Condition/Diagnosis/Problem||CMS107v3|
2.16.840.1.113883.3.117.1.7.1.212|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.233:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.235:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.234:Hemorrhagic Stroke)|FY 2014 EH|Assessed for Rehabilitation|Condition/Diagnosis/Problem|0441|CMS102v3|
2.16.840.1.113883.3.117.1.7.1.212|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.233:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.235:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.234:Hemorrhagic Stroke)|FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Condition/Diagnosis/Problem|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.212|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.233:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.235:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.234:Hemorrhagic Stroke)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Condition/Diagnosis/Problem|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.212|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.233:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.235:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.234:Hemorrhagic Stroke)|FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Condition/Diagnosis/Problem|0438|CMS72v3|
2.16.840.1.113883.3.117.1.7.1.212|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.233:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.235:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.234:Hemorrhagic Stroke)|FY 2014 EH|Thrombolytic Therapy|Condition/Diagnosis/Problem|0437|CMS91v4|
2.16.840.1.113883.3.117.1.7.1.212|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.233:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.235:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.234:Hemorrhagic Stroke)|FY 2014 EH|Discharged on Antithrombotic Therapy|Condition/Diagnosis/Problem|0435|CMS104v3|
2.16.840.1.113883.3.117.1.7.1.212|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.233:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.235:Hemorrhagic Stroke),(2.16.840.1.113883.3.117.1.7.1.234:Hemorrhagic Stroke)|FY 2014 EH|Discharged on Statin Medication|Condition/Diagnosis/Problem|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.213|20140701|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Laboratory Test|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.213|20140701|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Laboratory Test|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.213|20140701|Joint Commission|Extensional||CY 2014 EP|ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range|Laboratory Test|NA|CMS179v3|
2.16.840.1.113883.3.117.1.7.1.213|20140701|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Laboratory Test|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.213|20140701|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Laboratory Test|0437|CMS91v4|
2.16.840.1.113883.3.117.1.7.1.214|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Device||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.214|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Device|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.214|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Device|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.215|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Statin Medication|Laboratory Test|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.217|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Statin Medication|Medication|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.218|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Medication||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.218|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Medication||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.218|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Medication|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.218|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Medication|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.219|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Medication||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.219|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Medication|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.219|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Medication|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.222|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Attribute||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.222|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Attribute|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.222|20140401|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Attribute|0437|CMS91v4|
2.16.840.1.113883.3.117.1.7.1.222|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Attribute||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.222|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Attribute|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.223|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Attribute||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.223|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Attribute|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.223|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Attribute|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.225|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Statin Medication|Medication|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.225|20140401|Joint Commission|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Medication|0639|CMS30v4|
2.16.840.1.113883.3.117.1.7.1.226|20140401|Joint Commission|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Medication|0438|CMS72v3|
2.16.840.1.113883.3.117.1.7.1.226|20140401|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Medication|0437|CMS91v4|
2.16.840.1.113883.3.117.1.7.1.230|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Device|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.230|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Device||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.230|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Device|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.232|20140701|Joint Commission|Extensional||CY 2014 EP|ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range|Medication|NA|CMS179v3|
2.16.840.1.113883.3.117.1.7.1.247|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.252:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.250:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.251:Ischemic Stroke)|FY 2014 EH|Discharged on Antithrombotic Therapy|Condition/Diagnosis/Problem|0435|CMS104v3|
2.16.840.1.113883.3.117.1.7.1.247|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.252:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.250:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.251:Ischemic Stroke)|FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Condition/Diagnosis/Problem|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.247|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.252:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.250:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.251:Ischemic Stroke)|FY 2014 EH|Discharged on Statin Medication|Condition/Diagnosis/Problem|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.247|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.252:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.250:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.251:Ischemic Stroke)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Condition/Diagnosis/Problem|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.247|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.252:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.250:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.251:Ischemic Stroke)|FY 2014 EH|Assessed for Rehabilitation|Condition/Diagnosis/Problem|0441|CMS102v3|
2.16.840.1.113883.3.117.1.7.1.247|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.252:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.250:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.251:Ischemic Stroke)|FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Condition/Diagnosis/Problem|0438|CMS72v3|
2.16.840.1.113883.3.117.1.7.1.247|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.252:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.250:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.251:Ischemic Stroke)|FY 2014 EH|Thrombolytic Therapy|Condition/Diagnosis/Problem|0437|CMS91v4|
2.16.840.1.113883.3.117.1.7.1.247|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.252:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.250:Ischemic Stroke),(2.16.840.1.113883.3.117.1.7.1.251:Ischemic Stroke)|FY 2014 EH|Stroke Education|Condition/Diagnosis/Problem||CMS107v3|
2.16.840.1.113883.3.117.1.7.1.25|20140401|Joint Commission|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Condition/Diagnosis/Problem|0480|CMS9v3|
2.16.840.1.113883.3.117.1.7.1.25|20140401|Joint Commission|Extensional||FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.117.1.7.1.253|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Procedure||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.255|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.365:General Surgery),(2.16.840.1.113883.3.117.1.7.1.362:General Surgery),(2.16.840.1.113883.3.117.1.7.1.361:General Surgery)|FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Procedure|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.255|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.365:General Surgery),(2.16.840.1.113883.3.117.1.7.1.362:General Surgery),(2.16.840.1.113883.3.117.1.7.1.361:General Surgery)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Procedure|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.256|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Device|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.256|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Device|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.256|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Device||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.257|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.313:Gynecological Surgery),(2.16.840.1.113883.3.117.1.7.1.310:Gynecological Surgery),(2.16.840.1.113883.3.117.1.7.1.312:Gynecological Surgery)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Procedure|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.257|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.313:Gynecological Surgery),(2.16.840.1.113883.3.117.1.7.1.310:Gynecological Surgery),(2.16.840.1.113883.3.117.1.7.1.312:Gynecological Surgery)|FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Procedure|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.258|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.323:Hip Fracture Surgery),(2.16.840.1.113883.3.117.1.7.1.325:Hip Fracture Surgery),(2.16.840.1.113883.3.117.1.7.1.324:Hip Fracture Surgery)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Procedure|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.258|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.323:Hip Fracture Surgery),(2.16.840.1.113883.3.117.1.7.1.325:Hip Fracture Surgery),(2.16.840.1.113883.3.117.1.7.1.324:Hip Fracture Surgery)|FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Procedure|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.259|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.319:Hip Replacement Surgery),(2.16.840.1.113883.3.117.1.7.1.321:Hip Replacement Surgery),(2.16.840.1.113883.3.117.1.7.1.320:Hip Replacement Surgery)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Procedure|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.259|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.319:Hip Replacement Surgery),(2.16.840.1.113883.3.117.1.7.1.321:Hip Replacement Surgery),(2.16.840.1.113883.3.117.1.7.1.320:Hip Replacement Surgery)|FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Procedure|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.26|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.76:Single Liveborn Newborn),(2.16.840.1.113883.3.117.1.7.1.24:Single Liveborn Newborn)|FY 2014 EH|Exclusive Breast Milk Feeding|Condition/Diagnosis/Problem|0480|CMS9v3|
2.16.840.1.113883.3.117.1.7.1.26|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.76:Single Liveborn Newborn),(2.16.840.1.113883.3.117.1.7.1.24:Single Liveborn Newborn)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.117.1.7.1.260|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.345:Intracranial Neurosurgery),(2.16.840.1.113883.3.117.1.7.1.344:Intracranial Neurosurgery),(2.16.840.1.113883.3.117.1.7.1.346:Intracranial Neurosurgery)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Procedure|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.260|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.345:Intracranial Neurosurgery),(2.16.840.1.113883.3.117.1.7.1.344:Intracranial Neurosurgery),(2.16.840.1.113883.3.117.1.7.1.346:Intracranial Neurosurgery)|FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Procedure|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.261|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.317:Knee Replacement Surgery),(2.16.840.1.113883.3.117.1.7.1.316:Knee Replacement Surgery),(2.16.840.1.113883.3.117.1.7.1.315:Knee Replacement Surgery)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Procedure|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.261|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.317:Knee Replacement Surgery),(2.16.840.1.113883.3.117.1.7.1.316:Knee Replacement Surgery),(2.16.840.1.113883.3.117.1.7.1.315:Knee Replacement Surgery)|FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Procedure|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.262|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.342:Mental Disorders),(2.16.840.1.113883.3.117.1.7.1.341:Mental Disorders),(2.16.840.1.113883.3.117.1.7.1.343:Mental Disorders)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Condition/Diagnosis/Problem|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.263|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.336:Obstetrics),(2.16.840.1.113883.3.117.1.7.1.335:Obstetrics),(2.16.840.1.113883.3.117.1.7.1.337:Obstetrics)|FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Condition/Diagnosis/Problem|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.263|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.336:Obstetrics),(2.16.840.1.113883.3.117.1.7.1.335:Obstetrics),(2.16.840.1.113883.3.117.1.7.1.337:Obstetrics)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Condition/Diagnosis/Problem|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.264|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.339:Obstetrics VTE),(2.16.840.1.113883.3.117.1.7.1.338:Obstetrics VTE),(2.16.840.1.113883.3.117.1.7.1.340:Obstetrics VTE)|FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Condition/Diagnosis/Problem||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.264|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.339:Obstetrics VTE),(2.16.840.1.113883.3.117.1.7.1.338:Obstetrics VTE),(2.16.840.1.113883.3.117.1.7.1.340:Obstetrics VTE)|FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Condition/Diagnosis/Problem|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.264|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.339:Obstetrics VTE),(2.16.840.1.113883.3.117.1.7.1.338:Obstetrics VTE),(2.16.840.1.113883.3.117.1.7.1.340:Obstetrics VTE)|FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Condition/Diagnosis/Problem|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.264|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.339:Obstetrics VTE),(2.16.840.1.113883.3.117.1.7.1.338:Obstetrics VTE),(2.16.840.1.113883.3.117.1.7.1.340:Obstetrics VTE)|FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Condition/Diagnosis/Problem||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.264|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.339:Obstetrics VTE),(2.16.840.1.113883.3.117.1.7.1.338:Obstetrics VTE),(2.16.840.1.113883.3.117.1.7.1.340:Obstetrics VTE)|FY 2014 EH|Venous Thromboembolism Discharge Instructions|Condition/Diagnosis/Problem||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.264|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.339:Obstetrics VTE),(2.16.840.1.113883.3.117.1.7.1.338:Obstetrics VTE),(2.16.840.1.113883.3.117.1.7.1.340:Obstetrics VTE)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Condition/Diagnosis/Problem|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.266|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Medication|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.267|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Laboratory Test||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.267|20140401|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Laboratory Test|0437|CMS91v4|
2.16.840.1.113883.3.117.1.7.1.269|20140401|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Risk Category/Assessment|0437|CMS91v4|
2.16.840.1.113883.3.117.1.7.1.27|20140401|Joint Commission|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Substance|0480|CMS9v3|
2.16.840.1.113883.3.117.1.7.1.271|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.270:Asthma ICD-10),(2.16.840.1.113883.3.117.1.7.1.471:Asthma SNOMED-CT),(2.16.840.1.113883.3.117.1.7.1.904:Asthma)|FY 2014 EH|Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver|Condition/Diagnosis/Problem||CMS26v2|
2.16.840.1.113883.3.117.1.7.1.272|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.333:Urological Surgery),(2.16.840.1.113883.3.117.1.7.1.331:Urological Surgery),(2.16.840.1.113883.3.117.1.7.1.332:Urological Surgery)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Procedure|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.272|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.333:Urological Surgery),(2.16.840.1.113883.3.117.1.7.1.331:Urological Surgery),(2.16.840.1.113883.3.117.1.7.1.332:Urological Surgery)|FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Procedure|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.276|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.275:VTE Diagnostic Test)|FY 2014 EH|Venous Thromboembolism Discharge Instructions|Diagnostic Study||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.276|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.275:VTE Diagnostic Test)|FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Diagnostic Study||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.276|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.275:VTE Diagnostic Test)|FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Diagnostic Study|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.276|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.275:VTE Diagnostic Test)|FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Diagnostic Study||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.277|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Condition/Diagnosis/Problem||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.278|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Procedure||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.279|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.328:Venous Thromboembolism),(2.16.840.1.113883.3.117.1.7.1.329:Venous Thromboembolism),(2.16.840.1.113883.3.117.1.7.1.330:Venous Thromboembolism)|FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Condition/Diagnosis/Problem|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.279|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.328:Venous Thromboembolism),(2.16.840.1.113883.3.117.1.7.1.329:Venous Thromboembolism),(2.16.840.1.113883.3.117.1.7.1.330:Venous Thromboembolism)|FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Condition/Diagnosis/Problem|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.279|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.328:Venous Thromboembolism),(2.16.840.1.113883.3.117.1.7.1.329:Venous Thromboembolism),(2.16.840.1.113883.3.117.1.7.1.330:Venous Thromboembolism)|FY 2014 EH|Venous Thromboembolism Discharge Instructions|Condition/Diagnosis/Problem||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.279|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.328:Venous Thromboembolism),(2.16.840.1.113883.3.117.1.7.1.329:Venous Thromboembolism),(2.16.840.1.113883.3.117.1.7.1.330:Venous Thromboembolism)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Condition/Diagnosis/Problem|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.279|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.328:Venous Thromboembolism),(2.16.840.1.113883.3.117.1.7.1.329:Venous Thromboembolism),(2.16.840.1.113883.3.117.1.7.1.330:Venous Thromboembolism)|FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Condition/Diagnosis/Problem||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.279|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.328:Venous Thromboembolism),(2.16.840.1.113883.3.117.1.7.1.329:Venous Thromboembolism),(2.16.840.1.113883.3.117.1.7.1.330:Venous Thromboembolism)|FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Condition/Diagnosis/Problem||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.281|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Physical Exam|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.282|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.367:Cesarean Section),(2.16.840.1.113883.3.117.1.7.1.369:Cesarean Section),(2.16.840.1.113883.3.117.1.7.1.368:Cesarean Section)|FY 2014 EH|Elective Delivery|Procedure|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.286|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.394:Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation),(2.16.840.1.113883.3.117.1.7.1.395:Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation),(2.16.840.1.113883.3.117.1.7.1.393:Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation)|FY 2014 EH|Elective Delivery|Condition/Diagnosis/Problem|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.288|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.384:Medical Induction of Labor),(2.16.840.1.113883.3.117.1.7.1.383:Medical Induction of Labor)|FY 2014 EH|Elective Delivery|Procedure|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Assessed for Rehabilitation|Encounter|0441|CMS102v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Encounter|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Encounter|0142|CMS100v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Encounter|0163|CMS53v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Median Admit Decision Time to ED Departure Time for Admitted Patients|Encounter|0497|CMS111v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Discharged ED Patients|Encounter|0496|CMS32v4|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Encounter||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Encounter|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Thrombolytic Therapy|Encounter|0437|CMS91v4|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Encounter||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Encounter|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Encounter|0438|CMS72v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Encounter|0435|CMS104v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Encounter|0147|CMS188v4|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Encounter||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Stroke Education|Encounter||CMS107v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Admitted ED Patients|Encounter|0495|CMS55v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Encounter|0164|CMS60v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Encounter|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Encounter|0639|CMS30v4|
2.16.840.1.113883.3.117.1.7.1.292|20140401|Lantana|Extensional||FY 2014 EH|Discharged on Statin Medication|Encounter|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.295|20140401|Lantana|Grouping|(2.16.840.1.113883.3.117.1.7.1.294:Decision to Admit to Hospital Inpatient)|FY 2014 EH|Median Admit Decision Time to ED Departure Time for Admitted Patients|Encounter|0497|CMS111v3|
2.16.840.1.113883.3.117.1.7.1.299|20140401|Lantana|Grouping|(2.16.840.1.113883.3.117.1.7.1.297:Psychiatric/Mental Health Patients),(2.16.840.1.113883.3.117.1.7.1.296:Psychiatric/Mental Health Patient),(2.16.840.1.113883.3.117.1.7.1.298:Psychiatric/Mental Health Patient)|FY 2014 EH|Median Admit Decision Time to ED Departure Time for Admitted Patients|Condition/Diagnosis/Problem|0497|CMS111v3|
2.16.840.1.113883.3.117.1.7.1.299|20140401|Lantana|Grouping|(2.16.840.1.113883.3.117.1.7.1.297:Psychiatric/Mental Health Patients),(2.16.840.1.113883.3.117.1.7.1.296:Psychiatric/Mental Health Patient),(2.16.840.1.113883.3.117.1.7.1.298:Psychiatric/Mental Health Patient)|FY 2014 EH|Median Time from ED Arrival to ED Departure for Admitted ED Patients|Condition/Diagnosis/Problem|0495|CMS55v3|
2.16.840.1.113883.3.117.1.7.1.299|20140401|Lantana|Grouping|(2.16.840.1.113883.3.117.1.7.1.297:Psychiatric/Mental Health Patients),(2.16.840.1.113883.3.117.1.7.1.296:Psychiatric/Mental Health Patient),(2.16.840.1.113883.3.117.1.7.1.298:Psychiatric/Mental Health Patient)|FY 2014 EH|Median Time from ED Arrival to ED Departure for Discharged ED Patients|Condition/Diagnosis/Problem|0496|CMS32v4|
2.16.840.1.113883.3.117.1.7.1.30|20140401|Joint Commission|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Substance|0480|CMS9v3|
2.16.840.1.113883.3.117.1.7.1.301|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Communication||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.302|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Communication||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.303|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Communication||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.304|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Communication||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.305|20140401|Joint Commission|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Encounter|0147|CMS188v4|
2.16.840.1.113883.3.117.1.7.1.305|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Encounter|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.305|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Encounter|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.308|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Attribute|0435|CMS104v3|
2.16.840.1.113883.3.117.1.7.1.308|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Statin Medication|Attribute|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.308|20140401|Joint Commission|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Attribute|0142|CMS100v3|
2.16.840.1.113883.3.117.1.7.1.308|20140401|Joint Commission|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Attribute|0639|CMS30v4|
2.16.840.1.113883.3.117.1.7.1.308|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Attribute|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.308|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Attribute||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.308|20140401|Joint Commission|Extensional||FY 2014 EH|Assessed for Rehabilitation|Attribute|0441|CMS102v3|
2.16.840.1.113883.3.117.1.7.1.308|20140401|Joint Commission|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Attribute|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.309|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Attribute|0435|CMS104v3|
2.16.840.1.113883.3.117.1.7.1.309|20140401|Joint Commission|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Attribute|0142|CMS100v3|
2.16.840.1.113883.3.117.1.7.1.309|20140401|Joint Commission|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Attribute|0639|CMS30v4|
2.16.840.1.113883.3.117.1.7.1.309|20140401|Joint Commission|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Attribute|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.309|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Attribute||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.309|20140401|Joint Commission|Extensional||FY 2014 EH|Hearing Screening Prior To Hospital Discharge|Individual Characteristic|1354|CMS31v3|
2.16.840.1.113883.3.117.1.7.1.309|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Statin Medication|Attribute|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.309|20140401|Joint Commission|Extensional||FY 2014 EH|Assessed for Rehabilitation|Attribute|0441|CMS102v3|
2.16.840.1.113883.3.117.1.7.1.309|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Attribute|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.309|20140401|Joint Commission|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Attribute|0480|CMS9v3|
2.16.840.1.113883.3.117.1.7.1.35|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.78:Galactosemia),(2.16.840.1.113883.3.117.1.7.1.33:Galactosemia),(2.16.840.1.113883.3.117.1.7.1.34:Galactosemia)|FY 2014 EH|Exclusive Breast Milk Feeding|Condition/Diagnosis/Problem|0480|CMS9v3|
2.16.840.1.113883.3.117.1.7.1.357|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Risk Category/Assessment|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.357|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Risk Category/Assessment|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.372|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Condition/Diagnosis/Problem|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.375|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Condition/Diagnosis/Problem|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.377|20140401|Joint Commission|Extensional||FY 2014 EH|Stroke Education|Communication||CMS107v3|
2.16.840.1.113883.3.117.1.7.1.378|20140401|Joint Commission|Extensional||FY 2014 EH|Stroke Education|Communication||CMS107v3|
2.16.840.1.113883.3.117.1.7.1.379|20140401|Joint Commission|Extensional||FY 2014 EH|Stroke Education|Communication||CMS107v3|
2.16.840.1.113883.3.117.1.7.1.38|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.79:Parenteral Infusion),(2.16.840.1.113883.3.117.1.7.1.37:Parenteral Infusion),(2.16.840.1.113883.3.117.1.7.1.36:Parenteral Infusion)|FY 2014 EH|Exclusive Breast Milk Feeding|Procedure|0480|CMS9v3|
2.16.840.1.113883.3.117.1.7.1.380|20140401|Joint Commission|Extensional||FY 2014 EH|Stroke Education|Communication||CMS107v3|
2.16.840.1.113883.3.117.1.7.1.381|20140401|Joint Commission|Extensional||FY 2014 EH|Stroke Education|Communication||CMS107v3|
2.16.840.1.113883.3.117.1.7.1.391|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Condition/Diagnosis/Problem|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.397|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Condition/Diagnosis/Problem|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.400|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Attribute|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.400|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Attribute|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.401|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Procedure|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.407|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Attribute||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.407|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Attribute||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.407|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Attribute||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.407|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Attribute|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.412|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Device,Medication||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.412|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Device,Medication||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.413|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Communication||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.414|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Communication||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.415|20140401|Joint Commission|Extensional||FY 2014 EH|Stroke Education|Communication||CMS107v3|
2.16.840.1.113883.3.117.1.7.1.415|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Communication||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.416|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Communication||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.417|20140401|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Physical Exam|0437|CMS91v4|
2.16.840.1.113883.3.117.1.7.1.421|20140401|Joint Commission|Grouping|(2.16.840.1.113883.3.117.1.7.1.418:Classical Cesarean Section),(2.16.840.1.113883.3.117.1.7.1.419:Classical Cesarean Section),(2.16.840.1.113883.3.117.1.7.1.420:Classical Cesarean Section)|FY 2014 EH|Elective Delivery|Procedure|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.422|20140401|Joint Commission|Extensional||FY 2014 EH|Elective Delivery|Procedure|0469|CMS113v3|
2.16.840.1.113883.3.117.1.7.1.423|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Statin Medication|Medication|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.423|20140401|Joint Commission|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Medication|0639|CMS30v4|
2.16.840.1.113883.3.117.1.7.1.424|20140401|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Encounter|0437|CMS91v4|
2.16.840.1.113883.3.117.1.7.1.424|20140401|Joint Commission|Extensional||FY 2014 EH|Assessed for Rehabilitation|Encounter|0441|CMS102v3|
2.16.840.1.113883.3.117.1.7.1.424|20140401|Joint Commission|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Encounter|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.424|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Encounter|0435|CMS104v3|
2.16.840.1.113883.3.117.1.7.1.424|20140401|Joint Commission|Extensional||FY 2014 EH|Stroke Education|Encounter||CMS107v3|
2.16.840.1.113883.3.117.1.7.1.424|20140401|Joint Commission|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Encounter|0438|CMS72v3|
2.16.840.1.113883.3.117.1.7.1.424|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Statin Medication|Encounter|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Device,Medication|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Device,Medication|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Medication|0437|CMS91v4|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Procedure|0163|CMS53v3|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Medication|0435|CMS104v3|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Statin Medication|Medication|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Medication|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Medication|0639|CMS30v4|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Procedure|0453|CMS178v4|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Medication|0142|CMS100v3|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Medication|0438|CMS72v3|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Medication|0164|CMS60v3|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Device,Medication|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Device,Medication|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.473|20140401|Joint Commission|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Medication|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.70|20140401|Joint Commission|Extensional||FY 2014 EH|Healthy Term Newborn|Attribute|0716|CMS185v3|
2.16.840.1.113883.3.117.1.7.1.70|20140401|Joint Commission|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Individual Characteristic|0480|CMS9v3|
2.16.840.1.113883.3.117.1.7.1.75|20140401|Joint Commission|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Attribute|0480|CMS9v3|
2.16.840.1.113883.3.117.1.7.1.799|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Laboratory Test|0639|CMS30v4|
2.16.840.1.113883.3.117.1.7.1.82|20140401|Joint Commission|Extensional||FY 2014 EH|Stroke Education|Attribute||CMS107v3|
2.16.840.1.113883.3.117.1.7.1.82|20140401|Joint Commission|Extensional||FY 2014 EH|Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver|Attribute||CMS26v2|
2.16.840.1.113883.3.117.1.7.1.82|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Attribute||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.87|20140401|Joint Commission|Extensional||FY 2014 EH|Healthy Term Newborn|Attribute|0716|CMS185v3|
2.16.840.1.113883.3.117.1.7.1.87|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Statin Medication|Attribute|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.87|20140401|Joint Commission|Extensional||FY 2014 EH|Assessed for Rehabilitation|Attribute|0441|CMS102v3|
2.16.840.1.113883.3.117.1.7.1.87|20140401|Joint Commission|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Attribute|0639|CMS30v4|
2.16.840.1.113883.3.117.1.7.1.87|20140401|Joint Commission|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Attribute|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.87|20140401|Joint Commission|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Attribute|0142|CMS100v3|
2.16.840.1.113883.3.117.1.7.1.87|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Attribute||CMS109v3|
2.16.840.1.113883.3.117.1.7.1.87|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Attribute|0373|CMS73v3|
2.16.840.1.113883.3.117.1.7.1.87|20140401|Joint Commission|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Attribute|0480|CMS9v3|
2.16.840.1.113883.3.117.1.7.1.87|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Attribute|0435|CMS104v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver|Communication||CMS26v2|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Medication|0438|CMS72v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Medication|0435|CMS104v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Device,Medication|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Device,Medication|0372|CMS190v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Medication|0142|CMS100v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Procedure|0163|CMS53v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Stroke Education|Communication||CMS107v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Device,Medication|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Device,Medication|0371|CMS108v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Discharged on Statin Medication|Medication|0439|CMS105v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Thrombolytic Therapy|Medication|0437|CMS91v4|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Assessed for Rehabilitation|Procedure|0441|CMS102v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Communication||CMS110v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Device,Medication||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Device,Medication||CMS114v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Medication|0436|CMS71v4|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Medication|0164|CMS60v3|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Medication|0639|CMS30v4|
2.16.840.1.113883.3.117.1.7.1.93|20140401|Joint Commission|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Medication|0373|CMS73v3|
2.16.840.1.113883.3.1257.1.1504|20140701|Center for Quality Assessment and Improvement in Mental Health|Grouping|(2.16.840.1.113883.3.1257.1.1804:BH Condition involving bipolar disorder SNOMED),(2.16.840.1.113883.3.1257.1.1805:BH Condition involving bipolar disorder ICD-10-CM),(2.16.840.1.113883.3.1257.1.1806:BH Condition involving bipolar disorder ICD-9-CM)|CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Condition/Diagnosis/Problem|0110|CMS169v3|
2.16.840.1.113883.3.1257.1.1505|20140701|Center for Quality Assessment and Improvement in Mental Health|Grouping|(2.16.840.1.113883.3.1257.1.1801:BH Condition involving unipolar depression ICD-9-CM),(2.16.840.1.113883.3.1257.1.1802:BH Condition involving unipolar depression ICD-10-CM),(2.16.840.1.113883.3.1257.1.1803:BH Condition involving unipolar depression SNOMED)|CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Condition/Diagnosis/Problem|0110|CMS169v3|
2.16.840.1.113883.3.1257.1.1533|20140701|Center for Quality Assessment and Improvement in Mental Health|Grouping|(2.16.840.1.113883.3.1257.1.1798:BH Electroconvulsive therapy ICD-10-PCS),(2.16.840.1.113883.3.1257.1.1797:BH Electroconvulsive therapy CPT),(2.16.840.1.113883.3.1257.1.1799:BH Electroconvulsive therapy SNOMED),(2.16.840.1.113883.3.1257.1.1796:BH Electroconvulsive therapy ICD-9-CM)|CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Procedure|0110|CMS169v3|
2.16.840.1.113883.3.1257.1.1604|20140701|Center for Quality Assessment and Improvement in Mental Health|Grouping|(2.16.840.1.113883.3.1257.1.1820:BH Assessment for alcohol or other drugs HCPCS),(2.16.840.1.113883.3.1257.1.1819:BH Assessment for alcohol or other drugs SNOMED),(2.16.840.1.113883.3.1257.1.1821:BH Assessment for alcohol or other drugs CPT),(2.16.840.1.113883.3.1257.1.1723:BH Assessment for alcohol or other drugs - SNOMED)|CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Procedure|0110|CMS169v3|
2.16.840.1.113883.3.1257.1.1616|20140701|Center for Quality Assessment and Improvement in Mental Health|Grouping|(2.16.840.1.113883.3.1257.1.1742:BH Counseling for depression SNOMED)|CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Procedure|0110|CMS169v3|
2.16.840.1.113883.3.1257.1.1652|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.1257.1.1823:BH Medical or psychiatric consultation CPT),(2.16.840.1.113883.3.1257.1.1822:BH Medical or psychiatric consultation ICD-9-CM),(2.16.840.1.113883.3.1257.1.1824:BH Medical or psychiatric consultation SNOMED)|CY 2014 EP|Maternal Depression Screening|Encounter|1401|CMS82v2|
2.16.840.1.113883.3.1257.1.950|20140701|Center for Quality Assessment and Improvement in Mental Health|Grouping|(2.16.840.1.113883.3.1257.1.1810:BH Mood Stabilizer Medication RxNorm)|CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Medication|0110|CMS169v3|
2.16.840.1.113883.3.1257.1.972|20140701|Center for Quality Assessment and Improvement in Mental Health|Grouping|(2.16.840.1.113883.3.1257.1.1776:BH Antidepressant Medication - Tetracyclic Antidepressants RxNorm),(2.16.840.1.113883.3.1257.1.1773:BH Antidepressant Medication - Phenylpiperazine Antidepressants RxNorm),(2.16.840.1.113883.3.1257.1.1772:BH Antidepressant Medication - Monoamine Oxidase Inhibitor Antidepressants RxNorm),(2.16.840.1.113883.3.1257.1.1788:BH Antidepressant Medication - Tricyclic Antidepressants RxNorm),(2.16.840.1.113883.3.1257.1.1811:BH Antidepressant Medication - Miscellaneous RxNorm),(2.16.840.1.113883.3.1257.1.1775:BH Antidepressant Medication - SSRI Antidepressants RxNorm),(2.16.840.1.113883.3.1257.1.1774:BH Antidepressant Medication - SSNRI Antidepressants RxNorm)|CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Medication|0110|CMS169v3|
2.16.840.1.113883.3.1257.1.973|20140701|Center for Quality Assessment and Improvement in Mental Health|Grouping|(2.16.840.1.113883.3.526.2.1923:Psych Visit - Diagnostic Evaluation),(2.16.840.1.113883.3.526.2.1927:Psych Visit - Psychotherapy),(2.16.840.1.113883.3.1257.1.1778:BH Outpatient psychotherapy ICD-9-CM),(2.16.840.1.113883.3.1257.1.1779:BH Outpatient psychotherapy SNOMED),(2.16.840.1.113883.3.1257.1.1807:BH Outpatient psychotherapy ICD-10-PCS)|CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Encounter|0110|CMS169v3|
2.16.840.1.113883.3.464.1.49|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.1257.1.1795:BH Outpatient encounter SNOMED),(2.16.840.1.113883.3.1257.1.1779:BH Outpatient psychotherapy SNOMED),(2.16.840.1.113883.3.1257.1.1778:BH Outpatient psychotherapy ICD-9-CM),(2.16.840.1.113883.3.1257.1.1794:BH Outpatient encounter CPT),(2.16.840.1.113883.3.1257.1.1777:BH Outpatient psychotherapy CPT),(2.16.840.1.113883.3.1257.1.1792:BH Outpatient encounter ICD-9-CM),(2.16.840.1.113883.3.1257.1.1807:BH Outpatient psychotherapy ICD-10-PCS)|CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Encounter|0110|CMS169v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Depression Remission at Twelve Months|Encounter|0710|CMS159v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|0104|CMS161v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Encounter|0069|CMS154v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Use of Imaging Studies for Low Back Pain|Encounter|0052|CMS166v4|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Encounter|0088|CMS167v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range|Encounter|NA|CMS179v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Controlling High Blood Pressure|Encounter|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Functional Status Assessment for Knee Replacement|Encounter|Not Applicable|CMS66v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Encounter|Not Applicable|CMS74v4|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Maternal Depression Screening|Encounter|1401|CMS82v2|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Functional Status Assessment for Complex Chronic Conditions|Encounter|Not Applicable|CMS90v4|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Children Who Have Dental Decay or Cavities|Encounter|Not Applicable|CMS75v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Use of Appropriate Medications for Asthma|Encounter|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Encounter|0004|CMS137v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Encounter|0385|CMS141v4|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Encounter|0070|CMS145v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Encounter|0024|CMS155v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0083|CMS144v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Encounter|0064|CMS163v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Encounter|0712|CMS160v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Encounter|0068|CMS164v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|1365|CMS177v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Functional Status Assessment for Hip Replacement|Encounter|Not Applicable|CMS56v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Childhood Immunization Status|Encounter|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Encounter|0059|CMS122v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Encounter|0043|CMS127v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Breast Cancer Screening|Encounter|Not Applicable|CMS125v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Diabetes: Urine Protein Screening|Encounter|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Falls: Screening for Future Fall Risk|Encounter|0101|CMS139v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Encounter|0089|CMS142v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Chlamydia Screening for Women|Encounter|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Use of High-Risk Medications in the Elderly|Encounter|0022|CMS156v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Encounter|0075|CMS182v4|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Dementia: Cognitive Assessment|Encounter|Not Applicable|CMS149v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Oncology: Medical and Radiation – Pain Intensity Quantified|Encounter|0384|CMS157v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Closing the Referral Loop: Receipt of Specialist Report|Encounter|Not Applicable|CMS50v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Cervical Cancer Screening|Encounter|0032|CMS124v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Anti-depressant Medication Management|Encounter|0105|CMS128v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Diabetes: Eye Exam|Encounter|0055|CMS131v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Diabetes: Foot Exam|Encounter|0056|CMS123v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Colorectal Cancer Screening|Encounter|0034|CMS130v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0081|CMS135v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Encounter|0387|CMS140v3|
2.16.840.1.113883.3.464.1003.101.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Encounter|0086|CMS143v3|
2.16.840.1.113883.3.464.1003.101.12.1002|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1010:Hospital Observation Care - Initial)|CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Encounter|0069|CMS154v3|
2.16.840.1.113883.3.464.1003.101.12.1002|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1010:Hospital Observation Care - Initial)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1002|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1010:Hospital Observation Care - Initial)|CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Encounter|0004|CMS137v3|
2.16.840.1.113883.3.464.1003.101.12.1004|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1020:Hospital Inpatient Visit - Initial)|CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Encounter|0004|CMS137v3|
2.16.840.1.113883.3.464.1003.101.12.1006|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1030:Discharge Services - Hospital Inpatient Same Day Discharge)|CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Encounter|0004|CMS137v3|
2.16.840.1.113883.3.464.1003.101.12.1007|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1035:Discharge Services - Hospital Inpatient)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0083|CMS144v3|
2.16.840.1.113883.3.464.1003.101.12.1007|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1035:Discharge Services - Hospital Inpatient)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0081|CMS135v3|
2.16.840.1.113883.3.464.1003.101.12.1007|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1035:Discharge Services - Hospital Inpatient)|CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Encounter|0004|CMS137v3|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|0104|CMS161v3|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|1365|CMS177v3|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Controlling High Blood Pressure|Encounter|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Encounter|0088|CMS167v3|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Functional Status Assessment for Hip Replacement|Encounter|Not Applicable|CMS56v3|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Functional Status Assessment for Knee Replacement|Encounter|Not Applicable|CMS66v3|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Encounter|0070|CMS145v3|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Dementia: Cognitive Assessment|Encounter|Not Applicable|CMS149v3|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Encounter|0086|CMS143v3|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0083|CMS144v3|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0081|CMS135v3|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Encounter|0089|CMS142v3|
2.16.840.1.113883.3.464.1003.101.12.1010|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1050:Emergency Department Visit)|CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|0104|CMS161v3|
2.16.840.1.113883.3.464.1003.101.12.1010|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1050:Emergency Department Visit)|CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Encounter|0069|CMS154v3|
2.16.840.1.113883.3.464.1003.101.12.1010|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1050:Emergency Department Visit)|CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Encounter|0004|CMS137v3|
2.16.840.1.113883.3.464.1003.101.12.1010|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1050:Emergency Department Visit)|CY 2014 EP|Use of Imaging Studies for Low Back Pain|Encounter|0052|CMS166v4|
2.16.840.1.113883.3.464.1003.101.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1060:Nursing Facility Visit)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Encounter|0088|CMS167v3|
2.16.840.1.113883.3.464.1003.101.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1060:Nursing Facility Visit)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0081|CMS135v3|
2.16.840.1.113883.3.464.1003.101.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1060:Nursing Facility Visit)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0083|CMS144v3|
2.16.840.1.113883.3.464.1003.101.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1060:Nursing Facility Visit)|CY 2014 EP|Dementia: Cognitive Assessment|Encounter|Not Applicable|CMS149v3|
2.16.840.1.113883.3.464.1003.101.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1060:Nursing Facility Visit)|CY 2014 EP|Falls: Screening for Future Fall Risk|Encounter|0101|CMS139v3|
2.16.840.1.113883.3.464.1003.101.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1060:Nursing Facility Visit)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Encounter|0089|CMS142v3|
2.16.840.1.113883.3.464.1003.101.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1060:Nursing Facility Visit)|CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Encounter|0086|CMS143v3|
2.16.840.1.113883.3.464.1003.101.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1060:Nursing Facility Visit)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1060:Nursing Facility Visit)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Encounter|0070|CMS145v3|
2.16.840.1.113883.3.464.1003.101.12.1013|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1065:Discharge Services - Nursing Facility)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility)|CY 2014 EP|Depression Remission at Twelve Months|Encounter|0710|CMS159v3|
2.16.840.1.113883.3.464.1003.101.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Encounter|0070|CMS145v3|
2.16.840.1.113883.3.464.1003.101.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0083|CMS144v3|
2.16.840.1.113883.3.464.1003.101.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility)|CY 2014 EP|Dementia: Cognitive Assessment|Encounter|Not Applicable|CMS149v3|
2.16.840.1.113883.3.464.1003.101.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility)|CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Encounter|0712|CMS160v3|
2.16.840.1.113883.3.464.1003.101.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0081|CMS135v3|
2.16.840.1.113883.3.464.1003.101.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility)|CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Encounter|0086|CMS143v3|
2.16.840.1.113883.3.464.1003.101.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Encounter|0088|CMS167v3|
2.16.840.1.113883.3.464.1003.101.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility)|CY 2014 EP|Falls: Screening for Future Fall Risk|Encounter|0101|CMS139v3|
2.16.840.1.113883.3.464.1003.101.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Encounter|0089|CMS142v3|
2.16.840.1.113883.3.464.1003.101.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Chlamydia Screening for Women|Encounter|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Encounter|0068|CMS164v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Diabetes: Foot Exam|Encounter|0056|CMS123v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0081|CMS135v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Cervical Cancer Screening|Encounter|0032|CMS124v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Encounter|0070|CMS145v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Dementia: Cognitive Assessment|Encounter|Not Applicable|CMS149v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Controlling High Blood Pressure|Encounter|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Encounter|0075|CMS182v4|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Use of Appropriate Medications for Asthma|Encounter|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Childhood Immunization Status|Encounter|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Breast Cancer Screening|Encounter|Not Applicable|CMS125v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Diabetes: Eye Exam|Encounter|0055|CMS131v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0083|CMS144v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Encounter|0024|CMS155v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Falls: Screening for Future Fall Risk|Encounter|0101|CMS139v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Use of High-Risk Medications in the Elderly|Encounter|0022|CMS156v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Encounter|0064|CMS163v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Encounter|0059|CMS122v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Anti-depressant Medication Management|Encounter|0105|CMS128v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Encounter|0043|CMS127v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Colorectal Cancer Screening|Encounter|0034|CMS130v3|
2.16.840.1.113883.3.464.1003.101.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services)|CY 2014 EP|Diabetes: Urine Protein Screening|Encounter|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.101.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17)|CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Encounter|0069|CMS154v3|
2.16.840.1.113883.3.464.1003.101.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Encounter|0024|CMS155v3|
2.16.840.1.113883.3.464.1003.101.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17)|CY 2014 EP|Childhood Immunization Status|Encounter|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.101.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17)|CY 2014 EP|Closing the Referral Loop: Receipt of Specialist Report|Encounter|Not Applicable|CMS50v3|
2.16.840.1.113883.3.464.1003.101.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17)|CY 2014 EP|Children Who Have Dental Decay or Cavities|Encounter|Not Applicable|CMS75v3|
2.16.840.1.113883.3.464.1003.101.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17)|CY 2014 EP|Use of Appropriate Medications for Asthma|Encounter|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.101.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17)|CY 2014 EP|Chlamydia Screening for Women|Encounter|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.101.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17)|CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Encounter|Not Applicable|CMS74v4|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Use of High-Risk Medications in the Elderly|Encounter|0022|CMS156v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Encounter|0068|CMS164v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Encounter|0075|CMS182v4|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Children Who Have Dental Decay or Cavities|Encounter|Not Applicable|CMS75v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Encounter|Not Applicable|CMS74v4|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Encounter|0059|CMS122v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Encounter|0043|CMS127v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Colorectal Cancer Screening|Encounter|0034|CMS130v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Breast Cancer Screening|Encounter|Not Applicable|CMS125v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Diabetes: Eye Exam|Encounter|0055|CMS131v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Diabetes: Foot Exam|Encounter|0056|CMS123v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Cervical Cancer Screening|Encounter|0032|CMS124v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Use of Appropriate Medications for Asthma|Encounter|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Encounter|0064|CMS163v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Falls: Screening for Future Fall Risk|Encounter|0101|CMS139v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Chlamydia Screening for Women|Encounter|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Controlling High Blood Pressure|Encounter|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Closing the Referral Loop: Receipt of Specialist Report|Encounter|Not Applicable|CMS50v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Anti-depressant Medication Management|Encounter|0105|CMS128v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Diabetes: Urine Protein Screening|Encounter|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.101.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1024|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17)|CY 2014 EP|Closing the Referral Loop: Receipt of Specialist Report|Encounter|Not Applicable|CMS50v3|
2.16.840.1.113883.3.464.1003.101.12.1024|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17)|CY 2014 EP|Children Who Have Dental Decay or Cavities|Encounter|Not Applicable|CMS75v3|
2.16.840.1.113883.3.464.1003.101.12.1024|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17)|CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Encounter|Not Applicable|CMS74v4|
2.16.840.1.113883.3.464.1003.101.12.1024|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17)|CY 2014 EP|Childhood Immunization Status|Encounter|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.101.12.1024|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17)|CY 2014 EP|Use of Appropriate Medications for Asthma|Encounter|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.101.12.1024|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17)|CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Encounter|0069|CMS154v3|
2.16.840.1.113883.3.464.1003.101.12.1024|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Encounter|0024|CMS155v3|
2.16.840.1.113883.3.464.1003.101.12.1024|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1024|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1024|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17)|CY 2014 EP|Chlamydia Screening for Women|Encounter|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Use of High-Risk Medications in the Elderly|Encounter|0022|CMS156v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Encounter|0075|CMS182v4|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Controlling High Blood Pressure|Encounter|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Encounter|0059|CMS122v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Encounter|0043|CMS127v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Chlamydia Screening for Women|Encounter|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Closing the Referral Loop: Receipt of Specialist Report|Encounter|Not Applicable|CMS50v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Diabetes: Foot Exam|Encounter|0056|CMS123v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Breast Cancer Screening|Encounter|Not Applicable|CMS125v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Anti-depressant Medication Management|Encounter|0105|CMS128v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Cervical Cancer Screening|Encounter|0032|CMS124v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Encounter|0064|CMS163v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Diabetes: Urine Protein Screening|Encounter|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Falls: Screening for Future Fall Risk|Encounter|0101|CMS139v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Encounter|0068|CMS164v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Encounter|Not Applicable|CMS74v4|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Children Who Have Dental Decay or Cavities|Encounter|Not Applicable|CMS75v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Use of Appropriate Medications for Asthma|Encounter|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Colorectal Cancer Screening|Encounter|0034|CMS130v3|
2.16.840.1.113883.3.464.1003.101.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up)|CY 2014 EP|Diabetes: Eye Exam|Encounter|0055|CMS131v3|
2.16.840.1.113883.3.464.1003.101.12.1026|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1130:Preventive Care Services-Individual Counseling)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Encounter|0024|CMS155v3|
2.16.840.1.113883.3.464.1003.101.12.1026|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1130:Preventive Care Services-Individual Counseling)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1026|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1130:Preventive Care Services-Individual Counseling)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1026|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1130:Preventive Care Services-Individual Counseling)|CY 2014 EP|Falls: Screening for Future Fall Risk|Encounter|0101|CMS139v3|
2.16.840.1.113883.3.464.1003.101.12.1026|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1130:Preventive Care Services-Individual Counseling)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.464.1003.101.12.1027|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1135:Preventive Care Services - Group Counseling)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Encounter|0024|CMS155v3|
2.16.840.1.113883.3.464.1003.101.12.1027|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1135:Preventive Care Services - Group Counseling)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1027|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1135:Preventive Care Services - Group Counseling)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.464.1003.101.12.1027|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1135:Preventive Care Services - Group Counseling)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1030|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1150:Preventive Care Services - Other)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.464.1003.101.12.1030|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1150:Preventive Care Services - Other)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1031|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1155:Telehealth Services)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1039|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1195:Discharge Services- Observation Care)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1046|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1215:Referral)|CY 2014 EP|Closing the Referral Loop: Receipt of Specialist Report|Intervention|Not Applicable|CMS50v3|
2.16.840.1.113883.3.464.1003.101.12.1047|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17),(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up),(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction),(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation),(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17),(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up),(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|Encounter|0405|CMS52v3|
2.16.840.1.113883.3.464.1003.101.12.1047|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17),(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up),(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction),(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation),(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17),(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up),(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|HIV/AIDS: Medical Visit|Encounter|Not Applicable|CMS62v3|
2.16.840.1.113883.3.464.1003.101.12.1047|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17),(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up),(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction),(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation),(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17),(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up),(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|HIV/AIDS: RNA Control for Patients with HIV|Encounter|Not Applicable|CMS77v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Encounter|0024|CMS155v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|0104|CMS161v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Encounter|0064|CMS163v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Encounter|0068|CMS164v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Use of Imaging Studies for Low Back Pain|Encounter|0052|CMS166v4|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range|Encounter|NA|CMS179v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Functional Status Assessment for Knee Replacement|Encounter|Not Applicable|CMS66v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Children Who Have Dental Decay or Cavities|Encounter|Not Applicable|CMS75v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Closing the Referral Loop: Receipt of Specialist Report|Encounter|Not Applicable|CMS50v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Encounter|0059|CMS122v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Diabetes: Foot Exam|Encounter|0056|CMS123v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Childhood Immunization Status|Encounter|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Use of Appropriate Medications for Asthma|Encounter|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Diabetes: Eye Exam|Encounter|0055|CMS131v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Encounter|0385|CMS141v4|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0083|CMS144v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Encounter|0070|CMS145v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Dementia: Cognitive Assessment|Encounter|Not Applicable|CMS149v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Chlamydia Screening for Women|Encounter|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|1365|CMS177v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Controlling High Blood Pressure|Encounter|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Encounter|0075|CMS182v4|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Encounter|Not Applicable|CMS74v4|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Functional Status Assessment for Hip Replacement|Encounter|Not Applicable|CMS56v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Maternal Depression Screening|Encounter|1401|CMS82v2|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Anti-depressant Medication Management|Encounter|0105|CMS128v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Diabetes: Urine Protein Screening|Encounter|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Encounter|0043|CMS127v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Colorectal Cancer Screening|Encounter|0034|CMS130v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Use of High-Risk Medications in the Elderly|Encounter|0022|CMS156v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0081|CMS135v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Falls: Screening for Future Fall Risk|Encounter|0101|CMS139v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Encounter|0069|CMS154v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Encounter|0089|CMS142v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Encounter|0004|CMS137v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Encounter|0387|CMS140v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Oncology: Medical and Radiation – Pain Intensity Quantified|Encounter|0384|CMS157v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Encounter|0088|CMS167v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Functional Status Assessment for Complex Chronic Conditions|Encounter|Not Applicable|CMS90v4|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Breast Cancer Screening|Encounter|Not Applicable|CMS125v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Cervical Cancer Screening|Encounter|0032|CMS124v3|
2.16.840.1.113883.3.464.1003.101.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction)|CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Encounter|0086|CMS143v3|
2.16.840.1.113883.3.464.1003.101.12.1053|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1220:Telephone Management)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1054|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1221:Behavioral Health Follow-up Visit)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1055|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1222:Psychotherapy and Pharmacologic Management)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1056|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services),(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up),(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction),(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation),(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility),(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up),(2.16.840.1.113883.3.464.1003.101.11.1060:Nursing Facility Visit),(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Hypertension: Improvement in Blood Pressure|Encounter|Not Applicable|CMS65v4|
2.16.840.1.113883.3.464.1003.101.12.1059|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1228:Detoxification Visit)|CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Encounter|0004|CMS137v3|
2.16.840.1.113883.3.464.1003.101.12.1060|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1224:Inpatient Encounter)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.101.12.1061|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17),(2.16.840.1.113883.3.464.1003.101.11.1010:Hospital Observation Care - Initial),(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up),(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction),(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17),(2.16.840.1.113883.3.464.1003.101.11.1050:Emergency Department Visit),(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up),(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Appropriate Testing for Children with Pharyngitis|Encounter|0002|CMS146v3|
2.16.840.1.113883.3.464.1003.102.12.1002|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.102.11.1006:Cystic Fibrosis),(2.16.840.1.113883.3.464.1003.102.11.1004:Cystic Fibrosis),(2.16.840.1.113883.3.464.1003.102.11.1005:Cystic Fibrosis)|CY 2014 EP|Use of Appropriate Medications for Asthma|Condition/Diagnosis/Problem|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.102.12.1004|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.102.11.1012:Emphysema),(2.16.840.1.113883.3.464.1003.102.11.1011:Emphysema),(2.16.840.1.113883.3.464.1003.102.11.1010:Emphysema)|CY 2014 EP|Use of Appropriate Medications for Asthma|Condition/Diagnosis/Problem|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.102.12.1007|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.102.11.1020:Chronic Obstructive Pulmonary Disease),(2.16.840.1.113883.3.464.1003.102.11.1021:Chronic Obstructive Pulmonary Disease),(2.16.840.1.113883.3.464.1003.102.11.1019:Chronic Obstructive Pulmonary Disease)|CY 2014 EP|Use of Appropriate Medications for Asthma|Condition/Diagnosis/Problem|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.102.12.1011|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.102.11.1032:Acute Pharyngitis),(2.16.840.1.113883.3.464.1003.102.11.1031:Acute Pharyngitis),(2.16.840.1.113883.3.464.1003.102.11.1033:Acute Pharyngitis)|CY 2014 EP|Appropriate Testing for Children with Pharyngitis|Condition/Diagnosis/Problem|0002|CMS146v3|
2.16.840.1.113883.3.464.1003.102.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.102.11.1035:Acute Tonsillitis),(2.16.840.1.113883.3.464.1003.102.11.1036:Acute Tonsillitis),(2.16.840.1.113883.3.464.1003.102.11.1034:Acute Tonsillitis)|CY 2014 EP|Appropriate Testing for Children with Pharyngitis|Condition/Diagnosis/Problem|0002|CMS146v3|
2.16.840.1.113883.3.464.1003.102.12.1017|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.102.11.1041:Infections of the Pharynx, Larynx, Tonsils and Adenoids),(2.16.840.1.113883.3.464.1003.102.11.1045:Pneumonia),(2.16.840.1.113883.3.464.1003.110.11.1006:Intestinal Infections),(2.16.840.1.113883.3.464.1003.112.11.1010:Inflammatory Diseases of Female Reproductive Organs),(2.16.840.1.113883.3.464.1003.110.11.1014:Lyme Disease and other Arthropod-Borne Diseases),(2.16.840.1.113883.3.464.1003.102.11.1031:Acute Pharyngitis),(2.16.840.1.113883.3.464.1003.112.11.1007:Chlamydia),(2.16.840.1.113883.3.464.1003.102.11.1032:Acute Pharyngitis),(2.16.840.1.113883.3.464.1003.113.11.1011:Cellulitis, Mastoiditis, and other Bone Infections),(2.16.840.1.113883.3.464.1003.113.11.1010:Cellulitis, Mastoiditis, and other Bone Infections),(2.16.840.1.113883.3.464.1003.102.11.1028:Acute Sinusitis),(2.16.840.1.113883.3.464.1003.112.11.1003:Gonococcal Infections and Venereal Diseases),(2.16.840.1.113883.3.464.1003.112.11.1016:Cystitis or Urinary Tract Infection),(2.16.840.1.113883.3.464.1003.110.11.1012:Unspecified Bacterial Infection),(2.16.840.1.113883.3.464.1003.110.11.1015:Lyme Disease and other Arthropod-Borne Diseases),(2.16.840.1.113883.3.464.1003.112.11.1012:Inflammatory Diseases of Female Reproductive Organs),(2.16.840.1.113883.3.464.1003.112.11.1018:Cystitis or Urinary Tract Infection),(2.16.840.1.113883.3.464.1003.119.11.1003:Otitis Media),(2.16.840.1.113883.3.464.1003.102.11.1039:Chronic Sinusitis),(2.16.840.1.113883.3.464.1003.113.11.1009:Cellulitis, Mastoiditis, and other Bone Infections),(2.16.840.1.113883.3.464.1003.102.11.1035:Acute Tonsillitis),(2.16.840.1.113883.3.464.1003.102.11.1038:Chronic Sinusitis),(2.16.840.1.113883.3.464.1003.119.11.1002:Otitis Media),(2.16.840.1.113883.3.464.1003.102.11.1043:Pneumonia),(2.16.840.1.113883.3.464.1003.112.11.1013:Infections of the Kidney),(2.16.840.1.113883.3.464.1003.116.11.1023:Impetigo),(2.16.840.1.113883.3.464.1003.116.11.1025:Skin Staph Infections),(2.16.840.1.113883.3.464.1003.116.11.1021:Impetigo),(2.16.840.1.113883.3.464.1003.112.11.1020:Prostatitis),(2.16.840.1.113883.3.464.1003.102.11.1044:Pneumonia),(2.16.840.1.113883.3.464.1003.102.11.1029:Acute Sinusitis),(2.16.840.1.113883.3.464.1003.199.11.1006:Acute Lymphadenitis),(2.16.840.1.113883.3.464.1003.110.11.1007:Pertussis),(2.16.840.1.113883.3.464.1003.102.11.1037:Chronic Sinusitis),(2.16.840.1.113883.3.464.1003.112.11.1011:Inflammatory Diseases of Female Reproductive Organs),(2.16.840.1.113883.3.464.1003.116.11.1024:Skin Staph Infections),(2.16.840.1.113883.3.464.1003.116.11.1029:Acne),(2.16.840.1.113883.3.464.1003.110.11.1008:Pertussis),(2.16.840.1.113883.3.464.1003.102.11.1040:Infections of the Pharynx, Larynx, Tonsils and Adenoids),(2.16.840.1.113883.3.464.1003.112.11.1004:Syphilis),(2.16.840.1.113883.3.464.1003.112.11.1014:Infections of the Kidney),(2.16.840.1.113883.3.464.1003.116.11.1027:Acne),(2.16.840.1.113883.3.464.1003.116.11.1028:Acne),(2.16.840.1.113883.3.464.1003.102.11.1042:Infections of the Pharynx, Larynx, Tonsils and Adenoids),(2.16.840.1.113883.3.464.1003.112.11.1001:Gonococcal Infections and Venereal Diseases),(2.16.840.1.113883.3.464.1003.112.11.1008:Chlamydia),(2.16.840.1.113883.3.464.1003.112.11.1009:Chlamydia),(2.16.840.1.113883.3.464.1003.116.11.1026:Skin Staph Infections),(2.16.840.1.113883.3.464.1003.110.11.1011:Unspecified Bacterial Infection),(2.16.840.1.113883.3.464.1003.110.11.1009:Pertussis),(2.16.840.1.113883.3.464.1003.119.11.1001:Otitis Media),(2.16.840.1.113883.3.464.1003.112.11.1006:Syphilis),(2.16.840.1.113883.3.464.1003.110.11.1013:Lyme Disease and other Arthropod-Borne Diseases),(2.16.840.1.113883.3.464.1003.116.11.1022:Impetigo),(2.16.840.1.113883.3.464.1003.102.11.1030:Acute Sinusitis),(2.16.840.1.113883.3.464.1003.112.11.1002:Gonococcal Infections and Venereal Diseases),(2.16.840.1.113883.3.464.1003.112.11.1017:Cystitis or Urinary Tract Infection),(2.16.840.1.113883.3.464.1003.110.11.1005:Intestinal Infections),(2.16.840.1.113883.3.464.1003.112.11.1015:Infections of the Kidney),(2.16.840.1.113883.3.464.1003.110.11.1004:Intestinal Infections),(2.16.840.1.113883.3.464.1003.102.11.1033:Acute Pharyngitis),(2.16.840.1.113883.3.464.1003.102.11.1034:Acute Tonsillitis),(2.16.840.1.113883.3.464.1003.199.11.1004:Acute Lymphadenitis),(2.16.840.1.113883.3.464.1003.112.11.1021:Prostatitis),(2.16.840.1.113883.3.464.1003.112.11.1005:Syphilis),(2.16.840.1.113883.3.464.1003.199.11.1005:Acute Lymphadenitis),(2.16.840.1.113883.3.464.1003.112.11.1019:Prostatitis),(2.16.840.1.113883.3.464.1003.102.11.1036:Acute Tonsillitis)|CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Condition/Diagnosis/Problem|0069|CMS154v3|
2.16.840.1.113883.3.464.1003.102.12.1018|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.102.11.1047:Acute Respiratory Failure),(2.16.840.1.113883.3.464.1003.102.11.1048:Acute Respiratory Failure),(2.16.840.1.113883.3.464.1003.102.11.1046:Acute Respiratory Failure)|CY 2014 EP|Use of Appropriate Medications for Asthma|Condition/Diagnosis/Problem|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.102.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.102.11.1059:Upper Respiratory Infection),(2.16.840.1.113883.3.464.1003.102.11.1058:Upper Respiratory Infection),(2.16.840.1.113883.3.464.1003.102.11.1060:Upper Respiratory Infection)|CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Condition/Diagnosis/Problem|0069|CMS154v3|
2.16.840.1.113883.3.464.1003.102.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.102.11.1062:Persistent Asthma),(2.16.840.1.113883.3.464.1003.102.11.1061:Persistent Asthma)|CY 2014 EP|Use of Appropriate Medications for Asthma|Condition/Diagnosis/Problem|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.103.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.103.11.1001:Diabetes),(2.16.840.1.113883.3.464.1003.103.11.1002:Diabetes),(2.16.840.1.113883.3.464.1003.103.11.1003:Diabetes)|CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Condition/Diagnosis/Problem|0064|CMS163v3|
2.16.840.1.113883.3.464.1003.103.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.103.11.1001:Diabetes),(2.16.840.1.113883.3.464.1003.103.11.1002:Diabetes),(2.16.840.1.113883.3.464.1003.103.11.1003:Diabetes)|CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Condition/Diagnosis/Problem|0059|CMS122v3|
2.16.840.1.113883.3.464.1003.103.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.103.11.1001:Diabetes),(2.16.840.1.113883.3.464.1003.103.11.1002:Diabetes),(2.16.840.1.113883.3.464.1003.103.11.1003:Diabetes)|CY 2014 EP|Diabetes: Foot Exam|Condition/Diagnosis/Problem|0056|CMS123v3|
2.16.840.1.113883.3.464.1003.103.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.103.11.1001:Diabetes),(2.16.840.1.113883.3.464.1003.103.11.1002:Diabetes),(2.16.840.1.113883.3.464.1003.103.11.1003:Diabetes)|CY 2014 EP|Diabetes: Eye Exam|Condition/Diagnosis/Problem|0055|CMS131v3|
2.16.840.1.113883.3.464.1003.103.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.103.11.1001:Diabetes),(2.16.840.1.113883.3.464.1003.103.11.1002:Diabetes),(2.16.840.1.113883.3.464.1003.103.11.1003:Diabetes)|CY 2014 EP|Hemoglobin A1c Test for Pediatric Patients|Condition/Diagnosis/Problem|0060|CMS148v3|
2.16.840.1.113883.3.464.1003.103.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.103.11.1001:Diabetes),(2.16.840.1.113883.3.464.1003.103.11.1002:Diabetes),(2.16.840.1.113883.3.464.1003.103.11.1003:Diabetes)|CY 2014 EP|Diabetes: Urine Protein Screening|Condition/Diagnosis/Problem|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.103.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1025:Hospital Inpatient Visit - Subsequent),(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17),(2.16.840.1.113883.3.464.1003.101.11.1195:Discharge Services- Observation Care),(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services),(2.16.840.1.113883.3.464.1003.101.11.1010:Hospital Observation Care - Initial),(2.16.840.1.113883.3.464.1003.101.11.1150:Preventive Care Services - Other),(2.16.840.1.113883.3.464.1003.101.11.1206:Ophthamologic Outpatient Visit),(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction),(2.16.840.1.113883.3.464.1003.101.11.1045:Inpatient Consultation),(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation),(2.16.840.1.113883.3.464.1003.101.11.1055:Critical Care Management),(2.16.840.1.113883.3.464.1003.101.11.1207:Ophthamologic Outpatient Visit),(2.16.840.1.113883.3.464.1003.101.11.1035:Discharge Services - Hospital Inpatient),(2.16.840.1.113883.3.464.1003.101.11.1020:Hospital Inpatient Visit - Initial),(2.16.840.1.113883.3.464.1003.101.11.1050:Emergency Department Visit),(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17),(2.16.840.1.113883.3.464.1003.101.11.1130:Preventive Care Services-Individual Counseling),(2.16.840.1.113883.3.464.1003.101.11.1218:Emergency Department or Hospital Interaction),(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Hemoglobin A1c Test for Pediatric Patients|Encounter|0060|CMS148v3|
2.16.840.1.113883.3.464.1003.103.12.1013|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.103.11.1018:Visual Exam of Foot)|CY 2014 EP|Diabetes: Foot Exam|Physical Exam|0056|CMS123v3|
2.16.840.1.113883.3.464.1003.103.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.103.11.1019:Sensory Exam of Foot)|CY 2014 EP|Diabetes: Foot Exam|Physical Exam|0056|CMS123v3|
2.16.840.1.113883.3.464.1003.103.12.1015|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.103.11.1020:Pulse Exam of Foot)|CY 2014 EP|Diabetes: Foot Exam|Physical Exam|0056|CMS123v3|
2.16.840.1.113883.3.464.1003.104.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1001:Acute Myocardial Infarction),(2.16.840.1.113883.3.464.1003.104.11.1002:Acute Myocardial Infarction),(2.16.840.1.113883.3.464.1003.104.11.1003:Acute Myocardial Infarction)|CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Condition/Diagnosis/Problem|0068|CMS164v3|
2.16.840.1.113883.3.464.1003.104.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1001:Acute Myocardial Infarction),(2.16.840.1.113883.3.464.1003.104.11.1002:Acute Myocardial Infarction),(2.16.840.1.113883.3.464.1003.104.11.1003:Acute Myocardial Infarction)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Condition/Diagnosis/Problem|0075|CMS182v4|
2.16.840.1.113883.3.464.1003.104.12.1002|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1005:Coronary Artery Bypass Graft),(2.16.840.1.113883.3.464.1003.104.11.1006:Coronary Artery Bypass Graft),(2.16.840.1.113883.3.464.1003.104.11.1004:Coronary Artery Bypass Graft)|CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Procedure|0068|CMS164v3|
2.16.840.1.113883.3.464.1003.104.12.1002|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1005:Coronary Artery Bypass Graft),(2.16.840.1.113883.3.464.1003.104.11.1006:Coronary Artery Bypass Graft),(2.16.840.1.113883.3.464.1003.104.11.1004:Coronary Artery Bypass Graft)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Procedure|0075|CMS182v4|
2.16.840.1.113883.3.464.1003.104.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1009:Ischemic Vascular Disease),(2.16.840.1.113883.3.464.1003.104.11.1007:Ischemic Vascular Disease),(2.16.840.1.113883.3.464.1003.104.11.1008:Ischemic Vascular Disease)|CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Condition/Diagnosis/Problem|0068|CMS164v3|
2.16.840.1.113883.3.464.1003.104.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1009:Ischemic Vascular Disease),(2.16.840.1.113883.3.464.1003.104.11.1007:Ischemic Vascular Disease),(2.16.840.1.113883.3.464.1003.104.11.1008:Ischemic Vascular Disease)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Condition/Diagnosis/Problem|0075|CMS182v4|
2.16.840.1.113883.3.464.1003.104.12.1010|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1026:Percutaneous Coronary Interventions),(2.16.840.1.113883.3.464.1003.104.11.1028:Percutaneous Coronary Interventions)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Procedure|0075|CMS182v4|
2.16.840.1.113883.3.464.1003.104.12.1010|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1026:Percutaneous Coronary Interventions),(2.16.840.1.113883.3.464.1003.104.11.1028:Percutaneous Coronary Interventions)|CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Procedure|0068|CMS164v3|
2.16.840.1.113883.3.464.1003.104.12.1011|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1030:Essential Hypertension),(2.16.840.1.113883.3.464.1003.104.11.1031:Essential Hypertension),(2.16.840.1.113883.3.464.1003.104.11.1029:Essential Hypertension)|CY 2014 EP|Controlling High Blood Pressure|Condition/Diagnosis/Problem|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.104.12.1011|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1030:Essential Hypertension),(2.16.840.1.113883.3.464.1003.104.11.1031:Essential Hypertension),(2.16.840.1.113883.3.464.1003.104.11.1029:Essential Hypertension)|CY 2014 EP|Hypertension: Improvement in Blood Pressure|Condition/Diagnosis/Problem|Not Applicable|CMS65v4|
2.16.840.1.113883.3.464.1003.104.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1032:HDL-C Laboratory Test)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Laboratory Test|0075|CMS182v4|
2.16.840.1.113883.3.464.1003.104.12.1013|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1033:Total Cholesterol Laboratory Test)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Laboratory Test|0075|CMS182v4|
2.16.840.1.113883.3.464.1003.104.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1034:Triglycerides Laboratory Test)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Laboratory Test|0075|CMS182v4|
2.16.840.1.113883.3.464.1003.104.12.1017|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1039:Valvular Heart Disease),(2.16.840.1.113883.3.464.1003.104.11.1040:Valvular Heart Disease),(2.16.840.1.113883.3.464.1003.104.11.1041:Valvular Heart Disease)|CY 2014 EP|ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range|Condition/Diagnosis/Problem|NA|CMS179v3|
2.16.840.1.113883.3.464.1003.104.12.1018|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.104.11.1042:Computed Value INR percent TTR)|CY 2014 EP|ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range|Laboratory Test|NA|CMS179v3|
2.16.840.1.113883.3.464.1003.105.12.1004|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.105.11.1011:Mental Health Diagnoses),(2.16.840.1.113883.3.464.1003.105.11.1012:Mental Health Diagnoses),(2.16.840.1.113883.3.464.1003.105.11.1010:Mental Health Diagnoses)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Condition/Diagnosis/Problem|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.105.12.1007|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.105.11.1018:Major Depression),(2.16.840.1.113883.3.464.1003.105.11.1019:Major Depression),(2.16.840.1.113883.3.464.1003.105.11.1017:Major Depression)|CY 2014 EP|Anti-depressant Medication Management|Condition/Diagnosis/Problem|0105|CMS128v3|
2.16.840.1.113883.3.464.1003.106.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.106.11.1001:Alcohol and Drug Dependence),(2.16.840.1.113883.3.464.1003.106.11.1002:Alcohol and Drug Dependence),(2.16.840.1.113883.3.464.1003.106.11.1003:Alcohol and Drug Dependence)|CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Condition/Diagnosis/Problem|0004|CMS137v3|
2.16.840.1.113883.3.464.1003.106.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.106.11.1006:IV Drug Abuse),(2.16.840.1.113883.3.464.1003.106.11.1008:IV Drug Abuse),(2.16.840.1.113883.3.464.1003.106.11.1007:IV Drug Abuse)|CY 2014 EP|Use of Imaging Studies for Low Back Pain|Condition/Diagnosis/Problem|0052|CMS166v4|
2.16.840.1.113883.3.464.1003.106.12.1004|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.106.11.1011:Substance Abuse),(2.16.840.1.113883.3.464.1003.106.11.1010:Substance Abuse),(2.16.840.1.113883.3.464.1003.106.11.1009:Substance Abuse)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Condition/Diagnosis/Problem|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.106.12.1005|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.106.11.1012:Alcohol and Drug Dependence Treatment)|CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Encounter|0004|CMS137v3|
2.16.840.1.113883.3.464.1003.108.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.108.11.1001:Malignant Neoplasm of Colon),(2.16.840.1.113883.3.464.1003.108.11.1002:Malignant Neoplasm of Colon),(2.16.840.1.113883.3.464.1003.108.11.1003:Malignant Neoplasm of Colon)|CY 2014 EP|Colorectal Cancer Screening|Condition/Diagnosis/Problem|0034|CMS130v3|
2.16.840.1.113883.3.464.1003.108.12.1009|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.108.11.1026:Malignant Neoplasm of Lymphatic and Hematopietic Tissue),(2.16.840.1.113883.3.464.1003.108.11.1025:Malignant Neoplasm of Lymphatic and Hematopietic Tissue),(2.16.840.1.113883.3.464.1003.108.11.1027:Malignant Neoplasm of Lymphatic and Hematopietic Tissue)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.108.12.1011|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.108.11.1008:Malignant Neoplasm of Digestive Organs Other than Colon and Peritoneum),(2.16.840.1.113883.3.464.1003.108.11.1001:Malignant Neoplasm of Colon),(2.16.840.1.113883.3.464.1003.108.11.1004:Malignant Neoplasm of Lip, Oral Cavity and Pharynx),(2.16.840.1.113883.3.464.1003.108.11.1024:Malignant Neoplasm of Other and Unspecified Sites),(2.16.840.1.113883.3.464.1003.108.11.1018:Malignant Melanoma of the Skin),(2.16.840.1.113883.3.464.1003.108.11.1002:Malignant Neoplasm of Colon),(2.16.840.1.113883.3.464.1003.108.11.1016:Malignant Melanoma of the Skin),(2.16.840.1.113883.3.464.1003.108.11.1009:Malignant Neoplasm of Digestive Organs Other than Colon and Peritoneum),(2.16.840.1.113883.3.464.1003.108.11.1011:Malignant Neoplasm of Respiratory and Intrathoracic Organs),(2.16.840.1.113883.3.464.1003.108.11.1022:Malignant Neoplasm of Other and Unspecified Sites),(2.16.840.1.113883.3.464.1003.108.11.1007:Malignant Neoplasm of Digestive Organs Other than Colon and Peritoneum),(2.16.840.1.113883.3.464.1003.108.11.1012:Malignant Neoplasm of Respiratory and Intrathoracic Organs),(2.16.840.1.113883.3.464.1003.108.11.1014:Malignant Neoplasm of Bone, Connective Tissue Skin (Other than Malignant Melanoma of the Skin) and Breast),(2.16.840.1.113883.3.464.1003.108.11.1015:Malignant Neoplasm of Bone, Connective Tissue Skin (Other than Malignant Melanoma of the Skin) and Breast),(2.16.840.1.113883.3.464.1003.108.11.1026:Malignant Neoplasm of Lymphatic and Hematopietic Tissue),(2.16.840.1.113883.3.464.1003.108.11.1010:Malignant Neoplasm of Respiratory and Intrathoracic Organs),(2.16.840.1.113883.3.464.1003.108.11.1005:Malignant Neoplasm of Lip, Oral Cavity and Pharynx),(2.16.840.1.113883.3.464.1003.108.11.1021:Malignant Neoplasm of Gentiourinary Organs),(2.16.840.1.113883.3.464.1003.108.11.1023:Malignant Neoplasm of Other and Unspecified Sites),(2.16.840.1.113883.3.464.1003.108.11.1025:Malignant Neoplasm of Lymphatic and Hematopietic Tissue),(2.16.840.1.113883.3.464.1003.108.11.1013:Malignant Neoplasm of Bone, Connective Tissue Skin (Other than Malignant Melanoma of the Skin) and Breast),(2.16.840.1.113883.3.464.1003.108.11.1019:Malignant Neoplasm of Gentiourinary Organs),(2.16.840.1.113883.3.464.1003.108.11.1006:Malignant Neoplasm of Lip, Oral Cavity and Pharynx),(2.16.840.1.113883.3.464.1003.108.11.1017:Malignant Melanoma of the Skin),(2.16.840.1.113883.3.464.1003.108.11.1020:Malignant Neoplasm of Gentiourinary Organs),(2.16.840.1.113883.3.464.1003.108.11.1003:Malignant Neoplasm of Colon),(2.16.840.1.113883.3.464.1003.108.11.1027:Malignant Neoplasm of Lymphatic and Hematopietic Tissue)|CY 2014 EP|Use of Imaging Studies for Low Back Pain|Condition/Diagnosis/Problem|0052|CMS166v4|
2.16.840.1.113883.3.464.1003.108.12.1011|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.108.11.1008:Malignant Neoplasm of Digestive Organs Other than Colon and Peritoneum),(2.16.840.1.113883.3.464.1003.108.11.1001:Malignant Neoplasm of Colon),(2.16.840.1.113883.3.464.1003.108.11.1004:Malignant Neoplasm of Lip, Oral Cavity and Pharynx),(2.16.840.1.113883.3.464.1003.108.11.1024:Malignant Neoplasm of Other and Unspecified Sites),(2.16.840.1.113883.3.464.1003.108.11.1018:Malignant Melanoma of the Skin),(2.16.840.1.113883.3.464.1003.108.11.1002:Malignant Neoplasm of Colon),(2.16.840.1.113883.3.464.1003.108.11.1016:Malignant Melanoma of the Skin),(2.16.840.1.113883.3.464.1003.108.11.1009:Malignant Neoplasm of Digestive Organs Other than Colon and Peritoneum),(2.16.840.1.113883.3.464.1003.108.11.1011:Malignant Neoplasm of Respiratory and Intrathoracic Organs),(2.16.840.1.113883.3.464.1003.108.11.1022:Malignant Neoplasm of Other and Unspecified Sites),(2.16.840.1.113883.3.464.1003.108.11.1007:Malignant Neoplasm of Digestive Organs Other than Colon and Peritoneum),(2.16.840.1.113883.3.464.1003.108.11.1012:Malignant Neoplasm of Respiratory and Intrathoracic Organs),(2.16.840.1.113883.3.464.1003.108.11.1014:Malignant Neoplasm of Bone, Connective Tissue Skin (Other than Malignant Melanoma of the Skin) and Breast),(2.16.840.1.113883.3.464.1003.108.11.1015:Malignant Neoplasm of Bone, Connective Tissue Skin (Other than Malignant Melanoma of the Skin) and Breast),(2.16.840.1.113883.3.464.1003.108.11.1026:Malignant Neoplasm of Lymphatic and Hematopietic Tissue),(2.16.840.1.113883.3.464.1003.108.11.1010:Malignant Neoplasm of Respiratory and Intrathoracic Organs),(2.16.840.1.113883.3.464.1003.108.11.1005:Malignant Neoplasm of Lip, Oral Cavity and Pharynx),(2.16.840.1.113883.3.464.1003.108.11.1021:Malignant Neoplasm of Gentiourinary Organs),(2.16.840.1.113883.3.464.1003.108.11.1023:Malignant Neoplasm of Other and Unspecified Sites),(2.16.840.1.113883.3.464.1003.108.11.1025:Malignant Neoplasm of Lymphatic and Hematopietic Tissue),(2.16.840.1.113883.3.464.1003.108.11.1013:Malignant Neoplasm of Bone, Connective Tissue Skin (Other than Malignant Melanoma of the Skin) and Breast),(2.16.840.1.113883.3.464.1003.108.11.1019:Malignant Neoplasm of Gentiourinary Organs),(2.16.840.1.113883.3.464.1003.108.11.1006:Malignant Neoplasm of Lip, Oral Cavity and Pharynx),(2.16.840.1.113883.3.464.1003.108.11.1017:Malignant Melanoma of the Skin),(2.16.840.1.113883.3.464.1003.108.11.1020:Malignant Neoplasm of Gentiourinary Organs),(2.16.840.1.113883.3.464.1003.108.11.1003:Malignant Neoplasm of Colon),(2.16.840.1.113883.3.464.1003.108.11.1027:Malignant Neoplasm of Lymphatic and Hematopietic Tissue)|CY 2014 EP|Functional Status Assessment for Complex Chronic Conditions|Condition/Diagnosis/Problem|Not Applicable|CMS90v4|
2.16.840.1.113883.3.464.1003.108.12.1017|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.108.11.1044:Pap Test)|CY 2014 EP|Cervical Cancer Screening|Laboratory Test|0032|CMS124v3|
2.16.840.1.113883.3.464.1003.108.12.1017|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.108.11.1044:Pap Test)|CY 2014 EP|Chlamydia Screening for Women|Laboratory Test|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.108.12.1018|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.108.11.1047:Mammogram),(2.16.840.1.113883.3.464.1003.108.11.1046:Mammogram)|CY 2014 EP|Breast Cancer Screening|Diagnostic Study|Not Applicable|CMS125v3|
2.16.840.1.113883.3.464.1003.108.12.1020|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.108.11.1051:Colonoscopy),(2.16.840.1.113883.3.464.1003.108.11.1053:Colonoscopy),(2.16.840.1.113883.3.464.1003.108.11.1052:Colonoscopy)|CY 2014 EP|Colorectal Cancer Screening|Procedure|0034|CMS130v3|
2.16.840.1.113883.3.464.1003.109.12.1004|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1009:Diabetic Nephropathy),(2.16.840.1.113883.3.464.1003.109.11.1010:Diabetic Nephropathy),(2.16.840.1.113883.3.464.1003.109.11.1008:Diabetic Nephropathy)|CY 2014 EP|Diabetes: Urine Protein Screening|Condition/Diagnosis/Problem|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.109.12.1005|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1011:Microalbumin Test)|CY 2014 EP|Diabetes: Urine Protein Screening|Laboratory Test|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.109.12.1011|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1022:Vascular Access for Dialysis),(2.16.840.1.113883.3.464.1003.109.11.1023:Vascular Access for Dialysis)|CY 2014 EP|Controlling High Blood Pressure|Procedure|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.109.12.1011|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1022:Vascular Access for Dialysis),(2.16.840.1.113883.3.464.1003.109.11.1023:Vascular Access for Dialysis)|CY 2014 EP|Diabetes: Urine Protein Screening|Procedure|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.109.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1025:Kidney Transplant),(2.16.840.1.113883.3.464.1003.109.11.1024:Kidney Transplant)|CY 2014 EP|Hypertension: Improvement in Blood Pressure|Procedure|Not Applicable|CMS65v4|
2.16.840.1.113883.3.464.1003.109.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1025:Kidney Transplant),(2.16.840.1.113883.3.464.1003.109.11.1024:Kidney Transplant)|CY 2014 EP|Controlling High Blood Pressure|Procedure|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.109.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1025:Kidney Transplant),(2.16.840.1.113883.3.464.1003.109.11.1024:Kidney Transplant)|CY 2014 EP|Diabetes: Urine Protein Screening|Procedure|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.109.12.1013|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1028:Dialysis Services),(2.16.840.1.113883.3.464.1003.109.11.1026:Dialysis Services),(2.16.840.1.113883.3.464.1003.109.11.1027:Dialysis Services)|CY 2014 EP|Controlling High Blood Pressure|Procedure|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.109.12.1013|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1028:Dialysis Services),(2.16.840.1.113883.3.464.1003.109.11.1026:Dialysis Services),(2.16.840.1.113883.3.464.1003.109.11.1027:Dialysis Services)|CY 2014 EP|Diabetes: Urine Protein Screening|Procedure|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.109.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1029:ESRD Monthly Outpatient Services)|CY 2014 EP|Controlling High Blood Pressure|Encounter|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.109.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1029:ESRD Monthly Outpatient Services)|CY 2014 EP|Diabetes: Urine Protein Screening|Encounter|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.109.12.1015|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1030:Other Services Related to Dialysis)|CY 2014 EP|Controlling High Blood Pressure|Intervention|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.109.12.1015|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1030:Other Services Related to Dialysis)|CY 2014 EP|Diabetes: Urine Protein Screening|Intervention|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.109.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1031:Dialysis Education)|CY 2014 EP|Diabetes: Urine Protein Screening|Intervention|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.109.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1031:Dialysis Education)|CY 2014 EP|Controlling High Blood Pressure|Intervention|0018|CMS165v3|
2.16.840.1.113883.3.464.1003.109.12.1017|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1033:Hypertensive Chronic Kidney Disease),(2.16.840.1.113883.3.464.1003.109.11.1034:Hypertensive Chronic Kidney Disease),(2.16.840.1.113883.3.464.1003.109.11.1032:Hypertensive Chronic Kidney Disease)|CY 2014 EP|Diabetes: Urine Protein Screening|Condition/Diagnosis/Problem|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.109.12.1018|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1036:Glomerulonephritis and Nephrotic Syndrome),(2.16.840.1.113883.3.464.1003.109.11.1037:Glomerulonephritis and Nephrotic Syndrome),(2.16.840.1.113883.3.464.1003.109.11.1035:Glomerulonephritis and Nephrotic Syndrome)|CY 2014 EP|Diabetes: Urine Protein Screening|Condition/Diagnosis/Problem|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.109.12.1019|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.109.11.1038:Macroalbumin Test)|CY 2014 EP|Diabetes: Urine Protein Screening|Laboratory Test|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.110.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1065:DTaP Vaccine Administered),(2.16.840.1.113883.3.464.1003.110.11.1066:DTaP Vaccine Administered)|CY 2014 EP|Childhood Immunization Status|Procedure|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1024|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1069:Hepatitis A),(2.16.840.1.113883.3.464.1003.110.11.1070:Hepatitis A),(2.16.840.1.113883.3.464.1003.110.11.1068:Hepatitis A)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1071:Hepatitis B),(2.16.840.1.113883.3.464.1003.110.11.1073:Hepatitis B),(2.16.840.1.113883.3.464.1003.110.11.1072:Hepatitis B)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1027|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1095:Pneumococcal Vaccine)|CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Medication|0043|CMS127v3|
2.16.840.1.113883.3.464.1003.110.12.1028|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1108:History of Pneumococcal Vaccine)|CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Risk Category/Assessment|0043|CMS127v3|
2.16.840.1.113883.3.464.1003.110.12.1031|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1086:Measles, Mumps and Rubella (MMR) Vaccine Administered),(2.16.840.1.113883.3.464.1003.110.11.1085:Measles, Mumps and Rubella (MMR) Vaccine Administered)|CY 2014 EP|Childhood Immunization Status|Procedure|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1032|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1089:Mumps),(2.16.840.1.113883.3.464.1003.110.11.1087:Mumps),(2.16.840.1.113883.3.464.1003.110.11.1088:Mumps)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1034|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1134:Pneumococcal Vaccine Administered),(2.16.840.1.113883.3.464.1003.110.11.1094:Pneumococcal Vaccine Administered)|CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Procedure|0043|CMS127v3|
2.16.840.1.113883.3.464.1003.110.12.1037|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.110:Rubella),(2.16.840.1.113883.3.464.1003.110.11.1098:Rubella),(2.16.840.1.113883.3.464.1003.110.11.1099:Rubella)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1039|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1105:Varicella Zoster),(2.16.840.1.113883.3.464.1003.110.11.1104:Varicella Zoster),(2.16.840.1.113883.3.464.1003.110.11.1103:Varicella Zoster)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1040|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1106:Varicella Zoster Vaccine (VZV) Administered),(2.16.840.1.113883.3.464.1003.110.11.1107:Varicella Zoster Vaccine (VZV) Administered)|CY 2014 EP|Childhood Immunization Status|Procedure|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1041|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1110:Hepatitis A Vaccine Administered),(2.16.840.1.113883.3.464.1003.110.11.1109:Hepatitis A Vaccine Administered)|CY 2014 EP|Childhood Immunization Status|Procedure|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1042|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1112:Hepatitis B Vaccine Administered),(2.16.840.1.113883.3.464.1003.110.11.1111:Hepatitis B Vaccine Administered)|CY 2014 EP|Childhood Immunization Status|Procedure|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1043|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1113:Hemophilus Influenze B (HiB) Vaccine Administered),(2.16.840.1.113883.3.464.1003.110.11.1114:Hemophilus Influenze B (HiB) Vaccine Administered)|CY 2014 EP|Childhood Immunization Status|Procedure|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1044|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1115:Influenza Vaccine Administered),(2.16.840.1.113883.3.464.1003.110.11.1116:Influenza Vaccine Administered)|CY 2014 EP|Childhood Immunization Status|Procedure|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1045|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1118:Inactivated Polio Vaccine (IPV) Administered),(2.16.840.1.113883.3.464.1003.110.11.1117:Inactivated Polio Vaccine (IPV) Administered)|CY 2014 EP|Childhood Immunization Status|Procedure|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1046|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1119:Pneumococcal Conjugate Vaccine Administered),(2.16.840.1.113883.3.464.1003.110.11.1133:Pneumococcal Conjugate Vaccine Administered)|CY 2014 EP|Childhood Immunization Status|Procedure|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1047|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1120:Rotavirus Vaccine (3 dose schedule) Administered)|CY 2014 EP|Childhood Immunization Status|Procedure|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1048|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1121:Rotavirus Vaccine (2 dose schedule) Administered)|CY 2014 EP|Childhood Immunization Status|Procedure|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1049|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1122:Genital Herpes),(2.16.840.1.113883.3.464.1003.110.11.1123:Genital Herpes),(2.16.840.1.113883.3.464.1003.110.11.1124:Genital Herpes)|CY 2014 EP|Chlamydia Screening for Women|Condition/Diagnosis/Problem|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.110.12.1051|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1128:Lab Tests for Sexually Transmitted Infections)|CY 2014 EP|Chlamydia Screening for Women|Laboratory Test|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.110.12.1052|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1129:Chlamydia Screening)|CY 2014 EP|Chlamydia Screening for Women|Laboratory Test|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.110.12.1053|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1079:Measles),(2.16.840.1.113883.3.464.1003.110.11.1080:Measles),(2.16.840.1.113883.3.464.1003.110.11.1078:Measles)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.110.12.1054|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.110.11.1130:Seropositive)|CY 2014 EP|Childhood Immunization Status|Attribute|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.111.12.1006|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.111.11.1011:Other Female Reproductive Conditions),(2.16.840.1.113883.3.464.1003.111.11.1010:Other Female Reproductive Conditions),(2.16.840.1.113883.3.464.1003.111.11.1009:Other Female Reproductive Conditions)|CY 2014 EP|Chlamydia Screening for Women|Condition/Diagnosis/Problem|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.111.12.1007|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.111.11.1012:Lab Tests During Pregnancy)|CY 2014 EP|Chlamydia Screening for Women|Laboratory Test|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.111.12.1008|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.111.11.1013:Diagnostic Studies During Pregnancy)|CY 2014 EP|Chlamydia Screening for Women|Diagnostic Study|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.111.12.1009|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.111.11.1014:Procedures During Pregnancy),(2.16.840.1.113883.3.464.1003.111.11.1015:Procedures During Pregnancy)|CY 2014 EP|Chlamydia Screening for Women|Procedure|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.111.12.1010|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.111.11.1018:Procedures Involving Contraceptive Devices),(2.16.840.1.113883.3.464.1003.111.11.1017:Procedures Involving Contraceptive Devices),(2.16.840.1.113883.3.464.1003.111.11.1016:Procedures Involving Contraceptive Devices)|CY 2014 EP|Chlamydia Screening for Women|Procedure|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.111.12.1011|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.111.11.1019:Pregnancy Test)|CY 2014 EP|Chlamydia Screening for Women|Laboratory Test|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.111.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.111.11.1021:Complications of Pregnancy, Childbirth and the Puerperium),(2.16.840.1.113883.3.464.1003.111.11.1023:Complications of Pregnancy, Childbirth and the Puerperium),(2.16.840.1.113883.3.464.1003.111.11.1022:Complications of Pregnancy, Childbirth and the Puerperium)|CY 2014 EP|Chlamydia Screening for Women|Condition/Diagnosis/Problem|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.111.12.1013|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.111.11.1024:Maternal Post Partum Depression Care)|CY 2014 EP|Maternal Depression Screening|Intervention|1401|CMS82v2|
2.16.840.1.113883.3.464.1003.111.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.111.11.1025:Maternal Post Partum Depression Screening)|CY 2014 EP|Maternal Depression Screening|Intervention|1401|CMS82v2|
2.16.840.1.113883.3.464.1003.111.12.1015|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.111.11.1027:Delivery Live Births),(2.16.840.1.113883.3.464.1003.111.11.1026:Delivery Live Births)|CY 2014 EP|Chlamydia Screening for Women|Procedure|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.112.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.112.11.1003:Gonococcal Infections and Venereal Diseases),(2.16.840.1.113883.3.464.1003.112.11.1001:Gonococcal Infections and Venereal Diseases),(2.16.840.1.113883.3.464.1003.112.11.1002:Gonococcal Infections and Venereal Diseases)|CY 2014 EP|Chlamydia Screening for Women|Condition/Diagnosis/Problem|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.112.12.1002|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.112.11.1004:Syphilis),(2.16.840.1.113883.3.464.1003.112.11.1006:Syphilis),(2.16.840.1.113883.3.464.1003.112.11.1005:Syphilis)|CY 2014 EP|Chlamydia Screening for Women|Condition/Diagnosis/Problem|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.112.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.112.11.1007:Chlamydia),(2.16.840.1.113883.3.464.1003.112.11.1008:Chlamydia),(2.16.840.1.113883.3.464.1003.112.11.1009:Chlamydia)|CY 2014 EP|Chlamydia Screening for Women|Condition/Diagnosis/Problem|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.112.12.1004|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.112.11.1010:Inflammatory Diseases of Female Reproductive Organs),(2.16.840.1.113883.3.464.1003.112.11.1012:Inflammatory Diseases of Female Reproductive Organs),(2.16.840.1.113883.3.464.1003.112.11.1011:Inflammatory Diseases of Female Reproductive Organs)|CY 2014 EP|Chlamydia Screening for Women|Condition/Diagnosis/Problem|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.113.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.113.11.1001:Low Back Pain),(2.16.840.1.113883.3.464.1003.113.11.1003:Low Back Pain),(2.16.840.1.113883.3.464.1003.113.11.1002:Low Back Pain)|CY 2014 EP|Use of Imaging Studies for Low Back Pain|Condition/Diagnosis/Problem|0052|CMS166v4|
2.16.840.1.113883.3.464.1003.113.12.1033|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.113.11.1063:X-Ray of Lower Spine)|CY 2014 EP|Use of Imaging Studies for Low Back Pain|Diagnostic Study|0052|CMS166v4|
2.16.840.1.113883.3.464.1003.113.12.1034|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.113.11.1064:MRI of Lower Spine)|CY 2014 EP|Use of Imaging Studies for Low Back Pain|Diagnostic Study|0052|CMS166v4|
2.16.840.1.113883.3.464.1003.113.12.1035|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.113.11.1065:CT Scan of Lower Spine)|CY 2014 EP|Use of Imaging Studies for Low Back Pain|Diagnostic Study|0052|CMS166v4|
2.16.840.1.113883.3.464.1003.113.12.1036|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.113.11.1067:Trauma),(2.16.840.1.113883.3.464.1003.113.11.1068:Trauma),(2.16.840.1.113883.3.464.1003.113.11.1066:Trauma)|CY 2014 EP|Use of Imaging Studies for Low Back Pain|Condition/Diagnosis/Problem|0052|CMS166v4|
2.16.840.1.113883.3.464.1003.113.12.1037|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.113.11.1071:Fracture - Lower Body),(2.16.840.1.113883.3.464.1003.113.11.1069:Fracture - Lower Body),(2.16.840.1.113883.3.464.1003.113.11.1070:Fracture - Lower Body)|CY 2014 EP|Functional Status Assessment for Hip Replacement|Condition/Diagnosis/Problem|Not Applicable|CMS56v3|
2.16.840.1.113883.3.464.1003.113.12.1037|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.113.11.1071:Fracture - Lower Body),(2.16.840.1.113883.3.464.1003.113.11.1069:Fracture - Lower Body),(2.16.840.1.113883.3.464.1003.113.11.1070:Fracture - Lower Body)|CY 2014 EP|Functional Status Assessment for Knee Replacement|Condition/Diagnosis/Problem|Not Applicable|CMS66v3|
2.16.840.1.113883.3.464.1003.114.12.1007|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.114.11.1009:Encephalopathy),(2.16.840.1.113883.3.464.1003.114.11.1011:Encephalopathy),(2.16.840.1.113883.3.464.1003.114.11.1010:Encephalopathy)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.114.12.1011|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.114.11.1021:Narcolepsy),(2.16.840.1.113883.3.464.1003.114.11.1022:Narcolepsy),(2.16.840.1.113883.3.464.1003.114.11.1023:Narcolepsy)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Condition/Diagnosis/Problem|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.114.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.114.11.1025:Neurologic impairment),(2.16.840.1.113883.3.464.1003.114.11.1024:Neurologic impairment),(2.16.840.1.113883.3.464.1003.114.11.1026:Neurologic impairment)|CY 2014 EP|Use of Imaging Studies for Low Back Pain|Condition/Diagnosis/Problem|0052|CMS166v4|
2.16.840.1.113883.3.464.1003.115.12.1088|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.115.11.1248:Retinal or Dilated Eye Exam)|CY 2014 EP|Diabetes: Eye Exam|Physical Exam|0055|CMS131v3|
2.16.840.1.113883.3.464.1003.118.12.1009|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.118.11.1010:Patient not ambulatory)|CY 2014 EP|Falls: Screening for Future Fall Risk|Risk Category/Assessment|0101|CMS139v3|
2.16.840.1.113883.3.464.1003.118.12.1028|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.118.11.1077:Falls Screening)|CY 2014 EP|Falls: Screening for Future Fall Risk|Risk Category/Assessment|0101|CMS139v3|
2.16.840.1.113883.3.464.1003.118.12.1029|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.118.11.1039:Functional Status Assessment  for Hip Replacement)|CY 2014 EP|Functional Status Assessment for Hip Replacement|Functional Status|Not Applicable|CMS56v3|
2.16.840.1.113883.3.464.1003.118.12.1030|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.118.11.1040:Functional Status Assessment for Knee Replacement)|CY 2014 EP|Functional Status Assessment for Knee Replacement|Functional Status|Not Applicable|CMS66v3|
2.16.840.1.113883.3.464.1003.118.12.1031|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.118.11.1041:Functional Status Assessment for Heart Failure)|CY 2014 EP|Functional Status Assessment for Complex Chronic Conditions|Functional Status|Not Applicable|CMS90v4|
2.16.840.1.113883.3.464.1003.118.12.1035|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.118.11.1042:Counseling for Physical Activity)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Intervention|0024|CMS155v3|
2.16.840.1.113883.3.464.1003.120.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.120.11.1001:Disorders of the Immune System),(2.16.840.1.113883.3.464.1003.120.11.1002:Disorders of the Immune System),(2.16.840.1.113883.3.464.1003.120.11.1003:Disorders of the Immune System)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.120.12.1002|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.120.11.1004:HIV Viral Load)|CY 2014 EP|HIV/AIDS: RNA Control for Patients with HIV|Laboratory Test|Not Applicable|CMS77v3|
2.16.840.1.113883.3.464.1003.120.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.120.11.1007:HIV),(2.16.840.1.113883.3.464.1003.120.11.1005:HIV),(2.16.840.1.113883.3.464.1003.120.11.1006:HIV)|CY 2014 EP|HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|Condition/Diagnosis/Problem|0405|CMS52v3|
2.16.840.1.113883.3.464.1003.120.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.120.11.1007:HIV),(2.16.840.1.113883.3.464.1003.120.11.1005:HIV),(2.16.840.1.113883.3.464.1003.120.11.1006:HIV)|CY 2014 EP|HIV/AIDS: Medical Visit|Condition/Diagnosis/Problem|Not Applicable|CMS62v3|
2.16.840.1.113883.3.464.1003.120.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.120.11.1007:HIV),(2.16.840.1.113883.3.464.1003.120.11.1005:HIV),(2.16.840.1.113883.3.464.1003.120.11.1006:HIV)|CY 2014 EP|Chlamydia Screening for Women|Condition/Diagnosis/Problem|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.120.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.120.11.1007:HIV),(2.16.840.1.113883.3.464.1003.120.11.1005:HIV),(2.16.840.1.113883.3.464.1003.120.11.1006:HIV)|CY 2014 EP|HIV/AIDS: RNA Control for Patients with HIV|Condition/Diagnosis/Problem|Not Applicable|CMS77v3|
2.16.840.1.113883.3.464.1003.120.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.120.11.1007:HIV),(2.16.840.1.113883.3.464.1003.120.11.1005:HIV),(2.16.840.1.113883.3.464.1003.120.11.1006:HIV)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.121.12.1004|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.121.11.1006:CD4+ Count)|CY 2014 EP|HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|Laboratory Test|0405|CMS52v3|
2.16.840.1.113883.3.464.1003.121.12.1005|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.121.11.1009:CD4+ Percentage)|CY 2014 EP|HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|Laboratory Test|0405|CMS52v3|
2.16.840.1.113883.3.464.1003.121.12.1006|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.121.11.1011:Consultant Report)|CY 2014 EP|Closing the Referral Loop: Receipt of Specialist Report|Communication|Not Applicable|CMS50v3|
2.16.840.1.113883.3.464.1003.121.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.121.11.1028:BMI percentile)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Physical Exam|0024|CMS155v3|
2.16.840.1.113883.3.464.1003.121.12.1013|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.121.11.1027:Delta systolic blood pressure)|CY 2014 EP|Hypertension: Improvement in Blood Pressure|Physical Exam|Not Applicable|CMS65v4|
2.16.840.1.113883.3.464.1003.121.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.121.11.1030:Height)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Physical Exam|0024|CMS155v3|
2.16.840.1.113883.3.464.1003.121.12.1015|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.121.11.1031:Weight)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Physical Exam|0024|CMS155v3|
2.16.840.1.113883.3.464.1003.121.12.1016|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.195.11.1008:Positive Finding)|CY 2014 EP|Diabetes: Urine Protein Screening|Attribute|0062|CMS134v3|
2.16.840.1.113883.3.464.1003.122.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.122.11.1003:Ambulatory)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Attribute|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.125.12.1002|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.125.11.1004:Fluoride Varnish Application for Children),(2.16.840.1.113883.3.464.1003.125.11.1011:Fluoride Varnish Application for Children)|CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Procedure|Not Applicable|CMS74v4|
2.16.840.1.113883.3.464.1003.125.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.125.11.1010:Clinical Oral Evaluation)|CY 2014 EP|Children Who Have Dental Decay or Cavities|Encounter|Not Applicable|CMS75v3|
2.16.840.1.113883.3.464.1003.125.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.125.11.1010:Clinical Oral Evaluation)|CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Encounter|Not Applicable|CMS74v4|
2.16.840.1.113883.3.464.1003.125.12.1004|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.125.11.1009:Dental Caries),(2.16.840.1.113883.3.464.1003.125.11.1008:Dental Caries),(2.16.840.1.113883.3.464.1003.125.11.1007:Dental Caries)|CY 2014 EP|Children Who Have Dental Decay or Cavities|Condition/Diagnosis/Problem|Not Applicable|CMS75v3|
2.16.840.1.113883.3.464.1003.195.12.1002|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.195.11.1002:Negative Finding)|CY 2014 EP|Diabetes: Eye Exam|Attribute|0055|CMS131v3|
2.16.840.1.113883.3.464.1003.195.12.1003|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.195.11.1004:Counseling for Nutrition),(2.16.840.1.113883.3.464.1003.195.11.1003:Counseling for Nutrition)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Intervention|0024|CMS155v3|
2.16.840.1.113883.3.464.1003.196.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1001:Antibiotic Medications for Pharyngitis)|CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Medication|0069|CMS154v3|
2.16.840.1.113883.3.464.1003.196.12.1001|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1001:Antibiotic Medications for Pharyngitis)|CY 2014 EP|Appropriate Testing for Children with Pharyngitis|Medication|0002|CMS146v3|
2.16.840.1.113883.3.464.1003.196.12.1076|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1076:Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis)|CY 2014 EP|HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|Medication|0405|CMS52v3|
2.16.840.1.113883.3.464.1003.196.12.1080|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1080:Contraceptive Medications)|CY 2014 EP|Chlamydia Screening for Women|Medication|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.196.12.1143|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1143:Isotretinoin)|CY 2014 EP|Chlamydia Screening for Women|Medication|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.196.12.1170|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1234:Varicella Zoster Vaccine (VZV))|CY 2014 EP|Childhood Immunization Status|Medication|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.196.12.1171|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1171:ADHD Medications)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Medication|0108|CMS136v4|
2.16.840.1.113883.3.464.1003.196.12.1202|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1202:Dapsone and pyrimethamine)|CY 2014 EP|HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|Medication|0405|CMS52v3|
2.16.840.1.113883.3.464.1003.196.12.1205|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1205:Leucovorin)|CY 2014 EP|HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|Medication|0405|CMS52v3|
2.16.840.1.113883.3.464.1003.196.12.1211|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1211:Aspirin and Other Anti-thrombotics)|CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Medication|0068|CMS164v3|
2.16.840.1.113883.3.464.1003.196.12.1212|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1088:Leukotriene modifiers),(2.16.840.1.113883.3.464.1003.196.11.1086:Inhaled Steroid Combinations),(2.16.840.1.113883.3.464.1003.196.11.1024:Antiasthmatic Combinations),(2.16.840.1.113883.3.464.1003.196.11.1025:Antibody Inhibitor),(2.16.840.1.113883.3.464.1003.196.11.1097:Mast Cell Stabilizer),(2.16.840.1.113883.3.464.1003.196.11.1085:Inhaled Corticosteroids),(2.16.840.1.113883.3.464.1003.196.11.1099:Methylxanthines)|CY 2014 EP|Use of Appropriate Medications for Asthma|Medication|0036|CMS126v3|
2.16.840.1.113883.3.464.1003.196.12.1213|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1159:SSRI Antidepressants),(2.16.840.1.113883.3.464.1003.196.11.1194:Tricyclic Antidepressants),(2.16.840.1.113883.3.464.1003.196.11.1162:Tetracyclic Antidepressants),(2.16.840.1.113883.3.464.1003.196.11.1137:Phenylpiperazine Antidepressants),(2.16.840.1.113883.3.464.1003.196.11.1102:Miscellaneous Antidepressants),(2.16.840.1.113883.3.464.1003.196.11.1158:SSNRI Antidepressants),(2.16.840.1.113883.3.464.1003.196.11.1141:Psychotherapeutic combinations)|CY 2014 EP|Anti-depressant Medication Management|Medication|0105|CMS128v3|
2.16.840.1.113883.3.464.1003.196.12.1214|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1212:DTaP Vaccine)|CY 2014 EP|Childhood Immunization Status|Medication|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.196.12.1215|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1214:Hepatitis A Vaccine)|CY 2014 EP|Childhood Immunization Status|Medication|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.196.12.1216|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1216:Hepatitis B Vaccine)|CY 2014 EP|Childhood Immunization Status|Medication|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.196.12.1217|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1218:Hemophilus Influenze B (HiB) Vaccine)|CY 2014 EP|Childhood Immunization Status|Medication|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.196.12.1218|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1220:Influenza Vaccine)|CY 2014 EP|Childhood Immunization Status|Medication|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.196.12.1219|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1222:Inactivated Polio Vaccine (IPV))|CY 2014 EP|Childhood Immunization Status|Medication|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.196.12.1221|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1228:Pneumococcal Conjugate Vaccine)|CY 2014 EP|Childhood Immunization Status|Medication|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.196.12.1222|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1230:Rotavirus Vaccine (2 dose schedule))|CY 2014 EP|Childhood Immunization Status|Medication|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.196.12.1223|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1232:Rotavirus Vaccine (3 dose schedule))|CY 2014 EP|Childhood Immunization Status|Medication|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.196.12.1224|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1235:Measles, Mumps and Rubella (MMR) Vaccine)|CY 2014 EP|Childhood Immunization Status|Medication|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.196.12.1253|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1056:Amobarbital),(2.16.840.1.113883.3.464.1003.196.11.1168:Ergot Mesylate),(2.16.840.1.113883.3.464.1003.196.11.1251:Guanabenz),(2.16.840.1.113883.3.464.1003.196.11.1091:Amitriptyline),(2.16.840.1.113883.3.464.1003.196.11.1250:Glyburide),(2.16.840.1.113883.3.464.1003.196.11.1167:Dipyridamole),(2.16.840.1.113883.3.464.1003.196.11.1252:Guanfacine),(2.16.840.1.113883.3.464.1003.196.11.1036:Cyproheptadine),(2.16.840.1.113883.3.464.1003.196.11.1129:Desiccated Thyroid),(2.16.840.1.113883.3.464.1003.196.11.1156:Methocarbamol),(2.16.840.1.113883.3.464.1003.196.11.1178:Hydroxyzine Hydrochloride),(2.16.840.1.113883.3.464.1003.196.11.1257:Methyldopa),(2.16.840.1.113883.3.464.1003.196.11.1152:Carisoprodol),(2.16.840.1.113883.3.464.1003.196.11.1238:Benztropine),(2.16.840.1.113883.3.464.1003.196.11.1258:Ticlopidine),(2.16.840.1.113883.3.464.1003.196.11.1044:Diphenhydramine),(2.16.840.1.113883.3.464.1003.196.11.1261:Triprolidine),(2.16.840.1.113883.3.464.1003.196.11.1050:Promethazine),(2.16.840.1.113883.3.464.1003.196.11.1169:Isoxsuprine),(2.16.840.1.113883.3.464.1003.196.11.1109:Meperidine),(2.16.840.1.113883.3.464.1003.196.11.1118:Conjugated Estrogen),(2.16.840.1.113883.3.464.1003.196.11.1236:Brompheniramine),(2.16.840.1.113883.3.464.1003.196.11.1255:Megestrol),(2.16.840.1.113883.3.464.1003.196.11.1260:Trimipramine),(2.16.840.1.113883.3.464.1003.196.11.1245:Dexbrompheniramine),(2.16.840.1.113883.3.464.1003.196.11.1037:Dexchlorpheniramine),(2.16.840.1.113883.3.464.1003.196.11.1246:Disopyramide),(2.16.840.1.113883.3.464.1003.196.11.1060:Phenobarbital),(2.16.840.1.113883.3.464.1003.196.11.1057:Butabarbital),(2.16.840.1.113883.3.464.1003.196.11.1059:Pentobarbital),(2.16.840.1.113883.3.464.1003.196.11.1256:Meprobamate),(2.16.840.1.113883.3.464.1003.196.11.1061:Secobarbital),(2.16.840.1.113883.3.464.1003.196.11.1153:Chlorzoxazone),(2.16.840.1.113883.3.464.1003.196.11.1247:Doxylamine),(2.16.840.1.113883.3.464.1003.196.11.1239:Butalbital),(2.16.840.1.113883.3.464.1003.196.11.1120:Esterified Estrogen),(2.16.840.1.113883.3.464.1003.196.11.1112:Pentazocine),(2.16.840.1.113883.3.464.1003.196.11.1242:Clemastine),(2.16.840.1.113883.3.464.1003.196.11.1110:Meperidine-Promethazine),(2.16.840.1.113883.3.464.1003.196.11.1259:Trihexyphenidyl),(2.16.840.1.113883.3.464.1003.196.11.1254:Indomethacin),(2.16.840.1.113883.3.464.1003.196.11.1058:Mephobarbital),(2.16.840.1.113883.3.464.1003.196.11.1243:Clomipramine),(2.16.840.1.113883.3.464.1003.196.11.1248:Estradiol),(2.16.840.1.113883.3.464.1003.196.11.1244:Conjugated Synthetic Estrogens),(2.16.840.1.113883.3.464.1003.196.11.1053:Thioridazine),(2.16.840.1.113883.3.464.1003.196.11.1124:Chlorpropamide),(2.16.840.1.113883.3.464.1003.196.11.1253:Imipramine),(2.16.840.1.113883.3.464.1003.196.11.1122:Estropipate),(2.16.840.1.113883.3.464.1003.196.11.1240:Chloral Hydrate),(2.16.840.1.113883.3.464.1003.196.11.1241:Chlorpheniramine),(2.16.840.1.113883.3.464.1003.196.11.1078:Nifedipine),(2.16.840.1.113883.3.464.1003.196.11.1157:Orphenadrine),(2.16.840.1.113883.3.464.1003.196.11.1237:Carbinoxamine),(2.16.840.1.113883.3.464.1003.196.11.1154:Cyclobenzaprine),(2.16.840.1.113883.3.464.1003.196.11.1155:Metaxalone),(2.16.840.1.113883.3.464.1003.196.11.1022:Ketorolac)|CY 2014 EP|Use of High-Risk Medications in the Elderly|Medication|0022|CMS156v3|
2.16.840.1.113883.3.464.1003.196.12.1254|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.196.11.1263:Zolpidem),(2.16.840.1.113883.3.464.1003.196.11.1131:Nitrofurantoin),(2.16.840.1.113883.3.464.1003.196.11.1134:Nitrofurantoin Macrocrystallin),(2.16.840.1.113883.3.464.1003.196.11.1262:Zaleplon),(2.16.840.1.113883.3.464.1003.196.11.1249:Eszopiclone),(2.16.840.1.113883.3.464.1003.196.11.1133:Nitrofurantoin Monohydrate Macrocrystalline)|CY 2014 EP|Use of High-Risk Medications in the Elderly|Medication|0022|CMS156v3|
2.16.840.1.113883.3.464.1003.198.12.1005|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1005:Bilateral Mastectomy)|CY 2014 EP|Breast Cancer Screening|Procedure|Not Applicable|CMS125v3|
2.16.840.1.113883.3.464.1003.198.12.1006|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1039:Primary THA Procedure),(2.16.840.1.113883.3.464.1003.198.11.1009:Primary THA Procedure),(2.16.840.1.113883.3.464.1003.198.11.1080:Primary THA Procedure)|CY 2014 EP|Functional Status Assessment for Hip Replacement|Procedure|Not Applicable|CMS56v3|
2.16.840.1.113883.3.464.1003.198.12.1007|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1010:Primary TKA Procedure),(2.16.840.1.113883.3.464.1003.198.11.1011:Primary TKA Procedure)|CY 2014 EP|Functional Status Assessment for Knee Replacement|Procedure|Not Applicable|CMS66v3|
2.16.840.1.113883.3.464.1003.198.12.1010|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1016:Flexible Sigmoidoscopy),(2.16.840.1.113883.3.464.1003.198.11.1015:Flexible Sigmoidoscopy),(2.16.840.1.113883.3.464.1003.198.11.1017:Flexible Sigmoidoscopy)|CY 2014 EP|Colorectal Cancer Screening|Procedure|0034|CMS130v3|
2.16.840.1.113883.3.464.1003.198.12.1011|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1020:Fecal Occult Blood Test (FOBT))|CY 2014 EP|Colorectal Cancer Screening|Laboratory Test|0034|CMS130v3|
2.16.840.1.113883.3.464.1003.198.12.1012|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1023:Group A Streptococcus Test)|CY 2014 EP|Appropriate Testing for Children with Pharyngitis|Laboratory Test|0002|CMS146v3|
2.16.840.1.113883.3.464.1003.198.12.1013|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1024:HbA1c Laboratory Test)|CY 2014 EP|Hemoglobin A1c Test for Pediatric Patients|Laboratory Test|0060|CMS148v3|
2.16.840.1.113883.3.464.1003.198.12.1013|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1024:HbA1c Laboratory Test)|CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Laboratory Test|0059|CMS122v3|
2.16.840.1.113883.3.464.1003.198.12.1014|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1027:Hysterectomy with No Residual Cervix),(2.16.840.1.113883.3.464.1003.198.11.1026:Hysterectomy with No Residual Cervix)|CY 2014 EP|Cervical Cancer Screening|Procedure|0032|CMS124v3|
2.16.840.1.113883.3.464.1003.198.12.1019|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1035:Total Colectomy),(2.16.840.1.113883.3.464.1003.198.11.1036:Total Colectomy)|CY 2014 EP|Colorectal Cancer Screening|Procedure|0034|CMS130v3|
2.16.840.1.113883.3.464.1003.198.12.1020|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1038:Unilateral Mastectomy),(2.16.840.1.113883.3.464.1003.198.11.1037:Unilateral Mastectomy)|CY 2014 EP|Breast Cancer Screening|Procedure|Not Applicable|CMS125v3|
2.16.840.1.113883.3.464.1003.198.12.1028|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1049:Mumps Antigen Test)|CY 2014 EP|Childhood Immunization Status|Laboratory Test|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.198.12.1029|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1050:Measles Antigen Test)|CY 2014 EP|Childhood Immunization Status|Laboratory Test|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.198.12.1030|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1051:Rubella Antigen Test)|CY 2014 EP|Childhood Immunization Status|Laboratory Test|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.198.12.1031|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1052:Hepatitis B Antigen Test)|CY 2014 EP|Childhood Immunization Status|Laboratory Test|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.198.12.1032|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1053:Varicella Zoster Antigen Test)|CY 2014 EP|Childhood Immunization Status|Laboratory Test|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.198.12.1033|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1054:Hepatitis A Antigen Test)|CY 2014 EP|Childhood Immunization Status|Laboratory Test|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.198.12.1034|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.198.11.1055:X-Ray Study (all inclusive))|CY 2014 EP|Chlamydia Screening for Women|Diagnostic Study|0033|CMS153v3|
2.16.840.1.113883.3.464.1003.199.12.1021|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.199.11.1036:Anaphylactic Reaction to Rotavirus Vaccine)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.199.12.1022|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.199.11.1039:Anaphylactic Reaction to Influenza Vaccine)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.199.12.1023|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.199.11.1042:Anaphylactic Reaction to Inactivated Polio Vaccine (IPV))|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.199.12.1024|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.199.11.1045:Anaphylactic Reaction to Neomycin)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.199.12.1025|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.199.11.1048:Anaphylactic Reaction to Polymyxin)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.199.12.1026|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.199.11.1051:Anaphylactic Reaction to Hepatitis A Vaccine)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.199.12.1027|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.199.11.1054:Anaphylactic Reaction to Pneumococcal Conjugate Vaccine)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.199.12.1028|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.199.11.1057:Anaphylactic Reaction to Streptomycin)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.199.12.1029|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.199.11.1060:Anaphylactic Reaction to Hepatitis B Vaccine)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.199.12.1030|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.199.11.1063:Anaphylactic Reaction to Hemophilus Influenza B (HiB) Vaccine)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.199.12.1031|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.199.11.1064:Anaphylactic Reaction to DTaP Vaccine)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.464.1003.199.12.1032|20140701|National Committee for Quality Assurance|Grouping|(2.16.840.1.113883.3.464.1003.199.11.1034:Anaphylactic Reaction to Common Baker's Yeast)|CY 2014 EP|Childhood Immunization Status|Condition/Diagnosis/Problem|0038|CMS117v3|
2.16.840.1.113883.3.526.2.643|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Individual Characteristic|0527|CMS171v4|
2.16.840.1.113883.3.526.2.643|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Individual Characteristic|0147|CMS188v4|
2.16.840.1.113883.3.526.2.643|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Individual Characteristic|0142|CMS100v3|
2.16.840.1.113883.3.526.2.643|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Individual Characteristic|0163|CMS53v3|
2.16.840.1.113883.3.526.2.643|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Individual Characteristic|0164|CMS60v3|
2.16.840.1.113883.3.526.2.643|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Individual Characteristic|0639|CMS30v4|
2.16.840.1.113883.3.526.2.643|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Individual Characteristic|0528|CMS172v4|
2.16.840.1.113883.3.526.2.643|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Individual Characteristic|0453|CMS178v4|
2.16.840.1.113883.3.526.3.1002|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1036:Chronic Kidney Disease, Stage 5),(2.16.840.1.113883.3.526.2.1037:Chronic Kidney Disease, Stage 5),(2.16.840.1.113883.3.526.2.1035:Chronic Kidney Disease, Stage 5)|CY 2014 EP|Controlling High Blood Pressure|Condition/Diagnosis/Problem|0018|CMS165v3|
2.16.840.1.113883.3.526.3.1003|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1039:Proteinuria),(2.16.840.1.113883.3.526.2.1040:Proteinuria),(2.16.840.1.113883.3.526.2.1038:Proteinuria)|CY 2014 EP|Diabetes: Urine Protein Screening|Condition/Diagnosis/Problem|0062|CMS134v3|
2.16.840.1.113883.3.526.3.1005|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1066:Dementia & Mental Degenerations),(2.16.840.1.113883.3.526.2.1068:Dementia & Mental Degenerations),(2.16.840.1.113883.3.526.2.1067:Dementia & Mental Degenerations)|CY 2014 EP|Dementia: Cognitive Assessment|Condition/Diagnosis/Problem|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1006|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1069:Standardized Tools for Assessment of Cognition)|CY 2014 EP|Dementia: Cognitive Assessment|Risk Category/Assessment|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Dementia: Cognitive Assessment|Intervention,Risk Category/Assessment|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Dementia: Cognitive Assessment|Intervention,Risk Category/Assessment|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Medication|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Medication,Procedure|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Medication,Procedure|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Diagnostic Study|0088|CMS167v3|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Falls: Screening for Future Fall Risk|Risk Category/Assessment|0101|CMS139v3|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Medication|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Communication|0089|CMS142v3|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Risk Category/Assessment|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Medication|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Medication|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Diagnostic Study|0086|CMS143v3|
2.16.840.1.113883.3.526.3.1007|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.313:Medical Reason)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Medication|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1008|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.311:Patient Reason)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Diagnostic Study|0088|CMS167v3|
2.16.840.1.113883.3.526.3.1008|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.311:Patient Reason)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Medication|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1008|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.311:Patient Reason)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Communication|0089|CMS142v3|
2.16.840.1.113883.3.526.3.1008|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.311:Patient Reason)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Medication|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1008|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.311:Patient Reason)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Medication|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1008|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.311:Patient Reason)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Medication|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1008|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.311:Patient Reason)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Medication|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1008|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.311:Patient Reason)|CY 2014 EP|Dementia: Cognitive Assessment|Intervention,Risk Category/Assessment|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1008|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.311:Patient Reason)|CY 2014 EP|Dementia: Cognitive Assessment|Intervention,Risk Category/Assessment|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1008|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.311:Patient Reason)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Medication,Procedure|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1008|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.311:Patient Reason)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Medication,Procedure|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1009|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.310:System Reason)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Medication|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1009|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.310:System Reason)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Medication|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1009|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.310:System Reason)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Medication|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1009|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.310:System Reason)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Medication|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1009|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.310:System Reason)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Medication,Procedure|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1009|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.310:System Reason)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Medication,Procedure|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1009|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.310:System Reason)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Medication|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1010|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1078:Cancer),(2.16.840.1.113883.3.526.2.1079:Cancer),(2.16.840.1.113883.3.526.2.1077:Cancer)|CY 2014 EP|Oncology: Medical and Radiation – Pain Intensity Quantified|Condition/Diagnosis/Problem|0384|CMS157v3|
2.16.840.1.113883.3.526.3.1011|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1063:Occupational Therapy Evaluation)|CY 2014 EP|Dementia: Cognitive Assessment|Encounter|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1011|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1063:Occupational Therapy Evaluation)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1012|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1049:Patient Provider Interaction)|CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|1365|CMS177v3|
2.16.840.1.113883.3.526.3.1012|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1049:Patient Provider Interaction)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1012|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1049:Patient Provider Interaction)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1012|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1049:Patient Provider Interaction)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Encounter|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1012|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1049:Patient Provider Interaction)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Encounter|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1012|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1049:Patient Provider Interaction)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Encounter|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1012|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1049:Patient Provider Interaction)|CY 2014 EP|Dementia: Cognitive Assessment|Encounter|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1012|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1049:Patient Provider Interaction)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Encounter|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1018|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1058:Psych Visit - Family Psychotherapy)|CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|1365|CMS177v3|
2.16.840.1.113883.3.526.3.1020|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1060:Health & Behavioral Assessment - Individual)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1023|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1064:Behavioral/Neuropsych Assessment)|CY 2014 EP|Dementia: Cognitive Assessment|Encounter|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1024|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1076:Palliative Care)|CY 2014 EP|Depression Remission at Twelve Months|Intervention|0710|CMS159v3|
2.16.840.1.113883.3.526.3.1024|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1076:Palliative Care)|CY 2014 EP|Dementia: Cognitive Assessment|Intervention|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1024|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1076:Palliative Care)|CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Intervention|0712|CMS160v3|
2.16.840.1.113883.3.526.3.1025|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1074:Severe Dementia)|CY 2014 EP|Functional Status Assessment for Knee Replacement|Condition/Diagnosis/Problem|Not Applicable|CMS66v3|
2.16.840.1.113883.3.526.3.1025|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1074:Severe Dementia)|CY 2014 EP|Functional Status Assessment for Hip Replacement|Condition/Diagnosis/Problem|Not Applicable|CMS56v3|
2.16.840.1.113883.3.526.3.1025|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1074:Severe Dementia)|CY 2014 EP|Functional Status Assessment for Complex Chronic Conditions|Condition/Diagnosis/Problem|Not Applicable|CMS90v4|
2.16.840.1.113883.3.526.3.1025|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1074:Severe Dementia)|CY 2014 EP|Dementia: Cognitive Assessment|Condition/Diagnosis/Problem|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1026|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1071:Radiation Treatment Management),(2.16.840.1.113883.3.526.2.1072:Radiation Treatment Management)|CY 2014 EP|Oncology: Medical and Radiation – Pain Intensity Quantified|Procedure|0384|CMS157v3|
2.16.840.1.113883.3.526.3.1027|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1080:Chemotherapy Administration),(2.16.840.1.113883.3.526.2.1081:Chemotherapy Administration)|CY 2014 EP|Oncology: Medical and Radiation – Pain Intensity Quantified|Procedure|0384|CMS157v3|
2.16.840.1.113883.3.526.3.1028|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1073:Standardized Pain Assessment Tool)|CY 2014 EP|Oncology: Medical and Radiation – Pain Intensity Quantified|Risk Category/Assessment|0384|CMS157v3|
2.16.840.1.113883.3.526.3.1032|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1044:Systolic Blood Pressure)|CY 2014 EP|Controlling High Blood Pressure|Physical Exam|0018|CMS165v3|
2.16.840.1.113883.3.526.3.1032|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1044:Systolic Blood Pressure)|CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Physical Exam|Not Applicable|CMS22v3|
2.16.840.1.113883.3.526.3.1032|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1044:Systolic Blood Pressure)|CY 2014 EP|Hypertension: Improvement in Blood Pressure|Physical Exam|Not Applicable|CMS65v4|
2.16.840.1.113883.3.526.3.1033|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1045:Diastolic Blood Pressure)|CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Physical Exam|Not Applicable|CMS22v3|
2.16.840.1.113883.3.526.3.1033|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1045:Diastolic Blood Pressure)|CY 2014 EP|Controlling High Blood Pressure|Physical Exam|0018|CMS165v3|
2.16.840.1.113883.3.526.3.1083|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1151:Hemodialysis),(2.16.840.1.113883.3.526.2.1150:Hemodialysis)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Procedure|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1083|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1151:Hemodialysis),(2.16.840.1.113883.3.526.2.1150:Hemodialysis)|CY 2014 EP|Hypertension: Improvement in Blood Pressure|Procedure|Not Applicable|CMS65v4|
2.16.840.1.113883.3.526.3.1084|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1153:Peritoneal Dialysis),(2.16.840.1.113883.3.526.2.1152:Peritoneal Dialysis)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Procedure|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1084|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1153:Peritoneal Dialysis),(2.16.840.1.113883.3.526.2.1152:Peritoneal Dialysis)|CY 2014 EP|Hypertension: Improvement in Blood Pressure|Procedure|Not Applicable|CMS65v4|
2.16.840.1.113883.3.526.3.1090|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.861:Moderate or Severe LVSD)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1090|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.861:Moderate or Severe LVSD)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1090|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.861:Moderate or Severe LVSD)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Condition/Diagnosis/Problem|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1091|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.859:Left Ventricular Systolic Dysfunction)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Condition/Diagnosis/Problem|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1091|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.859:Left Ventricular Systolic Dysfunction)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1091|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.859:Left Ventricular Systolic Dysfunction)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1092|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.860:Moderate or Severe)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Attribute|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1092|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.860:Moderate or Severe)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Attribute|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1092|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.860:Moderate or Severe)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Attribute|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1098|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1027:Clinical Staging Procedure)|CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Procedure|0389|CMS129v4|
2.16.840.1.113883.3.526.3.1098|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1027:Clinical Staging Procedure)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Procedure|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1098|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1027:Clinical Staging Procedure)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Procedure|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1125|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1224:Clinical Trial Participant)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Individual Characteristic|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1125|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1224:Clinical Trial Participant)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Individual Characteristic|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1134|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1238:Ejection Fraction)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Diagnostic Study|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1134|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1238:Ejection Fraction)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Diagnostic Study|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1134|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1238:Ejection Fraction)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Diagnostic Study|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1139|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.39:ACE Inhibitor or ARB)|CY 2014 EP|Diabetes: Urine Protein Screening|Medication|0062|CMS134v3|
2.16.840.1.113883.3.526.3.1139|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.39:ACE Inhibitor or ARB)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Medication|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1140|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.305:Patient Reason for ACE Inhibitor or ARB Decline)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Communication|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1141|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1243:Psychoanalysis)|CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|1365|CMS177v3|
2.16.840.1.113883.3.526.3.1141|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1243:Psychoanalysis)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1141|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1243:Psychoanalysis)|CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|0104|CMS161v3|
2.16.840.1.113883.3.526.3.1151|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1244:Renal Failure Due to ACE Inhibitor)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1164|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1389:Breast Cancer Primary Tumor Size T1a)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1170|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.422:Tobacco User)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Individual Characteristic|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1174|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.133:Beta Blocker Therapy)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Medication|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1174|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.133:Beta Blocker Therapy)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Medication|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1176|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1341:Heart Rate)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Physical Exam|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1176|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1341:Heart Rate)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Physical Exam|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1177|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1333:Allergy to Beta Blocker Therapy)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Condition/Diagnosis/Problem|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1177|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1333:Allergy to Beta Blocker Therapy)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1178|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1334:Intolerance to Beta Blocker Therapy)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1178|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1334:Intolerance to Beta Blocker Therapy)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Condition/Diagnosis/Problem|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1184|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1342:Beta Blocker Therapy for LVSD)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Medication|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1184|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1342:Beta Blocker Therapy for LVSD)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Medication|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1185|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1347:Previous Receipt of Influenza Vaccine)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Communication|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1187|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1251:Group Psychotherapy)|CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|1365|CMS177v3|
2.16.840.1.113883.3.526.3.1189|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.511:Tobacco Non-User)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Individual Characteristic|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1190|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.423:Tobacco Use Cessation Pharmacotherapy)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Medication|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1193|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.303:Cardiac Pacer)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Device|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1193|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.303:Cardiac Pacer)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Device|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1197|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1388:Breast Cancer Primary Tumor Size T1mi)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1211|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1256:Allergy to ACE Inhibitor or ARB)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1212|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1257:Intolerance to ACE Inhibitor or ARB)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Encounter|0064|CMS163v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Encounter|0075|CMS182v4|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Breast Cancer Screening|Encounter|Not Applicable|CMS125v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Anti-depressant Medication Management|Encounter|0105|CMS128v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Colorectal Cancer Screening|Encounter|0034|CMS130v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Controlling High Blood Pressure|Encounter|0018|CMS165v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Diabetes: Urine Protein Screening|Encounter|0062|CMS134v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Falls: Screening for Future Fall Risk|Encounter|0101|CMS139v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Use of High-Risk Medications in the Elderly|Encounter|0022|CMS156v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Encounter|0068|CMS164v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Encounter|0059|CMS122v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Diabetes: Foot Exam|Encounter|0056|CMS123v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Encounter|0043|CMS127v3|
2.16.840.1.113883.3.526.3.1240|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit)|CY 2014 EP|Diabetes: Eye Exam|Encounter|0055|CMS131v3|
2.16.840.1.113883.3.526.3.1241|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1344:Acute and Subacute Iridocyclitis),(2.16.840.1.113883.3.526.2.1343:Acute and Subacute Iridocyclitis),(2.16.840.1.113883.3.526.2.1509:Acute and Subacute Iridocyclitis)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1241|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1344:Acute and Subacute Iridocyclitis),(2.16.840.1.113883.3.526.2.1343:Acute and Subacute Iridocyclitis),(2.16.840.1.113883.3.526.2.1509:Acute and Subacute Iridocyclitis)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1245|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1324:Health and Behavioral Assessment - Initial)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1248|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.260:LDL-C Laboratory Test)|CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Laboratory Test|0064|CMS163v3|
2.16.840.1.113883.3.526.3.1248|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.260:LDL-C Laboratory Test)|CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Laboratory Test|0075|CMS182v4|
2.16.840.1.113883.3.526.3.1251|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1364:Macular Exam)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Diagnostic Study|0088|CMS167v3|
2.16.840.1.113883.3.526.3.1251|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1364:Macular Exam)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Diagnostic Study|0089|CMS142v3|
2.16.840.1.113883.3.526.3.1252|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.464.1003.101.11.1110:Preventive Care - Initial Office Visit, 0 to 17),(2.16.840.1.113883.3.464.1003.101.11.1125:Preventive Care Services - Established Office Visit, 18 and Up),(2.16.840.1.113883.3.464.1003.101.11.1150:Preventive Care Services - Other),(2.16.840.1.113883.3.464.1003.101.11.1080:Home Healthcare Services),(2.16.840.1.113883.3.464.1003.101.11.1216:Face-to-Face Interaction),(2.16.840.1.113883.3.464.1003.101.11.1040:Outpatient Consultation),(2.16.840.1.113883.3.464.1003.101.11.1065:Discharge Services - Nursing Facility),(2.16.840.1.113883.3.464.1003.101.11.1070:Care Services in Long-Term Residential Facility),(2.16.840.1.113883.3.464.1003.101.11.1135:Preventive Care Services - Group Counseling),(2.16.840.1.113883.3.526.2.1363:Annual Wellness Visit),(2.16.840.1.113883.3.464.1003.101.11.1120:Preventive Care - Established Office Visit, 0 to 17),(2.16.840.1.113883.3.464.1003.101.11.1060:Nursing Facility Visit),(2.16.840.1.113883.3.464.1003.101.11.1115:Preventive Care Services-Initial Office Visit, 18 and Up),(2.16.840.1.113883.3.464.1003.101.11.1130:Preventive Care Services-Individual Counseling),(2.16.840.1.113883.3.464.1003.101.11.1005:Office Visit)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Encounter|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1253|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1346:Allergy to Eggs)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Condition/Diagnosis/Problem|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1254|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1348:Influenza Vaccine)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Medication|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1255|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.461:Influenza Vaccination Declined)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Communication|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1256|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1349:Allergy to Influenza Vaccine)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Condition/Diagnosis/Problem|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1257|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1350:Intolerance to Influenza Vaccine)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Condition/Diagnosis/Problem|0041|CMS147v4|
2.16.840.1.113883.3.526.3.1259|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1353:Limited Life Expectancy)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Condition/Diagnosis/Problem|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1270|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1390:Breast Cancer Primary Tumor Size T1b)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1278|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1372:Tobacco Use Screening)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Risk Category/Assessment|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1279|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.508:ECOG Performance Status-Poor)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Individual Characteristic|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1280|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1375:Allergy to Antineoplastic Therapy)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Condition/Diagnosis/Problem|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1283|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1377:Level of Severity of Retinopathy Findings)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Attribute|0088|CMS167v3|
2.16.840.1.113883.3.526.3.1283|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1377:Level of Severity of Retinopathy Findings)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Communication|0089|CMS142v3|
2.16.840.1.113883.3.526.3.1284|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1373:Macular Edema Findings Absent)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Attribute|0088|CMS167v3|
2.16.840.1.113883.3.526.3.1284|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1373:Macular Edema Findings Absent)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Communication|0089|CMS142v3|
2.16.840.1.113883.3.526.3.1285|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.111:Ophthalmological Services)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1285|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.111:Ophthalmological Services)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Encounter|0089|CMS142v3|
2.16.840.1.113883.3.526.3.1285|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.111:Ophthalmological Services)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Encounter|0088|CMS167v3|
2.16.840.1.113883.3.526.3.1285|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.111:Ophthalmological Services)|CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Encounter|0086|CMS143v3|
2.16.840.1.113883.3.526.3.1287|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1382:Intolerance to Antineoplastic Therapy)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Condition/Diagnosis/Problem|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1288|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1025:Chemotherapy for Colon Cancer - Capecitabine)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Medication|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1289|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1023:Chemotherapy for Colon Cancer - Fluorouracil)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Medication|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1290|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1024:Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Medication|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1291|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1026:Chemotherapy for Colon Cancer - Oxaliplatin)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Medication|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1292|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1002:Colon Cancer Primary Tumor Size T1)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1293|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1003:Colon Cancer Primary Tumor Size T2)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1294|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1004:Colon Cancer Primary Tumor Size T3)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1295|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1005:Colon Cancer Primary Tumor Size T4a)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1296|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1006:Colon Cancer Primary Tumor Size T4b)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1297|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1007:Colon Cancer Regional Lymph Node Status N1)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1298|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1008:Colon Cancer Regional Lymph Node Status N1c)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1299|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1011:Colon Cancer Regional Lymph Node Status N2)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1300|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1009:Colon Cancer Regional Lymph Node Status N2a)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1301|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1010:Colon Cancer Regional Lymph Node Status N2b)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1302|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1012:Breast Distant Metastasis Status M0)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1303|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1387:Breast Cancer ER or PR Positive)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Condition/Diagnosis/Problem|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1304|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1013:Breast Cancer Primary Tumor Size T0)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1305|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1015:Breast Cancer Primary Tumor Size T1)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1306|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1014:Breast Cancer Primary Tumor Size T1c)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1307|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1016:Breast Cancer Primary Tumor Size T2)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1308|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1017:Breast Cancer Primary Tumor Size T3)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1309|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1018:Breast Cancer Primary Tumor Size T4)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1310|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1019:Breast Cancer Regional Lymph Node Status N0)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1311|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1021:Breast Cancer Regional Lymph Node Status pN1a)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1312|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1020:Breast Cancer Regional Lymph Node Status pN1mi)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1313|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1022:Breast Cancer Regional Lymph Node Status N2)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1314|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1028:Breast Cancer Regional Lymph Node Status N3)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1315|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.285:Tamoxifen or Aromatase Inhibitor Therapy)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Medication|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1316|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.467:Gonadotropin-Releasing Hormone Analogue Medication)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Medication|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1317|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1383:Allergy to Tamoxifen or Aromatase Inhibitor Therapy)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Condition/Diagnosis/Problem|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1318|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1384:Intolerance to Tamoxifen or Aromatase Inhibitor Therapy)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Condition/Diagnosis/Problem|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1320|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1381:Macular Edema Findings Present)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Attribute|0088|CMS167v3|
2.16.840.1.113883.3.526.3.1320|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1381:Macular Edema Findings Present)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Communication|0089|CMS142v3|
2.16.840.1.113883.3.526.3.1325|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1394:Prostate Cancer Primary Tumor Size T1c)|CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Attribute|0389|CMS129v4|
2.16.840.1.113883.3.526.3.1326|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1395:Prostate Cancer Primary Tumor Size T2a)|CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Attribute|0389|CMS129v4|
2.16.840.1.113883.3.526.3.1327|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1396:Colon Cancer Regional Lymph Node Status N1a)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1328|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1397:Colon Cancer Regional Lymph Node Status N1b)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1329|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1398:Breast Cancer Regional Lymph Node Status N1)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1330|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1399:Breast Cancer Regional Lymph Node Status pN1b)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1331|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1400:Breast Cancer Regional Lymph Node Status pN1c)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Attribute|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1332|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1401:Cognitive Assessment)|CY 2014 EP|Dementia: Cognitive Assessment|Intervention|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1333|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1402:Cup to Disc Ratio)|CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Diagnostic Study|0086|CMS143v3|
2.16.840.1.113883.3.526.3.1334|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1403:Optic Disc Exam for Structural Abnormalities)|CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Diagnostic Study|0086|CMS143v3|
2.16.840.1.113883.3.526.3.1337|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1406:Colon Distant Metastasis Status M0)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Attribute|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1339|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1409:Radiation Therapy II),(2.16.840.1.113883.3.526.2.1408:Radiation Therapy II)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Procedure|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1405|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1510:Adhesions and Disruptions of Iris and Ciliary Body),(2.16.840.1.113883.3.526.2.1512:Adhesions and Disruptions of Iris and Ciliary Body),(2.16.840.1.113883.3.526.2.1511:Adhesions and Disruptions of Iris and Ciliary Body)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1406|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1513:Anomalies of Puillary Function),(2.16.840.1.113883.3.526.2.1514:Anomalies of Puillary Function),(2.16.840.1.113883.3.526.2.1515:Anomalies of Puillary Function)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1407|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1518:Aphakia and Other Disorders of Lens),(2.16.840.1.113883.3.526.2.1517:Aphakia and Other Disorders of Lens),(2.16.840.1.113883.3.526.2.1516:Aphakia and Other Disorders of Lens)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1408|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1519:Aspiration and Injection Procedures),(2.16.840.1.113883.3.526.2.1520:Aspiration and Injection Procedures)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Procedure|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1409|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1522:Burn Confined to Eye and Adnexa),(2.16.840.1.113883.3.526.2.1521:Burn Confined to Eye and Adnexa),(2.16.840.1.113883.3.526.2.1523:Burn Confined to Eye and Adnexa)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1409|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1522:Burn Confined to Eye and Adnexa),(2.16.840.1.113883.3.526.2.1521:Burn Confined to Eye and Adnexa),(2.16.840.1.113883.3.526.2.1523:Burn Confined to Eye and Adnexa)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1410|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1526:Cataract Secondary to Ocular Disorders),(2.16.840.1.113883.3.526.2.1525:Cataract Secondary to Ocular Disorders),(2.16.840.1.113883.3.526.2.1524:Cataract Secondary to Ocular Disorders)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1410|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1526:Cataract Secondary to Ocular Disorders),(2.16.840.1.113883.3.526.2.1525:Cataract Secondary to Ocular Disorders),(2.16.840.1.113883.3.526.2.1524:Cataract Secondary to Ocular Disorders)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1411|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1527:Cataract Surgery),(2.16.840.1.113883.3.526.2.1528:Cataract Surgery)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Procedure|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1411|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1527:Cataract Surgery),(2.16.840.1.113883.3.526.2.1528:Cataract Surgery)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Procedure|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1412|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1529:Cataract, Congenital),(2.16.840.1.113883.3.526.2.1530:Cataract, Congenital),(2.16.840.1.113883.3.526.2.1531:Cataract, Congenital)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1413|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1533:Cataract, Mature or Hypermature),(2.16.840.1.113883.3.526.2.1534:Cataract, Mature or Hypermature),(2.16.840.1.113883.3.526.2.1532:Cataract, Mature or Hypermature)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1414|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1537:Cataract, Posterior Polar),(2.16.840.1.113883.3.526.2.1536:Cataract, Posterior Polar),(2.16.840.1.113883.3.526.2.1535:Cataract, Posterior Polar)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1415|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1538:Certain Types of Iridocyclitis),(2.16.840.1.113883.3.526.2.1539:Certain Types of Iridocyclitis),(2.16.840.1.113883.3.526.2.1540:Certain Types of Iridocyclitis)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1415|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1538:Certain Types of Iridocyclitis),(2.16.840.1.113883.3.526.2.1539:Certain Types of Iridocyclitis),(2.16.840.1.113883.3.526.2.1540:Certain Types of Iridocyclitis)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1416|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1541:Chronic Iridocyclitis),(2.16.840.1.113883.3.526.2.1542:Chronic Iridocyclitis),(2.16.840.1.113883.3.526.2.1543:Chronic Iridocyclitis)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1416|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1541:Chronic Iridocyclitis),(2.16.840.1.113883.3.526.2.1542:Chronic Iridocyclitis),(2.16.840.1.113883.3.526.2.1543:Chronic Iridocyclitis)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1417|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1544:Cloudy Cornea),(2.16.840.1.113883.3.526.2.1546:Cloudy Cornea),(2.16.840.1.113883.3.526.2.1545:Cloudy Cornea)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1417|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1544:Cloudy Cornea),(2.16.840.1.113883.3.526.2.1546:Cloudy Cornea),(2.16.840.1.113883.3.526.2.1545:Cloudy Cornea)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1418|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1549:Corneal Edema),(2.16.840.1.113883.3.526.2.1548:Corneal Edema),(2.16.840.1.113883.3.526.2.1547:Corneal Edema)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1418|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1549:Corneal Edema),(2.16.840.1.113883.3.526.2.1548:Corneal Edema),(2.16.840.1.113883.3.526.2.1547:Corneal Edema)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1419|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1552:Corneal Opacity and Other Disorders of Cornea),(2.16.840.1.113883.3.526.2.1550:Corneal Opacity and Other Disorders of Cornea),(2.16.840.1.113883.3.526.2.1551:Corneal Opacity and Other Disorders of Cornea)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1419|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1552:Corneal Opacity and Other Disorders of Cornea),(2.16.840.1.113883.3.526.2.1550:Corneal Opacity and Other Disorders of Cornea),(2.16.840.1.113883.3.526.2.1551:Corneal Opacity and Other Disorders of Cornea)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1420|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1554:Cysts of Iris, Ciliary Body, and Anterior Chamber),(2.16.840.1.113883.3.526.2.1555:Cysts of Iris, Ciliary Body, and Anterior Chamber),(2.16.840.1.113883.3.526.2.1553:Cysts of Iris, Ciliary Body, and Anterior Chamber)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1421|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1557:Enophthalmos),(2.16.840.1.113883.3.526.2.1558:Enophthalmos),(2.16.840.1.113883.3.526.2.1556:Enophthalmos)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1422|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1560:Excision of Adhesions),(2.16.840.1.113883.3.526.2.1559:Excision of Adhesions)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Procedure|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1423|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1562:Glaucoma),(2.16.840.1.113883.3.526.2.1563:Glaucoma),(2.16.840.1.113883.3.526.2.1561:Glaucoma)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1423|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1562:Glaucoma),(2.16.840.1.113883.3.526.2.1563:Glaucoma),(2.16.840.1.113883.3.526.2.1561:Glaucoma)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1424|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1565:Hereditary Corneal Dystrophies),(2.16.840.1.113883.3.526.2.1564:Hereditary Corneal Dystrophies),(2.16.840.1.113883.3.526.2.1566:Hereditary Corneal Dystrophies)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1424|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1565:Hereditary Corneal Dystrophies),(2.16.840.1.113883.3.526.2.1564:Hereditary Corneal Dystrophies),(2.16.840.1.113883.3.526.2.1566:Hereditary Corneal Dystrophies)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1425|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1568:High Hyperopia),(2.16.840.1.113883.3.526.2.1567:High Hyperopia),(2.16.840.1.113883.3.526.2.1569:High Hyperopia)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1426|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1570:Hypotony of Eye),(2.16.840.1.113883.3.526.2.1571:Hypotony of Eye),(2.16.840.1.113883.3.526.2.1572:Hypotony of Eye)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1427|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1573:Injury to Optic Nerve and Pathways),(2.16.840.1.113883.3.526.2.1574:Injury to Optic Nerve and Pathways),(2.16.840.1.113883.3.526.2.1575:Injury to Optic Nerve and Pathways)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1427|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1573:Injury to Optic Nerve and Pathways),(2.16.840.1.113883.3.526.2.1574:Injury to Optic Nerve and Pathways),(2.16.840.1.113883.3.526.2.1575:Injury to Optic Nerve and Pathways)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1428|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1578:Central Corneal Ulcer),(2.16.840.1.113883.3.526.2.1577:Central Corneal Ulcer),(2.16.840.1.113883.3.526.2.1576:Central Corneal Ulcer)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1428|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1578:Central Corneal Ulcer),(2.16.840.1.113883.3.526.2.1577:Central Corneal Ulcer),(2.16.840.1.113883.3.526.2.1576:Central Corneal Ulcer)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1429|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1580:Lens Procedure),(2.16.840.1.113883.3.526.2.1579:Lens Procedure)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Procedure|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1430|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1582:Open Wound of Eyeball),(2.16.840.1.113883.3.526.2.1581:Open Wound of Eyeball),(2.16.840.1.113883.3.526.2.1583:Open Wound of Eyeball)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1430|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1582:Open Wound of Eyeball),(2.16.840.1.113883.3.526.2.1581:Open Wound of Eyeball),(2.16.840.1.113883.3.526.2.1583:Open Wound of Eyeball)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1432|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1587:Pathologic Myopia),(2.16.840.1.113883.3.526.2.1588:Pathologic Myopia),(2.16.840.1.113883.3.526.2.1586:Pathologic Myopia)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1432|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1587:Pathologic Myopia),(2.16.840.1.113883.3.526.2.1588:Pathologic Myopia),(2.16.840.1.113883.3.526.2.1586:Pathologic Myopia)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1433|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1591:Posterior Lenticonus),(2.16.840.1.113883.3.526.2.1590:Posterior Lenticonus),(2.16.840.1.113883.3.526.2.1589:Posterior Lenticonus)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1434|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1592:Prior Pars Plana Vitrectomy),(2.16.840.1.113883.3.526.2.1593:Prior Pars Plana Vitrectomy)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Procedure|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1435|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1594:Pseudoexfoliation Syndrome),(2.16.840.1.113883.3.526.2.1596:Pseudoexfoliation Syndrome),(2.16.840.1.113883.3.526.2.1595:Pseudoexfoliation Syndrome)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1436|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1598:Removal Procedures),(2.16.840.1.113883.3.526.2.1597:Removal Procedures)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Procedure|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1437|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1600:Retinal Repair Procedures),(2.16.840.1.113883.3.526.2.1599:Retinal Repair Procedures)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Procedure|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1438|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1601:Retrolental Fibroplasias),(2.16.840.1.113883.3.526.2.1603:Retrolental Fibroplasias),(2.16.840.1.113883.3.526.2.1602:Retrolental Fibroplasias)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1439|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1605:Revision Procedures),(2.16.840.1.113883.3.526.2.1604:Revision Procedures)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Procedure|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1440|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1606:Scleral Procedures),(2.16.840.1.113883.3.526.2.1607:Scleral Procedures)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Procedure|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1441|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1609:Senile Cataract),(2.16.840.1.113883.3.526.2.1610:Senile Cataract),(2.16.840.1.113883.3.526.2.1608:Senile Cataract)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1442|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1611:Use of Systemic Sympathetic alpha-1a Antagonist Medication for Treatment of Prostatic Hypertrophy)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Medication|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1443|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1612:Traumatic Cataract),(2.16.840.1.113883.3.526.2.1613:Traumatic Cataract),(2.16.840.1.113883.3.526.2.1614:Traumatic Cataract)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1444|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1617:Uveitis),(2.16.840.1.113883.3.526.2.1616:Uveitis),(2.16.840.1.113883.3.526.2.1615:Uveitis)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1444|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1617:Uveitis),(2.16.840.1.113883.3.526.2.1616:Uveitis),(2.16.840.1.113883.3.526.2.1615:Uveitis)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1445|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1620:Vascular Disorders of Iris and Ciliary Body),(2.16.840.1.113883.3.526.2.1618:Vascular Disorders of Iris and Ciliary Body),(2.16.840.1.113883.3.526.2.1619:Vascular Disorders of Iris and Ciliary Body)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Condition/Diagnosis/Problem|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1446|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1623:Visual Field Defects),(2.16.840.1.113883.3.526.2.1622:Visual Field Defects),(2.16.840.1.113883.3.526.2.1621:Visual Field Defects)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1447|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1625:Vitreous Procedures),(2.16.840.1.113883.3.526.2.1624:Vitreous Procedures)|CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Procedure|0564|CMS132v3|
2.16.840.1.113883.3.526.3.1448|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1626:Amblyopia),(2.16.840.1.113883.3.526.2.1628:Amblyopia),(2.16.840.1.113883.3.526.2.1627:Amblyopia)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1449|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1630:Chorioretinal Scars),(2.16.840.1.113883.3.526.2.1631:Chorioretinal Scars),(2.16.840.1.113883.3.526.2.1629:Chorioretinal Scars)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1450|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1633:Choroidal Degenerations),(2.16.840.1.113883.3.526.2.1632:Choroidal Degenerations),(2.16.840.1.113883.3.526.2.1634:Choroidal Degenerations)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1451|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1636:Choroidal Detachment),(2.16.840.1.113883.3.526.2.1635:Choroidal Detachment),(2.16.840.1.113883.3.526.2.1637:Choroidal Detachment)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1452|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1639:Choroidal Hemorrhage and Rupture),(2.16.840.1.113883.3.526.2.1640:Choroidal Hemorrhage and Rupture),(2.16.840.1.113883.3.526.2.1638:Choroidal Hemorrhage and Rupture)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1453|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1641:Degeneration of Macula and Posterior Pole),(2.16.840.1.113883.3.526.2.1642:Degeneration of Macula and Posterior Pole),(2.16.840.1.113883.3.526.2.1643:Degeneration of Macula and Posterior Pole)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1454|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1644:Degenerative Disorders of Globe),(2.16.840.1.113883.3.526.2.1645:Degenerative Disorders of Globe),(2.16.840.1.113883.3.526.2.1646:Degenerative Disorders of Globe)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1455|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1647:Diabetic Macular Edema),(2.16.840.1.113883.3.526.2.1648:Diabetic Macular Edema),(2.16.840.1.113883.3.526.2.1649:Diabetic Macular Edema)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1457|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1654:Disorders of Optic Chiasm),(2.16.840.1.113883.3.526.2.1653:Disorders of Optic Chiasm),(2.16.840.1.113883.3.526.2.1655:Disorders of Optic Chiasm)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1458|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1657:Disorders of Visual Cortex),(2.16.840.1.113883.3.526.2.1658:Disorders of Visual Cortex),(2.16.840.1.113883.3.526.2.1656:Disorders of Visual Cortex)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1459|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1660:Disseminated Chorioretinitis and Disseminated Retinochoroiditis),(2.16.840.1.113883.3.526.2.1661:Disseminated Chorioretinitis and Disseminated Retinochoroiditis),(2.16.840.1.113883.3.526.2.1659:Disseminated Chorioretinitis and Disseminated Retinochoroiditis)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1460|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1663:Focal Chorioretinitis and Focal Retinochoroiditis),(2.16.840.1.113883.3.526.2.1662:Focal Chorioretinitis and Focal Retinochoroiditis),(2.16.840.1.113883.3.526.2.1664:Focal Chorioretinitis and Focal Retinochoroiditis)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1461|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1666:Glaucoma Associated with Congenital Anomalies, Dystrophies, and Systemic Syndromes),(2.16.840.1.113883.3.526.2.1665:Glaucoma Associated with Congenital Anomalies, Dystrophies, and Systemic Syndromes),(2.16.840.1.113883.3.526.2.1667:Glaucoma Associated with Congenital Anomalies, Dystrophies, and Systemic Syndromes)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1462|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1668:Hereditary Choroidal Dystrophies),(2.16.840.1.113883.3.526.2.1670:Hereditary Choroidal Dystrophies),(2.16.840.1.113883.3.526.2.1669:Hereditary Choroidal Dystrophies)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1463|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1671:Hereditary Retinal Dystrophies),(2.16.840.1.113883.3.526.2.1672:Hereditary Retinal Dystrophies),(2.16.840.1.113883.3.526.2.1673:Hereditary Retinal Dystrophies)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1464|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1675:Moderate or Severe Impairment, Better Eye, Profound Impairment Lesser Eye),(2.16.840.1.113883.3.526.2.1676:Moderate or Severe Impairment, Better Eye, Profound Impairment Lesser Eye),(2.16.840.1.113883.3.526.2.1674:Moderate or Severe Impairment, Better Eye, Profound Impairment Lesser Eye)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1465|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1677:Nystagmus and Other Irregular Eye Movements),(2.16.840.1.113883.3.526.2.1678:Nystagmus and Other Irregular Eye Movements),(2.16.840.1.113883.3.526.2.1679:Nystagmus and Other Irregular Eye Movements)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1466|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1680:Optic Atrophy),(2.16.840.1.113883.3.526.2.1682:Optic Atrophy),(2.16.840.1.113883.3.526.2.1681:Optic Atrophy)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1467|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1684:Optic Neuritis),(2.16.840.1.113883.3.526.2.1683:Optic Neuritis),(2.16.840.1.113883.3.526.2.1685:Optic Neuritis)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1468|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1686:Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis),(2.16.840.1.113883.3.526.2.1688:Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis),(2.16.840.1.113883.3.526.2.1687:Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1469|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1691:Other Background Retinopathy and Retinal Vascular Changes),(2.16.840.1.113883.3.526.2.1689:Other Background Retinopathy and Retinal Vascular Changes),(2.16.840.1.113883.3.526.2.1690:Other Background Retinopathy and Retinal Vascular Changes)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1470|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1692:Other Corneal Deformities),(2.16.840.1.113883.3.526.2.1693:Other Corneal Deformities),(2.16.840.1.113883.3.526.2.1694:Other Corneal Deformities)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1471|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1695:Other Disorders of Optic Nerve),(2.16.840.1.113883.3.526.2.1697:Other Disorders of Optic Nerve),(2.16.840.1.113883.3.526.2.1696:Other Disorders of Optic Nerve)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1472|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1700:Other Disorders of Sclera),(2.16.840.1.113883.3.526.2.1699:Other Disorders of Sclera),(2.16.840.1.113883.3.526.2.1698:Other Disorders of Sclera)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1473|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1701:Other Endophthalmitis),(2.16.840.1.113883.3.526.2.1702:Other Endophthalmitis),(2.16.840.1.113883.3.526.2.1703:Other Endophthalmitis)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1474|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1704:Other Retinal Disorders),(2.16.840.1.113883.3.526.2.1705:Other Retinal Disorders),(2.16.840.1.113883.3.526.2.1706:Other Retinal Disorders)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1475|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1709:Prior Penetrating Keratoplasty),(2.16.840.1.113883.3.526.2.1707:Prior Penetrating Keratoplasty),(2.16.840.1.113883.3.526.2.1708:Prior Penetrating Keratoplasty)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1476|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1710:Profound Impairment, Both Eyes),(2.16.840.1.113883.3.526.2.1711:Profound Impairment, Both Eyes),(2.16.840.1.113883.3.526.2.1712:Profound Impairment, Both Eyes)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1477|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1714:Purulent Endophthalmitis),(2.16.840.1.113883.3.526.2.1715:Purulent Endophthalmitis),(2.16.840.1.113883.3.526.2.1713:Purulent Endophthalmitis)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1478|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1718:Retinal Detachment with Retinal Defect),(2.16.840.1.113883.3.526.2.1717:Retinal Detachment with Retinal Defect),(2.16.840.1.113883.3.526.2.1716:Retinal Detachment with Retinal Defect)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1479|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1721:Retinal Vascular Occlusion),(2.16.840.1.113883.3.526.2.1719:Retinal Vascular Occlusion),(2.16.840.1.113883.3.526.2.1720:Retinal Vascular Occlusion)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1480|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1724:Other Proliferative Retinopathy),(2.16.840.1.113883.3.526.2.1722:Other Proliferative Retinopathy),(2.16.840.1.113883.3.526.2.1723:Other Proliferative Retinopathy)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1481|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1727:Scleritis and Episcleritis),(2.16.840.1.113883.3.526.2.1726:Scleritis and Episcleritis),(2.16.840.1.113883.3.526.2.1725:Scleritis and Episcleritis)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1482|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1729:Separation of Retinal Layers),(2.16.840.1.113883.3.526.2.1728:Separation of Retinal Layers),(2.16.840.1.113883.3.526.2.1730:Separation of Retinal Layers)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1483|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1731:Visual Acuity 20/40 or Better)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Attribute|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1484|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1732:Suicide Risk Assessment)|CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Intervention|0104|CMS161v3|
2.16.840.1.113883.3.526.3.1484|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1732:Suicide Risk Assessment)|CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Intervention|1365|CMS177v3|
2.16.840.1.113883.3.526.3.1485|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1914:Chemotherapy for Colon Cancer - Capecitabine Ingredient)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Medication|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1486|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1915:Chemotherapy for Colon Cancer - Fluorouracil Ingredient)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Medication|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1487|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1913:Tamoxifen or Aromatase Inhibitor Therapy Ingredient)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Medication|0387|CMS140v3|
2.16.840.1.113883.3.526.3.1488|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1920:Best Corrected Visual Acuity)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Physical Exam|0565|CMS133v3|
2.16.840.1.113883.3.526.3.1489|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1926:ACE Inhibitor or ARB Ingredient)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Medication|0081|CMS135v3|
2.16.840.1.113883.3.526.3.1490|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1916:Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin Ingredient)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Medication|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1491|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1918:Major Depressive Disorder-Active),(2.16.840.1.113883.3.526.2.1922:Major Depressive Disorder-Active),(2.16.840.1.113883.3.526.2.1912:Major Depressive Disorder-Active)|CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Condition/Diagnosis/Problem|0104|CMS161v3|
2.16.840.1.113883.3.526.3.1491|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1918:Major Depressive Disorder-Active),(2.16.840.1.113883.3.526.2.1922:Major Depressive Disorder-Active),(2.16.840.1.113883.3.526.2.1912:Major Depressive Disorder-Active)|CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Condition/Diagnosis/Problem|1365|CMS177v3|
2.16.840.1.113883.3.526.3.1492|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1923:Psych Visit - Diagnostic Evaluation)|CY 2014 EP|Anti-depressant Medication Management|Encounter|0105|CMS128v3|
2.16.840.1.113883.3.526.3.1492|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1923:Psych Visit - Diagnostic Evaluation)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.526.3.1492|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1923:Psych Visit - Diagnostic Evaluation)|CY 2014 EP|Dementia: Cognitive Assessment|Encounter|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1492|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1923:Psych Visit - Diagnostic Evaluation)|CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|1365|CMS177v3|
2.16.840.1.113883.3.526.3.1492|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1923:Psych Visit - Diagnostic Evaluation)|CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|0104|CMS161v3|
2.16.840.1.113883.3.526.3.1492|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1923:Psych Visit - Diagnostic Evaluation)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.526.3.1493|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1921:Beta Blocker Therapy Ingredient)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Medication|0070|CMS145v3|
2.16.840.1.113883.3.526.3.1493|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1921:Beta Blocker Therapy Ingredient)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Medication|0083|CMS144v3|
2.16.840.1.113883.3.526.3.1494|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1925:Reason Documented)|CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Attribute|0389|CMS129v4|
2.16.840.1.113883.3.526.3.1495|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1917:Chemotherapy for Colon Cancer - Oxaliplatin Ingredient)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Medication|0385|CMS141v4|
2.16.840.1.113883.3.526.3.1496|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1927:Psych Visit - Psychotherapy)|CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|1365|CMS177v3|
2.16.840.1.113883.3.526.3.1496|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1927:Psych Visit - Psychotherapy)|CY 2014 EP|Anti-depressant Medication Management|Encounter|0105|CMS128v3|
2.16.840.1.113883.3.526.3.1496|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1927:Psych Visit - Psychotherapy)|CY 2014 EP|Dementia: Cognitive Assessment|Encounter|Not Applicable|CMS149v3|
2.16.840.1.113883.3.526.3.1496|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1927:Psych Visit - Psychotherapy)|CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Encounter|0104|CMS161v3|
2.16.840.1.113883.3.526.3.1496|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1927:Psych Visit - Psychotherapy)|CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Encounter|0108|CMS136v4|
2.16.840.1.113883.3.526.3.1496|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1927:Psych Visit - Psychotherapy)|CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Encounter|0004|CMS137v3|
2.16.840.1.113883.3.526.3.1496|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1927:Psych Visit - Psychotherapy)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Encounter|0028|CMS138v3|
2.16.840.1.113883.3.526.3.319|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.90:Prostate Cancer),(2.16.840.1.113883.3.526.2.92:Prostate Cancer),(2.16.840.1.113883.3.526.2.91:Prostate Cancer)|CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Condition/Diagnosis/Problem|0389|CMS129v4|
2.16.840.1.113883.3.526.3.320|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.1374:Bone Scan)|CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Diagnostic Study|0389|CMS129v4|
2.16.840.1.113883.3.526.3.326|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.73:Primary Open-Angle Glaucoma),(2.16.840.1.113883.3.526.2.74:Primary Open-Angle Glaucoma),(2.16.840.1.113883.3.526.2.72:Primary Open-Angle Glaucoma)|CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Condition/Diagnosis/Problem|0086|CMS143v3|
2.16.840.1.113883.3.526.3.327|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.80:Diabetic Retinopathy),(2.16.840.1.113883.3.526.2.78:Diabetic Retinopathy),(2.16.840.1.113883.3.526.2.76:Diabetic Retinopathy)|CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Condition/Diagnosis/Problem|0565|CMS133v3|
2.16.840.1.113883.3.526.3.327|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.80:Diabetic Retinopathy),(2.16.840.1.113883.3.526.2.78:Diabetic Retinopathy),(2.16.840.1.113883.3.526.2.76:Diabetic Retinopathy)|CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Condition/Diagnosis/Problem|0088|CMS167v3|
2.16.840.1.113883.3.526.3.327|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.80:Diabetic Retinopathy),(2.16.840.1.113883.3.526.2.78:Diabetic Retinopathy),(2.16.840.1.113883.3.526.2.76:Diabetic Retinopathy)|CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Condition/Diagnosis/Problem|0089|CMS142v3|
2.16.840.1.113883.3.526.3.353|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.589:End Stage Renal Disease),(2.16.840.1.113883.3.526.2.591:End Stage Renal Disease),(2.16.840.1.113883.3.526.2.590:End Stage Renal Disease)|CY 2014 EP|Controlling High Blood Pressure|Condition/Diagnosis/Problem|0018|CMS165v3|
2.16.840.1.113883.3.526.3.353|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.589:End Stage Renal Disease),(2.16.840.1.113883.3.526.2.591:End Stage Renal Disease),(2.16.840.1.113883.3.526.2.590:End Stage Renal Disease)|CY 2014 EP|Hypertension: Improvement in Blood Pressure|Condition/Diagnosis/Problem|Not Applicable|CMS65v4|
2.16.840.1.113883.3.526.3.362|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.60:Asthma),(2.16.840.1.113883.3.526.2.59:Asthma),(2.16.840.1.113883.3.526.2.61:Asthma)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Condition/Diagnosis/Problem|0070|CMS145v3|
2.16.840.1.113883.3.526.3.362|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.60:Asthma),(2.16.840.1.113883.3.526.2.59:Asthma),(2.16.840.1.113883.3.526.2.61:Asthma)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0083|CMS144v3|
2.16.840.1.113883.3.526.3.366|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.186:Arrhythmia),(2.16.840.1.113883.3.526.2.176:Arrhythmia),(2.16.840.1.113883.3.526.2.181:Arrhythmia)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0083|CMS144v3|
2.16.840.1.113883.3.526.3.366|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.186:Arrhythmia),(2.16.840.1.113883.3.526.2.176:Arrhythmia),(2.16.840.1.113883.3.526.2.181:Arrhythmia)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Condition/Diagnosis/Problem|0070|CMS145v3|
2.16.840.1.113883.3.526.3.367|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.177:Atrioventricular Block),(2.16.840.1.113883.3.526.2.264:Atrioventricular Block),(2.16.840.1.113883.3.526.2.187:Atrioventricular Block)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0083|CMS144v3|
2.16.840.1.113883.3.526.3.367|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.177:Atrioventricular Block),(2.16.840.1.113883.3.526.2.264:Atrioventricular Block),(2.16.840.1.113883.3.526.2.187:Atrioventricular Block)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Condition/Diagnosis/Problem|0070|CMS145v3|
2.16.840.1.113883.3.526.3.368|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.183:Cardiac Pacer in Situ),(2.16.840.1.113883.3.526.2.1924:Cardiac Pacer in Situ),(2.16.840.1.113883.3.526.2.178:Cardiac Pacer in Situ)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Condition/Diagnosis/Problem|0070|CMS145v3|
2.16.840.1.113883.3.526.3.368|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.183:Cardiac Pacer in Situ),(2.16.840.1.113883.3.526.2.1924:Cardiac Pacer in Situ),(2.16.840.1.113883.3.526.2.178:Cardiac Pacer in Situ)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0083|CMS144v3|
2.16.840.1.113883.3.526.3.369|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.56:Coronary Artery Disease No MI),(2.16.840.1.113883.3.526.2.120:Coronary Artery Disease No MI),(2.16.840.1.113883.3.526.2.57:Coronary Artery Disease No MI)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Condition/Diagnosis/Problem|0070|CMS145v3|
2.16.840.1.113883.3.526.3.370|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.185:Hypotension),(2.16.840.1.113883.3.526.2.175:Hypotension),(2.16.840.1.113883.3.526.2.180:Hypotension)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Condition/Diagnosis/Problem|0070|CMS145v3|
2.16.840.1.113883.3.526.3.370|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.185:Hypotension),(2.16.840.1.113883.3.526.2.175:Hypotension),(2.16.840.1.113883.3.526.2.180:Hypotension)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0083|CMS144v3|
2.16.840.1.113883.3.526.3.371|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.168:Cardiac Surgery),(2.16.840.1.113883.3.526.2.169:Cardiac Surgery)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Procedure|0070|CMS145v3|
2.16.840.1.113883.3.526.3.376|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.24:Heart Failure),(2.16.840.1.113883.3.526.2.25:Heart Failure),(2.16.840.1.113883.3.526.2.23:Heart Failure)|CY 2014 EP|Functional Status Assessment for Complex Chronic Conditions|Condition/Diagnosis/Problem|Not Applicable|CMS90v4|
2.16.840.1.113883.3.526.3.376|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.24:Heart Failure),(2.16.840.1.113883.3.526.2.25:Heart Failure),(2.16.840.1.113883.3.526.2.23:Heart Failure)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0081|CMS135v3|
2.16.840.1.113883.3.526.3.376|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.24:Heart Failure),(2.16.840.1.113883.3.526.2.25:Heart Failure),(2.16.840.1.113883.3.526.2.23:Heart Failure)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0083|CMS144v3|
2.16.840.1.113883.3.526.3.378|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.243:Pregnancy),(2.16.840.1.113883.3.526.2.532:Pregnancy),(2.16.840.1.113883.3.526.2.242:Pregnancy)|CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Condition/Diagnosis/Problem|0024|CMS155v3|
2.16.840.1.113883.3.526.3.378|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.243:Pregnancy),(2.16.840.1.113883.3.526.2.532:Pregnancy),(2.16.840.1.113883.3.526.2.242:Pregnancy)|CY 2014 EP|Hypertension: Improvement in Blood Pressure|Condition/Diagnosis/Problem|Not Applicable|CMS65v4|
2.16.840.1.113883.3.526.3.378|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.243:Pregnancy),(2.16.840.1.113883.3.526.2.532:Pregnancy),(2.16.840.1.113883.3.526.2.242:Pregnancy)|CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0081|CMS135v3|
2.16.840.1.113883.3.526.3.378|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.243:Pregnancy),(2.16.840.1.113883.3.526.2.532:Pregnancy),(2.16.840.1.113883.3.526.2.242:Pregnancy)|CY 2014 EP|Controlling High Blood Pressure|Condition/Diagnosis/Problem|0018|CMS165v3|
2.16.840.1.113883.3.526.3.389|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.97:Breast Cancer),(2.16.840.1.113883.3.526.2.98:Breast Cancer),(2.16.840.1.113883.3.526.2.96:Breast Cancer)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Condition/Diagnosis/Problem|0387|CMS140v3|
2.16.840.1.113883.3.526.3.391|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.316:Colon Cancer),(2.16.840.1.113883.3.526.2.344:Colon Cancer),(2.16.840.1.113883.3.526.2.345:Colon Cancer)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Condition/Diagnosis/Problem|0385|CMS141v4|
2.16.840.1.113883.3.526.3.397|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.282:Gleason Score)|CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Laboratory Test|0389|CMS129v4|
2.16.840.1.113883.3.526.3.398|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.213:Prostate Cancer Treatment),(2.16.840.1.113883.3.526.2.113:Prostate Cancer Treatment)|CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Procedure|0389|CMS129v4|
2.16.840.1.113883.3.526.3.399|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.323:Salvage Therapy),(2.16.840.1.113883.3.526.2.324:Salvage Therapy)|CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Procedure|0389|CMS129v4|
2.16.840.1.113883.3.526.3.401|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.215:Prostate Specific Antigen Test)|CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Laboratory Test|0389|CMS129v4|
2.16.840.1.113883.3.526.3.402|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.199:Influenza Vaccination),(2.16.840.1.113883.3.526.2.1351:Influenza Vaccination)|CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Procedure|0041|CMS147v4|
2.16.840.1.113883.3.526.3.403|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.118:Myocardial Infarction),(2.16.840.1.113883.3.526.2.58:Myocardial Infarction),(2.16.840.1.113883.3.526.2.119:Myocardial Infarction)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Condition/Diagnosis/Problem|0070|CMS145v3|
2.16.840.1.113883.3.526.3.412|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.408:Bradycardia),(2.16.840.1.113883.3.526.2.410:Bradycardia),(2.16.840.1.113883.3.526.2.411:Bradycardia)|CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Condition/Diagnosis/Problem|0083|CMS144v3|
2.16.840.1.113883.3.526.3.412|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.408:Bradycardia),(2.16.840.1.113883.3.526.2.410:Bradycardia),(2.16.840.1.113883.3.526.2.411:Bradycardia)|CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Condition/Diagnosis/Problem|0070|CMS145v3|
2.16.840.1.113883.3.526.3.447|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.446:Metastatic Sites Common to Breast Cancer),(2.16.840.1.113883.3.526.2.443:Metastatic Sites Common to Breast Cancer),(2.16.840.1.113883.3.526.2.445:Metastatic Sites Common to Breast Cancer)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Condition/Diagnosis/Problem|0387|CMS140v3|
2.16.840.1.113883.3.526.3.451|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.325:Pain Related to Prostate Cancer),(2.16.840.1.113883.3.526.2.449:Pain Related to Prostate Cancer),(2.16.840.1.113883.3.526.2.450:Pain Related to Prostate Cancer)|CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Condition/Diagnosis/Problem|0389|CMS129v4|
2.16.840.1.113883.3.526.3.471|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.469:Bilateral Oophorectomy),(2.16.840.1.113883.3.526.2.470:Bilateral Oophorectomy)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Procedure|0387|CMS140v3|
2.16.840.1.113883.3.526.3.485|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.483:Chemotherapy),(2.16.840.1.113883.3.526.2.484:Chemotherapy)|CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Procedure|0387|CMS140v3|
2.16.840.1.113883.3.526.3.490|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.488:Metastatic Sites Common to Colon Cancer),(2.16.840.1.113883.3.526.2.487:Metastatic Sites Common to Colon Cancer),(2.16.840.1.113883.3.526.2.489:Metastatic Sites Common to Colon Cancer)|CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Condition/Diagnosis/Problem|0385|CMS141v4|
2.16.840.1.113883.3.526.3.509|20140701|American Medical Association-convened Physician Consortium for Performance Improvement(R)|Grouping|(2.16.840.1.113883.3.526.2.424:Tobacco Use Cessation Counseling),(2.16.840.1.113883.3.526.2.425:Tobacco Use Cessation Counseling)|CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Intervention|0028|CMS138v3|
2.16.840.1.113883.3.560.100.1|20140701|National Quality Forum|Extensional||CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Individual Characteristic|Not Applicable|CMS64v4|
2.16.840.1.113883.3.560.100.1|20140701|National Quality Forum|Extensional||CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Individual Characteristic|Not Applicable|CMS61v4|
2.16.840.1.113883.3.560.100.1|20140701|National Quality Forum|Extensional||CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Individual Characteristic|0389|CMS129v4|
2.16.840.1.113883.3.560.100.2|20140701|National Quality Forum|Extensional||CY 2014 EP|Breast Cancer Screening|Individual Characteristic|Not Applicable|CMS125v3|
2.16.840.1.113883.3.560.100.2|20140701|National Quality Forum|Extensional||CY 2014 EP|Pregnant women that had HBsAg testing|Individual Characteristic|Not Applicable|CMS158v3|
2.16.840.1.113883.3.560.100.2|20140701|National Quality Forum|Extensional||CY 2014 EP|Chlamydia Screening for Women|Individual Characteristic|0033|CMS153v3|
2.16.840.1.113883.3.560.100.2|20140701|National Quality Forum|Extensional||CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Individual Characteristic|Not Applicable|CMS64v4|
2.16.840.1.113883.3.560.100.2|20140701|National Quality Forum|Extensional||CY 2014 EP|Cervical Cancer Screening|Individual Characteristic|0032|CMS124v3|
2.16.840.1.113883.3.560.100.2|20140701|National Quality Forum|Extensional||CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Individual Characteristic|0387|CMS140v3|
2.16.840.1.113883.3.560.100.2|20140701|National Quality Forum|Extensional||CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Individual Characteristic|Not Applicable|CMS61v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Individual Characteristic|0436|CMS71v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Individual Characteristic|0438|CMS72v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Individual Characteristic|0528|CMS172v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Individual Characteristic|0435|CMS104v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Stroke Education|Individual Characteristic||CMS107v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Assessed for Rehabilitation|Individual Characteristic|0441|CMS102v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Individual Characteristic||CMS114v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Individual Characteristic|0372|CMS190v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Elective Delivery|Individual Characteristic|0469|CMS113v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Individual Characteristic|0164|CMS60v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Individual Characteristic|0453|CMS178v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Thrombolytic Therapy|Individual Characteristic|0437|CMS91v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Individual Characteristic|0163|CMS53v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Individual Characteristic|0147|CMS188v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Individual Characteristic|0371|CMS108v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Individual Characteristic|0069|CMS154v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Individual Characteristic|0104|CMS161v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Individual Characteristic|Not Applicable|CMS22v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Functional Status Assessment for Hip Replacement|Individual Characteristic|Not Applicable|CMS56v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Individual Characteristic|Not Applicable|CMS64v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|HIV/AIDS: RNA Control for Patients with HIV|Individual Characteristic|Not Applicable|CMS77v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Individual Characteristic|0421|CMS69v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Childhood Immunization Status|Individual Characteristic|0038|CMS117v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Individual Characteristic|0059|CMS122v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Colorectal Cancer Screening|Individual Characteristic|0034|CMS130v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Diabetes: Urine Protein Screening|Individual Characteristic|0062|CMS134v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Breast Cancer Screening|Individual Characteristic|Not Applicable|CMS125v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Diabetes: Eye Exam|Individual Characteristic|0055|CMS131v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Cervical Cancer Screening|Individual Characteristic|0032|CMS124v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Individual Characteristic|0004|CMS137v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Individual Characteristic|0108|CMS136v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Use of High-Risk Medications in the Elderly|Individual Characteristic|0022|CMS156v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Individual Characteristic|0086|CMS143v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Individual Characteristic|0070|CMS145v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Individual Characteristic|0089|CMS142v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Individual Characteristic|0041|CMS147v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Individual Characteristic|0110|CMS169v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range|Individual Characteristic|NA|CMS179v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Individual Characteristic|0075|CMS182v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|Individual Characteristic|0405|CMS52v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Individual Characteristic|0418|CMS2v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Individual Characteristic|Not Applicable|CMS61v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Individual Characteristic|Not Applicable|CMS74v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Hypertension: Improvement in Blood Pressure|Individual Characteristic|Not Applicable|CMS65v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Functional Status Assessment for Knee Replacement|Individual Characteristic|Not Applicable|CMS66v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Documentation of Current Medications in the Medical Record|Individual Characteristic|0419|CMS68v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Diabetes: Foot Exam|Individual Characteristic|0056|CMS123v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Individual Characteristic|0043|CMS127v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Individual Characteristic|0564|CMS132v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Individual Characteristic|0024|CMS155v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Depression Remission at Twelve Months|Individual Characteristic|0710|CMS159v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Controlling High Blood Pressure|Individual Characteristic|0018|CMS165v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Falls: Screening for Future Fall Risk|Individual Characteristic|0101|CMS139v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Individual Characteristic|0028|CMS138v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Individual Characteristic|0387|CMS140v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Appropriate Testing for Children with Pharyngitis|Individual Characteristic|0002|CMS146v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Pregnant women that had HBsAg testing|Individual Characteristic|Not Applicable|CMS158v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Individual Characteristic|0712|CMS160v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Use of Imaging Studies for Low Back Pain|Individual Characteristic|0052|CMS166v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Individual Characteristic|0088|CMS167v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Hemoglobin A1c Test for Pediatric Patients|Individual Characteristic|0060|CMS148v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Individual Characteristic|0064|CMS163v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Individual Characteristic|0068|CMS164v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Individual Characteristic|1365|CMS177v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Functional Status Assessment for Complex Chronic Conditions|Individual Characteristic|Not Applicable|CMS90v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Children Who Have Dental Decay or Cavities|Individual Characteristic|Not Applicable|CMS75v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Maternal Depression Screening|Individual Characteristic|1401|CMS82v2|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Use of Appropriate Medications for Asthma|Individual Characteristic|0036|CMS126v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Anti-depressant Medication Management|Individual Characteristic|0105|CMS128v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Individual Characteristic|0565|CMS133v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Individual Characteristic|0081|CMS135v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Individual Characteristic|0385|CMS141v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Chlamydia Screening for Women|Individual Characteristic|0033|CMS153v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Individual Characteristic|0083|CMS144v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver|Individual Characteristic||CMS26v2|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Individual Characteristic|0639|CMS30v4|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Individual Characteristic||CMS109v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Discharged on Statin Medication|Individual Characteristic|0439|CMS105v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Individual Characteristic|0373|CMS73v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Individual Characteristic|0142|CMS100v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Individual Characteristic||CMS110v3|
2.16.840.1.113883.3.560.100.4|20140701|National Quality Forum|Extensional||FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Individual Characteristic|0527|CMS171v4|
2.16.840.1.113883.3.600.1.1498|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Medication|0421|CMS69v3|
2.16.840.1.113883.3.600.1.1499|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Medication|0421|CMS69v3|
2.16.840.1.113883.3.600.1.1502|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Physical Exam|0421|CMS69v3|
2.16.840.1.113883.3.600.1.1502|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Documentation of Current Medications in the Medical Record|Procedure|0419|CMS68v4|
2.16.840.1.113883.3.600.1.1503|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Physical Exam|0421|CMS69v3|
2.16.840.1.113883.3.600.1.1525|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1.1526:Above normal f/u snomed),(2.16.840.1.113883.3.600.1.1519:Abnormal f/u codes hcpcs),(2.16.840.1.113883.3.600.1.1524:Above Normal f/u CPT),(2.16.840.1.113883.3.600.1.1522:Above Normal f/u icd 9),(2.16.840.1.113883.3.600.1.1523:Above Normal f/u icd 10)|CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Intervention|0421|CMS69v3|
2.16.840.1.113883.3.600.1.1527|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1.1610:SNOMED Referral Codes)|CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Intervention|0421|CMS69v3|
2.16.840.1.113883.3.600.1.1528|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1.1550:Below BMI follow up HCPCS),(2.16.840.1.113883.3.600.1.1548:Below BMI follow up icd 9),(2.16.840.1.113883.3.600.1.1549:Below BMI follow up icd 10),(2.16.840.1.113883.3.600.1.1551:Below BMI follow up SNOMED)|CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Intervention|0421|CMS69v3|
2.16.840.1.113883.3.600.1.1579|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1.1578:Palliative  SNOMED),(2.16.840.1.113883.3.600.1.1575:Palliative care ICD 10),(2.16.840.1.113883.3.600.1.1572:Palliative ICD 9)|CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Procedure|Not Applicable|CMS64v4|
2.16.840.1.113883.3.600.1.1579|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1.1578:Palliative  SNOMED),(2.16.840.1.113883.3.600.1.1575:Palliative care ICD 10),(2.16.840.1.113883.3.600.1.1572:Palliative ICD 9)|CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Procedure|0421|CMS69v3|
2.16.840.1.113883.3.600.1.1579|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1.1578:Palliative  SNOMED),(2.16.840.1.113883.3.600.1.1575:Palliative care ICD 10),(2.16.840.1.113883.3.600.1.1572:Palliative ICD 9)|CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Procedure|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.1.1623|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1.1625:Pregnancy I9),(2.16.840.1.113883.3.600.1.1624:Pregnancy I10),(2.16.840.1.113883.3.600.1.1626:Pregnancy SNM)|CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Condition/Diagnosis/Problem|0421|CMS69v3|
2.16.840.1.113883.3.600.1.1751|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1.885:Encounter HCPCS codes),(2.16.840.1.113883.3.600.1.886:BMI Evaluation Management codes),(2.16.840.1.113883.3.600.1.695:BMI Outpatient encounter),(2.16.840.1.113883.3.600.2466:Dental Tooth Extraction)|CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Encounter|0421|CMS69v3|
2.16.840.1.113883.3.600.1.1834|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1.1917:Medication SNOMED Encounter Codes),(2.16.840.1.113883.3.600.1.1608:Encounters Meds HCPCS),(2.16.840.1.113883.3.600.1.1609:Encounter Medications CPT)|CY 2014 EP|Documentation of Current Medications in the Medical Record|Encounter|0419|CMS68v4|
2.16.840.1.113883.3.600.1.462|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Documentation of Current Medications in the Medical Record|Procedure|0419|CMS68v4|
2.16.840.1.113883.3.600.1.681|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Physical Exam|0421|CMS69v3|
2.16.840.1.113883.3.600.145|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.144:Depression Diagnosis ICD10),(2.16.840.1.113883.3.600.143:Depression Diagnosis ICD9),(2.16.840.1.113883.3.600.141:Depression Diagnosis SNOMED)|CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Condition/Diagnosis/Problem|0418|CMS2v4|
2.16.840.1.113883.3.600.1474|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Intervention|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.1475|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Intervention|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.1476|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Medication|Not Applicable|CMS64v4|
2.16.840.1.113883.3.600.1476|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Medication|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.1476|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Medication|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.1482|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.2462:Laboratory Tests for Hypertension LOINC)|CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Laboratory Test|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.1508|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Intervention|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.1510|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.805:Weight Reduction Recommended snomed),(2.16.840.1.113883.3.600.1509:Weight Reduction Recommended HCPCS)|CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Intervention|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.1515|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1514:Dietary Recommendations ICD10),(2.16.840.1.113883.3.600.1513:Dietary Recommendations ICD9),(2.16.840.1.113883.3.600.1512:Dietary Recommendations HCPCS),(2.16.840.1.113883.3.600.1511:Dietary Recommendations SNOMED)|CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Intervention|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.1518|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1516:Increased Physical Activity Recommendation HCPCS),(2.16.840.1.113883.3.600.810:Increased Physical Activity Recommendation SNOMED),(2.16.840.1.113883.3.600.1517:Increased Physical Activity Recommendation ICD9)|CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Intervention|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.1521|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Physical Exam|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.1537|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Intervention|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.1542|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Intervention|0418|CMS2v4|
2.16.840.1.113883.3.600.1545|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Intervention|0418|CMS2v4|
2.16.840.1.113883.3.600.1557|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Condition/Diagnosis/Problem|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.1557|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Condition/Diagnosis/Problem|Not Applicable|CMS64v4|
2.16.840.1.113883.3.600.1561|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1560:Framingham coronary heart disease 10 year risk LOINC)|CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Risk Category/Assessment|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.1561|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1560:Framingham coronary heart disease 10 year risk LOINC)|CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Risk Category/Assessment|Not Applicable|CMS64v4|
2.16.840.1.113883.3.600.1622|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1621:Pregnancy SNM),(2.16.840.1.113883.3.600.1620:Pregnancy I10),(2.16.840.1.113883.3.600.1619:Pregnancy I9)|CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Condition/Diagnosis/Problem|Not Applicable|CMS64v4|
2.16.840.1.113883.3.600.1622|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1621:Pregnancy SNM),(2.16.840.1.113883.3.600.1620:Pregnancy I10),(2.16.840.1.113883.3.600.1619:Pregnancy I9)|CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Condition/Diagnosis/Problem|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.1916|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1915:Depression Screening Denominator Encounter Codes HCPCS new),(2.16.840.1.113883.3.600.1914:Depression Screening Denominator Encounter Codes SNOMED),(2.16.840.1.113883.3.600.1538:Depression Screening Denominator Encounter Codes CPT)|CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Encounter|0418|CMS2v4|
2.16.840.1.113883.3.600.1920|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1918:BP Screening Denominator Encounter Codes SNOMED),(2.16.840.1.113883.3.600.1497:BP Screening Denominator Encounter Codes),(2.16.840.1.113883.3.600.2466:Dental Tooth Extraction),(2.16.840.1.113883.3.600.192:BP Screening Denominator Encounter Codes)|CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Encounter|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.1951|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1950:Cholesterol Measure Encounter Codes CPT),(2.16.840.1.113883.3.600.1947:Cholesterol Measure Encounter Codes SNOMED),(2.16.840.1.113883.3.600.1948:Cholesterol Measure Encounter Codes HCPCS)|CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Encounter|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.1951|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.1950:Cholesterol Measure Encounter Codes CPT),(2.16.840.1.113883.3.600.1947:Cholesterol Measure Encounter Codes SNOMED),(2.16.840.1.113883.3.600.1948:Cholesterol Measure Encounter Codes HCPCS)|CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Encounter|Not Applicable|CMS64v4|
2.16.840.1.113883.3.600.2387|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Attribute|0421|CMS69v3|
2.16.840.1.113883.3.600.2388|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Attribute|0421|CMS69v3|
2.16.840.1.113883.3.600.2390|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Individual Characteristic|Not Applicable|CMS64v4|
2.16.840.1.113883.3.600.2390|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Individual Characteristic|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.2395|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Attribute|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.2448|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.2447:ECG 12 lead),(2.16.840.1.113883.3.600.2446:ECG Study)|CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Diagnostic Study|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.2449|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Risk Category/Assessment|0418|CMS2v4|
2.16.840.1.113883.3.600.2450|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Attribute|0418|CMS2v4|
2.16.840.1.113883.3.600.2451|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Attribute|0418|CMS2v4|
2.16.840.1.113883.3.600.2452|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Risk Category/Assessment|0418|CMS2v4|
2.16.840.1.113883.3.600.2454|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Attribute|0418|CMS2v4|
2.16.840.1.113883.3.600.263|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.259:Diagnosis of hypertension SNOMED),(2.16.840.1.113883.3.600.261:Diagnosis of hypertension - ICD-10),(2.16.840.1.113883.3.600.260:Diagnosis of hypertension - ICD-9)|CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Condition/Diagnosis/Problem|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.263|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.259:Diagnosis of hypertension SNOMED),(2.16.840.1.113883.3.600.261:Diagnosis of hypertension - ICD-10),(2.16.840.1.113883.3.600.260:Diagnosis of hypertension - ICD-9)|CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Condition/Diagnosis/Problem|Not Applicable|CMS64v4|
2.16.840.1.113883.3.600.263|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.259:Diagnosis of hypertension SNOMED),(2.16.840.1.113883.3.600.261:Diagnosis of hypertension - ICD-10),(2.16.840.1.113883.3.600.260:Diagnosis of hypertension - ICD-9)|CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Condition/Diagnosis/Problem|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.450|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.448:Bipolar Diagnosis ICD10),(2.16.840.1.113883.3.600.449:Bipolar Diagnosis SNOMED),(2.16.840.1.113883.3.600.447:Bipolar Diagnosis ICD9)|CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Condition/Diagnosis/Problem|0418|CMS2v4|
2.16.840.1.113883.3.600.467|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Intervention|0418|CMS2v4|
2.16.840.1.113883.3.600.468|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Intervention|0418|CMS2v4|
2.16.840.1.113883.3.600.469|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Medication|0418|CMS2v4|
2.16.840.1.113883.3.600.470|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Medication|0418|CMS2v4|
2.16.840.1.113883.3.600.537|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Intervention|0418|CMS2v4|
2.16.840.1.113883.3.600.538|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Intervention|0418|CMS2v4|
2.16.840.1.113883.3.600.559|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Procedure|0418|CMS2v4|
2.16.840.1.113883.3.600.791|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Physical Exam|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.791|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Laboratory Test|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.791|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Risk Category/Assessment|0418|CMS2v4|
2.16.840.1.113883.3.600.792|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Risk Category/Assessment|0418|CMS2v4|
2.16.840.1.113883.3.600.823|20140701|Quality Insights of Pennslyvania|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Intervention|Not Applicable|CMS22v3|
2.16.840.1.113883.3.600.863|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.854:CHD or CHD Risk Equivalent I9),(2.16.840.1.113883.3.600.862:CHD or CHD Risk Equivalent SNOMED),(2.16.840.1.113883.3.600.858:CHD or CHD Risk Equivalent I10)|CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Condition/Diagnosis/Problem|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.863|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.854:CHD or CHD Risk Equivalent I9),(2.16.840.1.113883.3.600.862:CHD or CHD Risk Equivalent SNOMED),(2.16.840.1.113883.3.600.858:CHD or CHD Risk Equivalent I10)|CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Condition/Diagnosis/Problem|Not Applicable|CMS64v4|
2.16.840.1.113883.3.600.872|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.869:LDL Code LOINC)|CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Laboratory Test|Not Applicable|CMS64v4|
2.16.840.1.113883.3.600.872|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.869:LDL Code LOINC)|CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Laboratory Test|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.875|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.873:High Density Lipoprotein (HDL) LOINC)|CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Laboratory Test|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.875|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.873:High Density Lipoprotein (HDL) LOINC)|CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Laboratory Test|Not Applicable|CMS64v4|
2.16.840.1.113883.3.600.879|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.877:Total Cholesterol LOINC)|CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Laboratory Test|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.879|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.877:Total Cholesterol LOINC)|CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Laboratory Test|Not Applicable|CMS64v4|
2.16.840.1.113883.3.600.883|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.881:Triglycerides LOINC)|CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Laboratory Test|Not Applicable|CMS61v4|
2.16.840.1.113883.3.600.883|20140701|Quality Insights of Pennslyvania|Grouping|(2.16.840.1.113883.3.600.881:Triglycerides LOINC)|CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Laboratory Test|Not Applicable|CMS64v4|
2.16.840.1.113883.3.666.5.1058|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.1058|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.1108|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Attribute|0528|CMS172v4|
2.16.840.1.113883.3.666.5.1108|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Attribute|0147|CMS188v4|
2.16.840.1.113883.3.666.5.1108|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Attribute|0527|CMS171v4|
2.16.840.1.113883.3.666.5.1109|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Attribute|0147|CMS188v4|
2.16.840.1.113883.3.666.5.1111|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Attribute|0528|CMS172v4|
2.16.840.1.113883.3.666.5.1111|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Attribute|0147|CMS188v4|
2.16.840.1.113883.3.666.5.1112|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Attribute|0147|CMS188v4|
2.16.840.1.113883.3.666.5.1145|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Medication|0142|CMS100v3|
2.16.840.1.113883.3.666.5.1145|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Medication|0639|CMS30v4|
2.16.840.1.113883.3.666.5.1151|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Procedure|0163|CMS53v3|
2.16.840.1.113883.3.666.5.1151|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Procedure|0164|CMS60v3|
2.16.840.1.113883.3.666.5.1566|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1680:Impaired Fetal Growth I10),(2.16.840.1.113883.3.666.5.1681:Impaired Fetal Growth S),(2.16.840.1.113883.3.666.5.1679:Impaired Fetal Growth I9)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1567|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1686:Birth Trauma or Injuries I9),(2.16.840.1.113883.3.666.5.1687:Birth Trauma or Injuries I10),(2.16.840.1.113883.3.666.5.1688:Birth Trauma or Injuries S)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1568|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1675:Newborn Affected by Unbilical Cord Complications I9),(2.16.840.1.113883.3.666.5.1674:Newborn Affected by Placenta or Abruption S),(2.16.840.1.113883.3.666.5.1678:Newborn Affected by Unbilical Cord Complications S),(2.16.840.1.113883.3.666.5.1672:Newborn Affected by Placenta or Abruption I9),(2.16.840.1.113883.3.666.5.1677:Newborn Affected by Unbilical Cord Complications I10),(2.16.840.1.113883.3.666.5.1673:Newborn Affected by Placenta or Abruption I10)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1570|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1565:Congenital Anomalies I9),(2.16.840.1.113883.3.666.5.1671:Congenital Anomalies S),(2.16.840.1.113883.3.666.5.1670:Congenital Anomalies I10)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1571|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1683:Hemolytic Disease I9),(2.16.840.1.113883.3.666.5.1685:Hemolytic Disease S),(2.16.840.1.113883.3.666.5.1684:Hemolytic Disease I10)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1573|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1696:Hydrops I9),(2.16.840.1.113883.3.666.5.1697:Hydrops I10),(2.16.840.1.113883.3.666.5.1689:Hydrops S)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1574|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1694:Drug Withdrawal Syndrome I10),(2.16.840.1.113883.3.666.5.1695:Drug Withdrawal Syndrome S),(2.16.840.1.113883.3.666.5.1693:Drug Withdrawal Syndrome I9)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1576|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1709:Laryngeal Stenosis I9),(2.16.840.1.113883.3.666.5.1710:Laryngeal Stenosis S)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1577|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1703:Hypoxia or Asphyxia I9),(2.16.840.1.113883.3.666.5.1702:Hypoxia or Asphyxia S),(2.16.840.1.113883.3.666.5.1704:Hypoxia or Asphyxia I10)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1580|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1690:Congenital or Infantile Cerebral Palsy I9),(2.16.840.1.113883.3.666.5.1691:Congenital or Infantile Cerebral Palsy I10),(2.16.840.1.113883.3.666.5.1692:Congenital or Infantile Cerebral Palsy S)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1581|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1730:Shock and Complications S),(2.16.840.1.113883.3.666.5.1731:Shock and Complications I9),(2.16.840.1.113883.3.666.5.1733:Shock and Complications I10)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1582|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1932:Arterial or Umbilical Venous Cath S),(2.16.840.1.113883.3.666.5.1763:Arterial or Umbilical Venous Cath I9),(2.16.840.1.113883.3.666.5.1931:Arterial or Umbilical Venous Cath I10)|FY 2014 EH|Healthy Term Newborn|Procedure|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1583|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1946:TPN Procedure S),(2.16.840.1.113883.3.666.5.1764:TPN Procedure I10),(2.16.840.1.113883.3.666.5.1945:TPN Procedure  I9)|FY 2014 EH|Healthy Term Newborn|Procedure|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1584|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1765:Gastrostomy I9),(2.16.840.1.113883.3.666.5.1682:Gastrostomy I10),(2.16.840.1.113883.3.666.5.1935:Gastrostomy S)|FY 2014 EH|Healthy Term Newborn|Procedure|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1585|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1936:Gavage Feeding I10),(2.16.840.1.113883.3.666.5.2308:Enteral Feeding),(2.16.840.1.113883.3.666.5.1766:Gavage Feeding I9)|FY 2014 EH|Healthy Term Newborn|Procedure|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1586|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1933:Cardiopulmonary Resuscitation I10),(2.16.840.1.113883.3.666.5.1767:Cardiopulmonary Resuscitation I9),(2.16.840.1.113883.3.666.5.1934:Cardiopulmonary Resuscitation S)|FY 2014 EH|Healthy Term Newborn|Procedure|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1588|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1728:Respiratory Problems I9),(2.16.840.1.113883.3.666.5.1729:Respiratory Problems I10),(2.16.840.1.113883.3.666.5.1727:Respiratory Problems S)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1589|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1768:Respiratory Procedures I9),(2.16.840.1.113883.3.666.5.1944:Respiratory Procedures S),(2.16.840.1.113883.3.666.5.1943:Respiratory Procedures I10)|FY 2014 EH|Healthy Term Newborn|Procedure|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1590|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1706:Infection I9),(2.16.840.1.113883.3.666.5.1705:Infection S),(2.16.840.1.113883.3.666.5.1707:Infection I10)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1591|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1720:Neurologic Complications I10),(2.16.840.1.113883.3.666.5.1714:Neurologic Complications S),(2.16.840.1.113883.3.666.5.1713:Neurologic Complications I9)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1592|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1769:Neurologic Procedure I9),(2.16.840.1.113883.3.666.5.1938:Neurologic Procedure I10),(2.16.840.1.113883.3.666.5.1939:Neurologic Procedure S)|FY 2014 EH|Healthy Term Newborn|Procedure|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1593|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1699:Hyperbilirubinemia I9),(2.16.840.1.113883.3.666.5.1700:Hyperbilirubinemia I10),(2.16.840.1.113883.3.666.5.1701:Hyperbilirubinemia IS)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1594|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1770:Phototherapy Procedure I9),(2.16.840.1.113883.3.666.5.1942:Phototherapy Procedure S),(2.16.840.1.113883.3.666.5.1941:Phototherapy Procedure I10)|FY 2014 EH|Healthy Term Newborn|Procedure|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1595|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1736:Social Reasons I9),(2.16.840.1.113883.3.666.5.1737:Social Reasons I10),(2.16.840.1.113883.3.666.5.1735:Social Reasons S)|FY 2014 EH|Healthy Term Newborn|Condition/Diagnosis/Problem|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1596|20140401|California Maternal Quality Care Collaborative|Grouping|(2.16.840.1.113883.3.666.5.1738:Term Newborn S),(2.16.840.1.113883.3.666.5.1739:Term Newborn I9)|FY 2014 EH|Healthy Term Newborn|Physical Exam|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1618|20140401|California Maternal Quality Care Collaborative|Extensional||FY 2014 EH|Healthy Term Newborn|Attribute|0716|CMS185v3|
2.16.840.1.113883.3.666.5.1726|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2345:Hospital Measures-Immunodeficient Conditions I9),(2.16.840.1.113883.3.666.5.2342:Hospital Measures-Immunodeficient Conditions SM-CT),(2.16.840.1.113883.3.666.5.2344:Hospital Measures-Immunodeficient Conditions I10)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.1741|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1087:Hospital Measures-Pacemaker or implantable defibrillator procedure),(2.16.840.1.113883.3.666.5.1840:Hospital Measures-Pacemaker or implantable defibrillator procedure),(2.16.840.1.113883.3.666.5.1838:Hospital Measures-Pacemaker or implantable defibrillator procedure)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113883.3.666.5.1741|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1087:Hospital Measures-Pacemaker or implantable defibrillator procedure),(2.16.840.1.113883.3.666.5.1840:Hospital Measures-Pacemaker or implantable defibrillator procedure),(2.16.840.1.113883.3.666.5.1838:Hospital Measures-Pacemaker or implantable defibrillator procedure)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.666.5.1743|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.117.1.7.1.348:General or Neuraxial Anesthesia),(2.16.840.1.113762.1.4.1045.38:General Or Neuraxial Anesthesia)|FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Procedure|0372|CMS190v3|
2.16.840.1.113883.3.666.5.1743|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.117.1.7.1.348:General or Neuraxial Anesthesia),(2.16.840.1.113762.1.4.1045.38:General Or Neuraxial Anesthesia)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113883.3.666.5.1743|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.117.1.7.1.348:General or Neuraxial Anesthesia),(2.16.840.1.113762.1.4.1045.38:General Or Neuraxial Anesthesia)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.666.5.1743|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.117.1.7.1.348:General or Neuraxial Anesthesia),(2.16.840.1.113762.1.4.1045.38:General Or Neuraxial Anesthesia)|FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Procedure|0453|CMS178v4|
2.16.840.1.113883.3.666.5.1743|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.117.1.7.1.348:General or Neuraxial Anesthesia),(2.16.840.1.113762.1.4.1045.38:General Or Neuraxial Anesthesia)|FY 2014 EH|Venous Thromboembolism Prophylaxis|Procedure|0371|CMS108v3|
2.16.840.1.113883.3.666.5.1816|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1813:Hospital measures-knee arthroplasty),(2.16.840.1.113883.3.666.5.1812:Hospital measures-knee arthroplasty),(2.16.840.1.113883.3.666.5.704:Hospital measures-knee arthroplasty)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.666.5.1816|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1813:Hospital measures-knee arthroplasty),(2.16.840.1.113883.3.666.5.1812:Hospital measures-knee arthroplasty),(2.16.840.1.113883.3.666.5.704:Hospital measures-knee arthroplasty)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113883.3.666.5.1921|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2260:Hospital measures-Caesarean section),(2.16.840.1.113883.3.666.5.711:Hospital measures-Caesarean section),(2.16.840.1.113883.3.666.5.1835:Hospital measures-Caesarean section)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113883.3.666.5.1940|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1740:Hospital Measures-Immunocompromised Conditions I9),(2.16.840.1.113883.3.666.5.2343:Hospital Measures-Immunocompromised Conditons SM-CT),(2.16.840.1.113883.3.666.5.2328:Hospital Measures-Immunocompromised Conditions I10)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2128|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Medication|0453|CMS178v4|
2.16.840.1.113883.3.666.5.2129|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Medication|0453|CMS178v4|
2.16.840.1.113883.3.666.5.2160|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2158:Hospital Measures-Restrictive lung disease I10),(2.16.840.1.113883.3.666.5.778:Hospital Measures-Restrictive lung disease),(2.16.840.1.113883.3.666.5.2166:Hospital Measures-Restrictive lung disease I9)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2162|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1057:Hospital Measures-Respiratory infection),(2.16.840.1.113883.3.666.5.2165:Hospital Measures-Respiratory infection I9),(2.16.840.1.113883.3.666.5.2157:Hospital Measures-Respiratory infection I10)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2192|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2193:Hospital Measures-Wound Care I10),(2.16.840.1.113883.3.666.5.2194:Hospital Measures-Wound Care I9),(2.16.840.1.113883.3.666.5.2196:Hospital Measures-Wound Care SM-CT)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Intervention|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2197|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2199:Hospital Measures-Prolonged QT Interval I9),(2.16.840.1.113883.3.666.5.2198:Hospital Measures-Prolonged QT Interval I10),(2.16.840.1.113883.3.666.5.2200:Hospital Measures-Prolonged QT Interval SM-CT)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2202|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Transfer of Care|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2203|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2204|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2205|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2208:Hospital Measures-Francisella Tularensis or Yersinia pestis SM-CT),(2.16.840.1.113883.3.666.5.2206:Hospital Measures-Francisella Tularensis or Yersinia pestis I10),(2.16.840.1.113883.3.666.5.2207:Hospital Measures-Francisella Tularensis or Yersinia pestis I9)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2254|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Attribute|0528|CMS172v4|
2.16.840.1.113883.3.666.5.2256|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.902:Hospital Measures - Any Infection (ICD-9-CM)),(2.16.840.1.113883.3.666.5.2316:Hospital measures - any infection SNOMED),(2.16.840.1.113883.3.666.5.2259:Any Infection Prior to Anesthesia Concepts),(2.16.840.1.113883.3.666.5.2257:Any Infection Prior to Anesthesia Concepts),(2.16.840.1.113883.3.666.5.903:Hospital Measures - Any Infection (ICD-10-CM)),(2.16.840.1.113883.3.666.5.2258:Any Infection Prior to Anesthesia Concepts)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Condition/Diagnosis/Problem|0527|CMS171v4|
2.16.840.1.113883.3.666.5.2256|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.902:Hospital Measures - Any Infection (ICD-9-CM)),(2.16.840.1.113883.3.666.5.2316:Hospital measures - any infection SNOMED),(2.16.840.1.113883.3.666.5.2259:Any Infection Prior to Anesthesia Concepts),(2.16.840.1.113883.3.666.5.2257:Any Infection Prior to Anesthesia Concepts),(2.16.840.1.113883.3.666.5.903:Hospital Measures - Any Infection (ICD-10-CM)),(2.16.840.1.113883.3.666.5.2258:Any Infection Prior to Anesthesia Concepts)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Condition/Diagnosis/Problem|0528|CMS172v4|
2.16.840.1.113883.3.666.5.2275|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2307:Hospital measures-Cardiac Valve Surgery ICD10),(2.16.840.1.113883.3.666.5.2276:Hospital measures-Cardiac Valve Surgery SNOMED),(2.16.840.1.113883.3.666.5.722:Hospital measures-Cardiac valve surgery)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.666.5.2278|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.716:Hospital Measures-MRSA Colonization or Infection),(2.16.840.1.113883.3.666.5.2279:Hospital Measures-MRSA Colonization or Infection),(2.16.840.1.113883.3.666.5.2277:Hospital Measures-MRSA Infection)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Condition/Diagnosis/Problem|0528|CMS172v4|
2.16.840.1.113883.3.666.5.2282|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2281:Hospital measures-Hemodialysis or peritoneal dialysis),(2.16.840.1.113883.3.666.5.2280:Hospital measures-Hemodialysis or peritoneal dialysis),(2.16.840.1.113883.3.666.5.718:Hospital Measures-Hemodialysis or peritoneal dialysis)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.666.5.2282|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2281:Hospital measures-Hemodialysis or peritoneal dialysis),(2.16.840.1.113883.3.666.5.2280:Hospital measures-Hemodialysis or peritoneal dialysis),(2.16.840.1.113883.3.666.5.718:Hospital Measures-Hemodialysis or peritoneal dialysis)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Procedure|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2289|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Encounter|0528|CMS172v4|
2.16.840.1.113883.3.666.5.2310|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113762.1.4.1045.46:SCIP Urological/Perineal procedures with potential need of indwelling catheters),(2.16.840.1.113883.3.666.5.819:Hospital Measures-SCIP Urological/Perineal procedures with potential need of indwelling catheters),(2.16.840.1.113883.3.666.5.2309:SCIP Urological/Perineal procedures with potential need of indwelling catheters ICD9CM)|FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Procedure|0453|CMS178v4|
2.16.840.1.113883.3.666.5.2313|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2312:Hospital Measures-SCIP urinary diversion procedures ICD10PCS),(2.16.840.1.113883.3.666.5.2311:Hospital Measures-SCIP urinary diversion procedures ICD9CM),(2.16.840.1.113883.3.666.5.1050:Hospital Measures-SCIP urinary diversion procedures)|FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Procedure|0453|CMS178v4|
2.16.840.1.113883.3.666.5.2319|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.673:Hospital Measures-Respiratory failure acute or chronic),(2.16.840.1.113883.3.666.5.2320:Hospital Measures-Respiratory failure acute or chronic I10),(2.16.840.1.113883.3.666.5.2321:Hospital Measures-Respiratory failure acute or chronic I9)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2348|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2351:Hospital Measures-Immunocompromised Therapies SM-CT),(2.16.840.1.113883.3.666.5.2350:Hospital Measures-Immunocompromised Therapies I9),(2.16.840.1.113883.3.666.5.2349:Hospital Measures-Immunocompromised Therapies I10)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Procedure|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2365|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Attribute|0147|CMS188v4|
2.16.840.1.113883.3.666.5.2486|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Attribute|0453|CMS178v4|
2.16.840.1.113883.3.666.5.3006|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Transfer of Care|0164|CMS60v3|
2.16.840.1.113883.3.666.5.3006|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Transfer of Care|0163|CMS53v3|
2.16.840.1.113883.3.666.5.3011|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.3024:Hospital Measures-AMI),(2.16.840.1.113883.3.666.5.623:Hospital Measures-AMI),(2.16.840.1.113883.3.666.5.622:Hospital Measures-AMI)|FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Condition/Diagnosis/Problem|0164|CMS60v3|
2.16.840.1.113883.3.666.5.3011|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.3024:Hospital Measures-AMI),(2.16.840.1.113883.3.666.5.623:Hospital Measures-AMI),(2.16.840.1.113883.3.666.5.622:Hospital Measures-AMI)|FY 2014 EH|Aspirin Prescribed at Discharge|Condition/Diagnosis/Problem|0142|CMS100v3|
2.16.840.1.113883.3.666.5.3011|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.3024:Hospital Measures-AMI),(2.16.840.1.113883.3.666.5.623:Hospital Measures-AMI),(2.16.840.1.113883.3.666.5.622:Hospital Measures-AMI)|FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Condition/Diagnosis/Problem|0163|CMS53v3|
2.16.840.1.113883.3.666.5.3011|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.3024:Hospital Measures-AMI),(2.16.840.1.113883.3.666.5.623:Hospital Measures-AMI),(2.16.840.1.113883.3.666.5.622:Hospital Measures-AMI)|FY 2014 EH|Statin Prescribed at Discharge|Condition/Diagnosis/Problem|0639|CMS30v4|
2.16.840.1.113883.3.666.5.3013|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Transfer of Care|0164|CMS60v3|
2.16.840.1.113883.3.666.5.3013|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Transfer of Care|0163|CMS53v3|
2.16.840.1.113883.3.666.5.3015|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.3016:Hospital Measures-Ventricular Assist Device placement),(2.16.840.1.113883.3.666.5.3014:Hospital Measures-Ventricular Assist Device placement),(2.16.840.1.113883.3.666.5.3017:Hospital Measures-Ventricular Assist Device placement)|FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Procedure|0163|CMS53v3|
2.16.840.1.113883.3.666.5.3015|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.3016:Hospital Measures-Ventricular Assist Device placement),(2.16.840.1.113883.3.666.5.3014:Hospital Measures-Ventricular Assist Device placement),(2.16.840.1.113883.3.666.5.3017:Hospital Measures-Ventricular Assist Device placement)|FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Procedure|0164|CMS60v3|
2.16.840.1.113883.3.666.5.3022|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1098:Hospital Measures-Acute or Evolving MI SNOMED-CT),(2.16.840.1.113883.3.666.5.3023:Hospital Measures-Acute or Evolving MI),(2.16.840.1.113883.3.666.5.3025:Hospital Measures-Acute or Evolving MI)|FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Attribute|0163|CMS53v3|
2.16.840.1.113883.3.666.5.3022|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1098:Hospital Measures-Acute or Evolving MI SNOMED-CT),(2.16.840.1.113883.3.666.5.3023:Hospital Measures-Acute or Evolving MI),(2.16.840.1.113883.3.666.5.3025:Hospital Measures-Acute or Evolving MI)|FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Attribute|0164|CMS60v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Encounter||CMS114v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Healthy Term Newborn|Encounter|0716|CMS185v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Encounter|0164|CMS60v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Encounter|0372|CMS190v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Encounter|0480|CMS9v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Discharged ED Patients|Encounter|0496|CMS32v4|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Encounter|0371|CMS108v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Median Admit Decision Time to ED Departure Time for Admitted Patients|Encounter|0497|CMS111v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Encounter|0142|CMS100v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Encounter|0528|CMS172v4|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Encounter|0163|CMS53v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Hearing Screening Prior To Hospital Discharge|Encounter|1354|CMS31v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Admitted ED Patients|Encounter|0495|CMS55v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Encounter|0527|CMS171v4|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Elective Delivery|Encounter|0469|CMS113v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver|Encounter||CMS26v2|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Encounter|0639|CMS30v4|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Encounter|0147|CMS188v4|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Encounter|0453|CMS178v4|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Encounter|0373|CMS73v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Encounter||CMS110v3|
2.16.840.1.113883.3.666.5.307|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Encounter||CMS109v3|
2.16.840.1.113883.3.666.5.463|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.465|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.626|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Medication|0142|CMS100v3|
2.16.840.1.113883.3.666.5.672|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.954:Hospital Measures-Septicemia I10),(2.16.840.1.113883.3.666.5.953:Hospital Measures-Septicemia I9),(2.16.840.1.113883.3.666.5.2318:Hospital Measures-Septicemia SM-CT)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.678|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Diagnostic Study|0147|CMS188v4|
2.16.840.1.113883.3.666.5.680|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Diagnostic Study|0147|CMS188v4|
2.16.840.1.113883.3.666.5.684|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Transfer of Care|0528|CMS172v4|
2.16.840.1.113883.3.666.5.684|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Transfer of Care|0147|CMS188v4|
2.16.840.1.113883.3.666.5.684|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Discharged ED Patients|Transfer of Care|0496|CMS32v4|
2.16.840.1.113883.3.666.5.687|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Transfer of Care|0147|CMS188v4|
2.16.840.1.113883.3.666.5.687|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Transfer of Care|0163|CMS53v3|
2.16.840.1.113883.3.666.5.687|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Transfer of Care|0164|CMS60v3|
2.16.840.1.113883.3.666.5.693|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.693|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.694|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1669:Hospital Measures-CABG ICD9),(2.16.840.1.113883.3.666.5.1668:Hospital Measures-CABG ICD10),(2.16.840.1.113883.3.666.5.2262:Hospital measures-CABG SNOMED)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113883.3.666.5.694|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1669:Hospital Measures-CABG ICD9),(2.16.840.1.113883.3.666.5.1668:Hospital Measures-CABG ICD10),(2.16.840.1.113883.3.666.5.2262:Hospital measures-CABG SNOMED)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.666.5.696|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.902:Hospital Measures - Any Infection (ICD-9-CM)),(2.16.840.1.113883.3.666.5.2316:Hospital measures - any infection SNOMED),(2.16.840.1.113883.3.666.5.903:Hospital Measures - Any Infection (ICD-10-CM))|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Condition/Diagnosis/Problem|0528|CMS172v4|
2.16.840.1.113883.3.666.5.696|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.902:Hospital Measures - Any Infection (ICD-9-CM)),(2.16.840.1.113883.3.666.5.2316:Hospital measures - any infection SNOMED),(2.16.840.1.113883.3.666.5.903:Hospital Measures - Any Infection (ICD-10-CM))|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.696|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.902:Hospital Measures - Any Infection (ICD-9-CM)),(2.16.840.1.113883.3.666.5.2316:Hospital measures - any infection SNOMED),(2.16.840.1.113883.3.666.5.903:Hospital Measures - Any Infection (ICD-10-CM))|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Condition/Diagnosis/Problem|0527|CMS171v4|
2.16.840.1.113883.3.666.5.701|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2265:Hospital measures-other cardiac surgery SNOMED),(2.16.840.1.113883.3.666.5.1836:Hospital Measures-Other cardiac surgery),(2.16.840.1.113883.3.666.5.1837:Hospital Measures-Other cardiac surgery)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113883.3.666.5.701|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2265:Hospital measures-other cardiac surgery SNOMED),(2.16.840.1.113883.3.666.5.1836:Hospital Measures-Other cardiac surgery),(2.16.840.1.113883.3.666.5.1837:Hospital Measures-Other cardiac surgery)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.666.5.703|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1061:Hospital Measures-Hip Arthroplasty ICD10),(2.16.840.1.113883.3.666.5.2264:Hospital measures-hip arthroplasty SNOMED),(2.16.840.1.113883.3.666.5.1809:Hospital Measures-Hip arthroplasty ICD9)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113883.3.666.5.703|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1061:Hospital Measures-Hip Arthroplasty ICD10),(2.16.840.1.113883.3.666.5.2264:Hospital measures-hip arthroplasty SNOMED),(2.16.840.1.113883.3.666.5.1809:Hospital Measures-Hip arthroplasty ICD9)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.666.5.705|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1828:Hospital measures-Colon surgery),(2.16.840.1.113883.3.666.5.2263:Hospital measures-colon surgery SNOMED),(2.16.840.1.113883.3.666.5.1815:Hospital measures-Colon surgery)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113883.3.666.5.705|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1828:Hospital measures-Colon surgery),(2.16.840.1.113883.3.666.5.2263:Hospital measures-colon surgery SNOMED),(2.16.840.1.113883.3.666.5.1815:Hospital measures-Colon surgery)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.666.5.708|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.710|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1830:Hospital measures-Abdominal hysterectomy),(2.16.840.1.113883.3.666.5.1829:Hospital measures-Abdominal hysterectomy),(2.16.840.1.113883.3.666.5.2261:Hospital measures-abdominal hysterectomy SNOMED)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.666.5.710|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1830:Hospital measures-Abdominal hysterectomy),(2.16.840.1.113883.3.666.5.1829:Hospital measures-Abdominal hysterectomy),(2.16.840.1.113883.3.666.5.2261:Hospital measures-abdominal hysterectomy SNOMED)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113883.3.666.5.712|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1827:Hospital measures-vaginal hysterectomy),(2.16.840.1.113883.3.666.5.2266:Hospital measures-vaginal hysterectomy SNOMED),(2.16.840.1.113883.3.666.5.1831:Hospital measures-Vaginal hysterectomy)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113883.3.666.5.712|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1827:Hospital measures-vaginal hysterectomy),(2.16.840.1.113883.3.666.5.2266:Hospital measures-vaginal hysterectomy SNOMED),(2.16.840.1.113883.3.666.5.1831:Hospital measures-Vaginal hysterectomy)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.666.5.713|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1833:Hospital measures-vascular surgery),(2.16.840.1.113883.3.666.5.2267:Hospital measures-vascular surgery SNOMED),(2.16.840.1.113883.3.666.5.1832:Hospital measures-vascular surgery)|FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Procedure|0527|CMS171v4|
2.16.840.1.113883.3.666.5.713|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1833:Hospital measures-vascular surgery),(2.16.840.1.113883.3.666.5.2267:Hospital measures-vascular surgery SNOMED),(2.16.840.1.113883.3.666.5.1832:Hospital measures-vascular surgery)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Procedure|0528|CMS172v4|
2.16.840.1.113883.3.666.5.719|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Intervention|0528|CMS172v4|
2.16.840.1.113883.3.666.5.720|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.724|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.725|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.727|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.727|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.728|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.729|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.730|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.957:Expired),(2.16.840.1.113883.3.666.5.956:Expired),(2.16.840.1.113883.3.666.5.2317:Expired)|FY 2014 EH|Median Time from ED Arrival to ED Departure for Discharged ED Patients|Attribute|0496|CMS32v4|
2.16.840.1.113883.3.666.5.730|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.957:Expired),(2.16.840.1.113883.3.666.5.956:Expired),(2.16.840.1.113883.3.666.5.2317:Expired)|FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Individual Characteristic|0528|CMS172v4|
2.16.840.1.113883.3.666.5.730|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.957:Expired),(2.16.840.1.113883.3.666.5.956:Expired),(2.16.840.1.113883.3.666.5.2317:Expired)|FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Individual Characteristic|0453|CMS178v4|
2.16.840.1.113883.3.666.5.735|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.972:Hospital Measures-ECG),(2.16.840.1.113883.3.666.5.973:Hospital Measures-ECG),(2.16.840.1.113762.1.4.1045.70:Electrocardiogram (ECG))|FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Diagnostic Study|0163|CMS53v3|
2.16.840.1.113883.3.666.5.735|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.972:Hospital Measures-ECG),(2.16.840.1.113883.3.666.5.973:Hospital Measures-ECG),(2.16.840.1.113762.1.4.1045.70:Electrocardiogram (ECG))|FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Diagnostic Study|0164|CMS60v3|
2.16.840.1.113883.3.666.5.736|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Medication|0164|CMS60v3|
2.16.840.1.113883.3.666.5.736|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Medication|0163|CMS53v3|
2.16.840.1.113883.3.666.5.748|20140401|American Board of Internal Medicine|Grouping|(2.16.840.1.113883.3.666.5.1081:Hospital Measures-Cardiopulmonary arrest ICD-9),(2.16.840.1.113883.3.666.5.1082:Hospital Measures-Cardiopulmonary arrest ICD-10),(2.16.840.1.113883.3.666.5.3020:Hospital Measures-Cardiopulmonary arrest SNOMED-CT)|FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Condition/Diagnosis/Problem|0163|CMS53v3|
2.16.840.1.113883.3.666.5.748|20140401|American Board of Internal Medicine|Grouping|(2.16.840.1.113883.3.666.5.1081:Hospital Measures-Cardiopulmonary arrest ICD-9),(2.16.840.1.113883.3.666.5.1082:Hospital Measures-Cardiopulmonary arrest ICD-10),(2.16.840.1.113883.3.666.5.3020:Hospital Measures-Cardiopulmonary arrest SNOMED-CT)|FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Condition/Diagnosis/Problem|0164|CMS60v3|
2.16.840.1.113883.3.666.5.752|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2152:Hospital Measures-Pneumonia SM-CT),(2.16.840.1.113883.3.666.5.2161:Hospital Measures-Pneumonia  ICD-10),(2.16.840.1.113883.3.666.5.756:Hospital Measures-Pneumonia)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.758|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.759|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.760|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.765|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Medication|0527|CMS171v4|
2.16.840.1.113883.3.666.5.765|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.766|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.766|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Medication|0527|CMS171v4|
2.16.840.1.113883.3.666.5.767|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.768|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.770|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.772|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.773|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.959:Hospital Measures-Bronchiectasis),(2.16.840.1.113883.3.666.5.960:Hospital Measures-Bronchiectasis),(2.16.840.1.113883.3.666.5.2131:Hospital Measures-Bronchiectasis SM-CT)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.774|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1142:Hospital Measures-Structural lung disease),(2.16.840.1.113883.3.666.5.1141:Hospital Measures-Structural lung disease),(2.16.840.1.113883.3.666.5.2153:Hospital Measures-Structural lung disease SM-CT)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.775|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.931:Hospital Measures-Chronic bronchitis),(2.16.840.1.113883.3.666.5.915:Hospital Measures-Chronic bronchitis),(2.16.840.1.113883.3.666.5.2133:Hospital Measures-Chronic bronchitis SM-CT)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.776|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.918:Hospital Measures-COPD),(2.16.840.1.113883.3.666.5.2135:Hospital Measures-COPD SM-CT),(2.16.840.1.113883.3.666.5.909:Hospital Measures-COPD)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.777|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.2137:Hospital Measures-Interstital lung disease SM-CT),(2.16.840.1.113883.3.666.5.1003:Hospital Measures-Interstital lung disease),(2.16.840.1.113883.3.666.5.1079:Hospital Measures-Interstital lung disease)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.779|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.782|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Intervention|0147|CMS188v4|
2.16.840.1.113883.3.666.5.783|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1001:Hospital Measures-Healthcare associated pneumonia),(2.16.840.1.113883.3.666.5.2138:Hospital Measures-Healthcare associated pneumonia SM-CT),(2.16.840.1.113883.3.666.5.1000:Hospital Measures-Healthcare associated pneumonia)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.787|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.1035:Hospital Measures-Neutrophil count),(2.16.840.1.113883.3.666.5.1036:Hospital Measures-Neutrophil count)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Laboratory Test|0147|CMS188v4|
2.16.840.1.113883.3.666.5.801|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.666.5.358:Organ transplant SNOMED),(2.16.840.1.113883.3.666.5.912:Hospital Measures-Organ Transplant I9),(2.16.840.1.113883.3.666.5.913:Hospital Measures-Organ Transplant I10)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Procedure|0147|CMS188v4|
2.16.840.1.113883.3.666.5.803|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.805|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.806|20140401|Oklahoma Foundation for Medical Quality|Grouping|(2.16.840.1.113883.3.464.1003.102.11.1010:Emphysema),(2.16.840.1.113883.3.464.1003.102.11.1011:Emphysema),(2.16.840.1.113883.3.464.1003.102.11.1012:Emphysema)|FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Condition/Diagnosis/Problem|0147|CMS188v4|
2.16.840.1.113883.3.666.5.822|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Physical Exam|0453|CMS178v4|
2.16.840.1.113883.3.666.5.825|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Intervention|0453|CMS178v4|
2.16.840.1.113883.3.666.5.827|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Device|0453|CMS178v4|
2.16.840.1.113883.3.666.5.829|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Medication|0453|CMS178v4|
2.16.840.1.113883.3.666.5.835|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Medication|0527|CMS171v4|
2.16.840.1.113883.3.666.5.840|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.666.5.893|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Medication|0528|CMS172v4|
2.16.840.1.113883.3.666.5.896|20140401|Oklahoma Foundation for Medical Quality|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Medication|0147|CMS188v4|
2.16.840.1.113883.3.67.1.101.1.128|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.67.1.101.1.44:Bipolar Disorder),(2.16.840.1.113883.3.67.1.101.1.43:Bipolar Disorder),(2.16.840.1.113883.3.67.1.101.1.45:Bipolar Disorder)|CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Condition/Diagnosis/Problem|0712|CMS160v3|
2.16.840.1.113883.3.67.1.101.1.128|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.67.1.101.1.44:Bipolar Disorder),(2.16.840.1.113883.3.67.1.101.1.43:Bipolar Disorder),(2.16.840.1.113883.3.67.1.101.1.45:Bipolar Disorder)|CY 2014 EP|Depression Remission at Twelve Months|Condition/Diagnosis/Problem|0710|CMS159v3|
2.16.840.1.113883.3.67.1.101.1.246|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.67.1.101.1.249:Personality Disorder),(2.16.840.1.113883.3.67.1.101.1.248:Personality Disorder),(2.16.840.1.113883.3.67.1.101.1.247:Personality Disorder)|CY 2014 EP|Depression Remission at Twelve Months|Condition/Diagnosis/Problem|0710|CMS159v3|
2.16.840.1.113883.3.67.1.101.1.246|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.67.1.101.1.249:Personality Disorder),(2.16.840.1.113883.3.67.1.101.1.248:Personality Disorder),(2.16.840.1.113883.3.67.1.101.1.247:Personality Disorder)|CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Condition/Diagnosis/Problem|0712|CMS160v3|
2.16.840.1.113883.3.67.1.101.1.254|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.67.1.101.1.256:Dysthymia),(2.16.840.1.113883.3.67.1.101.1.257:Dysthymia),(2.16.840.1.113883.3.67.1.101.1.255:Dysthymia)|CY 2014 EP|Depression Remission at Twelve Months|Condition/Diagnosis/Problem|0710|CMS159v3|
2.16.840.1.113883.3.67.1.101.1.254|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.67.1.101.1.256:Dysthymia),(2.16.840.1.113883.3.67.1.101.1.257:Dysthymia),(2.16.840.1.113883.3.67.1.101.1.255:Dysthymia)|CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Condition/Diagnosis/Problem|0712|CMS160v3|
2.16.840.1.113883.3.67.1.101.1.269|20140701|OptumInsight|Grouping|(2.16.840.1.113883.3.67.1.101.1.272:Hepatitis B),(2.16.840.1.113883.3.67.1.101.1.271:Hepatitis B),(2.16.840.1.113883.3.67.1.101.1.270:Hepatitis B)|CY 2014 EP|Pregnant women that had HBsAg testing|Condition/Diagnosis/Problem|Not Applicable|CMS158v3|
2.16.840.1.113883.3.67.1.101.1.278|20140701|OptumInsight|Grouping|(2.16.840.1.113762.1.4.1078.3:Delivery),(2.16.840.1.113883.3.67.1.101.1.83:Delivery ICD9Dx),(2.16.840.1.113883.3.67.1.101.1.82:Delivery)|CY 2014 EP|Pregnant women that had HBsAg testing|Condition/Diagnosis/Problem|Not Applicable|CMS158v3|
2.16.840.1.113883.3.67.1.101.1.279|20140701|OptumInsight|Grouping|(2.16.840.1.113883.3.67.1.101.1.281:HBsAg),(2.16.840.1.113883.3.67.1.101.1.2435:HBsAg)|CY 2014 EP|Pregnant women that had HBsAg testing|Laboratory Test|Not Applicable|CMS158v3|
2.16.840.1.113883.3.67.1.101.11.721|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.67.1.101.1.262:Deceased)|CY 2014 EP|Depression Remission at Twelve Months|Individual Characteristic|0710|CMS159v3|
2.16.840.1.113883.3.67.1.101.11.721|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.67.1.101.1.262:Deceased)|CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Individual Characteristic|0712|CMS160v3|
2.16.840.1.113883.3.67.1.101.11.723|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.67.1.101.1.263:PHQ-9 Tool)|CY 2014 EP|Depression Remission at Twelve Months|Risk Category/Assessment|0710|CMS159v3|
2.16.840.1.113883.3.67.1.101.11.723|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.67.1.101.1.263:PHQ-9 Tool)|CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Risk Category/Assessment|0712|CMS160v3|
2.16.840.1.113883.3.67.1.101.950|20140401|American Board of Internal Medicine|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Transfer of Care|0163|CMS53v3|
2.16.840.1.113883.3.67.1.101.950|20140401|American Board of Internal Medicine|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Transfer of Care|0164|CMS60v3|
2.16.840.1.114222.4.1.214079.1.1.1|20140401|CDC National Center on Birth Defects and Developmental Disabilities|Extensional||FY 2014 EH|Hearing Screening Prior To Hospital Discharge|Condition/Diagnosis/Problem|1354|CMS31v3|
2.16.840.1.114222.4.1.214079.1.1.3|20140401|CDC National Center on Birth Defects and Developmental Disabilities|Extensional||FY 2014 EH|Hearing Screening Prior To Hospital Discharge|Diagnostic Study|1354|CMS31v3|
2.16.840.1.114222.4.1.214079.1.1.4|20140401|CDC National Center on Birth Defects and Developmental Disabilities|Extensional||FY 2014 EH|Hearing Screening Prior To Hospital Discharge|Diagnostic Study|1354|CMS31v3|
2.16.840.1.114222.4.1.214079.1.1.6|20140401|CDC National Center on Birth Defects and Developmental Disabilities|Extensional||FY 2014 EH|Hearing Screening Prior To Hospital Discharge|Attribute|1354|CMS31v3|
2.16.840.1.114222.4.1.214079.1.1.7|20140401|CDC National Center on Birth Defects and Developmental Disabilities|Extensional||FY 2014 EH|Hearing Screening Prior To Hospital Discharge|Diagnostic Study|1354|CMS31v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Median Admit Decision Time to ED Departure Time for Admitted Patients|Individual Characteristic|0497|CMS111v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver|Individual Characteristic||CMS26v2|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Individual Characteristic|0438|CMS72v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Elective Delivery|Individual Characteristic|0469|CMS113v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Admitted ED Patients|Individual Characteristic|0495|CMS55v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Thrombolytic Therapy|Individual Characteristic|0437|CMS91v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Individual Characteristic|0142|CMS100v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Individual Characteristic|0435|CMS104v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Individual Characteristic|0163|CMS53v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Individual Characteristic|0480|CMS9v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Individual Characteristic|0453|CMS178v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Individual Characteristic|0372|CMS190v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Individual Characteristic|0371|CMS108v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Individual Characteristic|0147|CMS188v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Healthy Term Newborn|Individual Characteristic|0716|CMS185v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Assessed for Rehabilitation|Individual Characteristic|0441|CMS102v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Individual Characteristic||CMS110v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Individual Characteristic|0436|CMS71v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Hearing Screening Prior To Hospital Discharge|Individual Characteristic|1354|CMS31v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Hemoglobin A1c Test for Pediatric Patients|Individual Characteristic|0060|CMS148v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Dementia: Cognitive Assessment|Individual Characteristic|Not Applicable|CMS149v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Use of High-Risk Medications in the Elderly|Individual Characteristic|0022|CMS156v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Individual Characteristic|0712|CMS160v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Pregnant women that had HBsAg testing|Individual Characteristic|Not Applicable|CMS158v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Depression Remission at Twelve Months|Individual Characteristic|0710|CMS159v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Individual Characteristic|0068|CMS164v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Individual Characteristic|0104|CMS161v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Individual Characteristic|0110|CMS169v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range|Individual Characteristic|NA|CMS179v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Individual Characteristic|0075|CMS182v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Documentation of Current Medications in the Medical Record|Individual Characteristic|0419|CMS68v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Individual Characteristic|Not Applicable|CMS74v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Children Who Have Dental Decay or Cavities|Individual Characteristic|Not Applicable|CMS75v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Maternal Depression Screening|Individual Characteristic|1401|CMS82v2|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Functional Status Assessment for Hip Replacement|Individual Characteristic|Not Applicable|CMS56v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Individual Characteristic|0421|CMS69v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Individual Characteristic|0059|CMS122v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Diabetes: Foot Exam|Individual Characteristic|0056|CMS123v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Use of Appropriate Medications for Asthma|Individual Characteristic|0036|CMS126v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Individual Characteristic|0387|CMS140v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Chlamydia Screening for Women|Individual Characteristic|0033|CMS153v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Individual Characteristic|0069|CMS154v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Individual Characteristic|0083|CMS144v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Individual Characteristic|0064|CMS163v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Use of Imaging Studies for Low Back Pain|Individual Characteristic|0052|CMS166v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Individual Characteristic|Not Applicable|CMS22v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Individual Characteristic|0418|CMS2v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Individual Characteristic|1365|CMS177v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Individual Characteristic|Not Applicable|CMS64v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Childhood Immunization Status|Individual Characteristic|0038|CMS117v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Closing the Referral Loop: Receipt of Specialist Report|Individual Characteristic|Not Applicable|CMS50v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|HIV/AIDS: Medical Visit|Individual Characteristic|Not Applicable|CMS62v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Functional Status Assessment for Knee Replacement|Individual Characteristic|Not Applicable|CMS66v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|HIV/AIDS: RNA Control for Patients with HIV|Individual Characteristic|Not Applicable|CMS77v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Cervical Cancer Screening|Individual Characteristic|0032|CMS124v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Individual Characteristic|0564|CMS132v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Diabetes: Urine Protein Screening|Individual Characteristic|0062|CMS134v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Anti-depressant Medication Management|Individual Characteristic|0105|CMS128v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Individual Characteristic|0389|CMS129v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Colorectal Cancer Screening|Individual Characteristic|0034|CMS130v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Individual Characteristic|0088|CMS167v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Individual Characteristic|0565|CMS133v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Individual Characteristic|0086|CMS143v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Individual Characteristic|0028|CMS138v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Appropriate Testing for Children with Pharyngitis|Individual Characteristic|0002|CMS146v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Individual Characteristic|0385|CMS141v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Individual Characteristic|0089|CMS142v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Individual Characteristic|0070|CMS145v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Individual Characteristic|0081|CMS135v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Individual Characteristic|0108|CMS136v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Individual Characteristic|0004|CMS137v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Falls: Screening for Future Fall Risk|Individual Characteristic|0101|CMS139v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Individual Characteristic|0024|CMS155v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Controlling High Blood Pressure|Individual Characteristic|0018|CMS165v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Oncology: Medical and Radiation – Pain Intensity Quantified|Individual Characteristic|0384|CMS157v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|Individual Characteristic|0405|CMS52v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Hypertension: Improvement in Blood Pressure|Individual Characteristic|Not Applicable|CMS65v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Individual Characteristic|Not Applicable|CMS61v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Functional Status Assessment for Complex Chronic Conditions|Individual Characteristic|Not Applicable|CMS90v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Individual Characteristic|0043|CMS127v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Diabetes: Eye Exam|Individual Characteristic|0055|CMS131v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Breast Cancer Screening|Individual Characteristic|Not Applicable|CMS125v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Individual Characteristic|0041|CMS147v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Individual Characteristic|0527|CMS171v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Individual Characteristic|0639|CMS30v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Discharged on Statin Medication|Individual Characteristic|0439|CMS105v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Individual Characteristic||CMS114v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Individual Characteristic||CMS109v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Individual Characteristic|0373|CMS73v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Individual Characteristic|0528|CMS172v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Stroke Education|Individual Characteristic||CMS107v3|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Discharged ED Patients|Individual Characteristic|0496|CMS32v4|
2.16.840.1.114222.4.11.3591|20140701|Public Health Data Standards Consortium|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Individual Characteristic|0164|CMS60v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Assessed for Rehabilitation|Individual Characteristic|0441|CMS102v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Individual Characteristic|0147|CMS188v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Individual Characteristic|0438|CMS72v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Individual Characteristic|0371|CMS108v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Individual Characteristic|0435|CMS104v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Individual Characteristic||CMS109v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Individual Characteristic|0373|CMS73v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Median Admit Decision Time to ED Departure Time for Admitted Patients|Individual Characteristic|0497|CMS111v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Thrombolytic Therapy|Individual Characteristic|0437|CMS91v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Individual Characteristic|0142|CMS100v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Individual Characteristic|0528|CMS172v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Individual Characteristic||CMS114v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Individual Characteristic|0527|CMS171v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Stroke Education|Individual Characteristic||CMS107v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Hearing Screening Prior To Hospital Discharge|Individual Characteristic|1354|CMS31v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Individual Characteristic|0164|CMS60v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Individual Characteristic|0163|CMS53v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Use of High-Risk Medications in the Elderly|Individual Characteristic|0022|CMS156v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Oncology: Medical and Radiation – Pain Intensity Quantified|Individual Characteristic|0384|CMS157v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Chlamydia Screening for Women|Individual Characteristic|0033|CMS153v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Individual Characteristic|0069|CMS154v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Depression Remission at Twelve Months|Individual Characteristic|0710|CMS159v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Controlling High Blood Pressure|Individual Characteristic|0018|CMS165v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Individual Characteristic|0088|CMS167v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Individual Characteristic|0110|CMS169v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|Individual Characteristic|0405|CMS52v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Individual Characteristic|0418|CMS2v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Documentation of Current Medications in the Medical Record|Individual Characteristic|0419|CMS68v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Individual Characteristic|0421|CMS69v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Individual Characteristic|Not Applicable|CMS74v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|HIV/AIDS: RNA Control for Patients with HIV|Individual Characteristic|Not Applicable|CMS77v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Maternal Depression Screening|Individual Characteristic|1401|CMS82v2|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Individual Characteristic|0059|CMS122v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Childhood Immunization Status|Individual Characteristic|0038|CMS117v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Breast Cancer Screening|Individual Characteristic|Not Applicable|CMS125v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Use of Appropriate Medications for Asthma|Individual Characteristic|0036|CMS126v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetes: Eye Exam|Individual Characteristic|0055|CMS131v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Individual Characteristic|0564|CMS132v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Individual Characteristic|0565|CMS133v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Individual Characteristic|0108|CMS136v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Falls: Screening for Future Fall Risk|Individual Characteristic|0101|CMS139v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Individual Characteristic|0089|CMS142v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Individual Characteristic|0028|CMS138v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Individual Characteristic|0024|CMS155v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Individual Characteristic|0070|CMS145v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Appropriate Testing for Children with Pharyngitis|Individual Characteristic|0002|CMS146v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Individual Characteristic|0041|CMS147v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Individual Characteristic|0387|CMS140v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Individual Characteristic|1365|CMS177v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Individual Characteristic|Not Applicable|CMS22v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Individual Characteristic|Not Applicable|CMS64v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Individual Characteristic|0104|CMS161v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Individual Characteristic|0068|CMS164v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range|Individual Characteristic|NA|CMS179v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Individual Characteristic|0075|CMS182v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Hypertension: Improvement in Blood Pressure|Individual Characteristic|Not Applicable|CMS65v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Functional Status Assessment for Knee Replacement|Individual Characteristic|Not Applicable|CMS66v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Children Who Have Dental Decay or Cavities|Individual Characteristic|Not Applicable|CMS75v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Closing the Referral Loop: Receipt of Specialist Report|Individual Characteristic|Not Applicable|CMS50v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Individual Characteristic|Not Applicable|CMS61v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Functional Status Assessment for Complex Chronic Conditions|Individual Characteristic|Not Applicable|CMS90v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Individual Characteristic|0004|CMS137v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetes: Foot Exam|Individual Characteristic|0056|CMS123v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Individual Characteristic|0043|CMS127v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Use of Imaging Studies for Low Back Pain|Individual Characteristic|0052|CMS166v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Individual Characteristic|0081|CMS135v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Individual Characteristic|0385|CMS141v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetes: Urine Protein Screening|Individual Characteristic|0062|CMS134v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Hemoglobin A1c Test for Pediatric Patients|Individual Characteristic|0060|CMS148v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Pregnant women that had HBsAg testing|Individual Characteristic|Not Applicable|CMS158v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Individual Characteristic|0712|CMS160v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Individual Characteristic|0064|CMS163v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|HIV/AIDS: Medical Visit|Individual Characteristic|Not Applicable|CMS62v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Functional Status Assessment for Hip Replacement|Individual Characteristic|Not Applicable|CMS56v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Cervical Cancer Screening|Individual Characteristic|0032|CMS124v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Anti-depressant Medication Management|Individual Characteristic|0105|CMS128v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Individual Characteristic|0389|CMS129v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Colorectal Cancer Screening|Individual Characteristic|0034|CMS130v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Dementia: Cognitive Assessment|Individual Characteristic|Not Applicable|CMS149v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Individual Characteristic|0086|CMS143v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Individual Characteristic|0083|CMS144v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver|Individual Characteristic||CMS26v2|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Individual Characteristic|0436|CMS71v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Healthy Term Newborn|Individual Characteristic|0716|CMS185v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Individual Characteristic|0453|CMS178v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Admitted ED Patients|Individual Characteristic|0495|CMS55v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Individual Characteristic|0639|CMS30v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Discharged ED Patients|Individual Characteristic|0496|CMS32v4|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Elective Delivery|Individual Characteristic|0469|CMS113v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Individual Characteristic||CMS110v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Discharged on Statin Medication|Individual Characteristic|0439|CMS105v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Individual Characteristic|0372|CMS190v3|
2.16.840.1.114222.4.11.836|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Individual Characteristic|0480|CMS9v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Assessed for Rehabilitation|Individual Characteristic|0441|CMS102v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Incidence of Potentially-Preventable Venous Thromboembolism|Individual Characteristic||CMS114v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision|Individual Characteristic|0527|CMS171v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Discharged ED Patients|Individual Characteristic|0496|CMS32v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Healthy Term Newborn|Individual Characteristic|0716|CMS185v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Intensive Care Unit Venous Thromboembolism Prophylaxis|Individual Characteristic|0372|CMS190v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Median Time from ED Arrival to ED Departure for Admitted ED Patients|Individual Characteristic|0495|CMS55v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Exclusive Breast Milk Feeding|Individual Characteristic|0480|CMS9v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Thrombolytic Therapy|Individual Characteristic|0437|CMS91v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Elective Delivery|Individual Characteristic|0469|CMS113v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero|Individual Characteristic|0453|CMS178v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Prophylactic Antibiotic Selection for Surgical Patients|Individual Characteristic|0528|CMS172v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Primary PCI Received Within 90 Minutes of Hospital Arrival|Individual Characteristic|0163|CMS53v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Median Admit Decision Time to ED Departure Time for Admitted Patients|Individual Characteristic|0497|CMS111v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver|Individual Characteristic||CMS26v2|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Venous Thromboembolism Prophylaxis|Individual Characteristic|0371|CMS108v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Discharged on Statin Medication|Individual Characteristic|0439|CMS105v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|Individual Characteristic|0373|CMS73v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Appropriate Treatment for Children with Upper Respiratory Infection (URI)|Individual Characteristic|0069|CMS154v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents|Individual Characteristic|0024|CMS155v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Use of High-Risk Medications in the Elderly|Individual Characteristic|0022|CMS156v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Adult Major Depressive Disorder (MDD): Suicide Risk Assessment|Individual Characteristic|0104|CMS161v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Controlling High Blood Pressure|Individual Characteristic|0018|CMS165v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use|Individual Characteristic|0110|CMS169v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented|Individual Characteristic|Not Applicable|CMS22v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Closing the Referral Loop: Receipt of Specialist Report|Individual Characteristic|Not Applicable|CMS50v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Functional Status Assessment for Knee Replacement|Individual Characteristic|Not Applicable|CMS66v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|HIV/AIDS: Medical Visit|Individual Characteristic|Not Applicable|CMS62v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan|Individual Characteristic|0421|CMS69v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Children Who Have Dental Decay or Cavities|Individual Characteristic|Not Applicable|CMS75v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Maternal Depression Screening|Individual Characteristic|1401|CMS82v2|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetes: Hemoglobin A1c Poor Control|Individual Characteristic|0059|CMS122v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Individual Characteristic|0081|CMS135v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Initiation and Engagement of Alcohol and Other Drug Dependence Treatment|Individual Characteristic|0004|CMS137v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention|Individual Characteristic|0028|CMS138v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|Individual Characteristic|0387|CMS140v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range|Individual Characteristic|NA|CMS179v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Depression Remission at Twelve Months|Individual Characteristic|0710|CMS159v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Use of Imaging Studies for Low Back Pain|Individual Characteristic|0052|CMS166v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment|Individual Characteristic|1365|CMS177v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Functional Status Assessment for Hip Replacement|Individual Characteristic|Not Applicable|CMS56v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Hypertension: Improvement in Blood Pressure|Individual Characteristic|Not Applicable|CMS65v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Functional Status Assessment for Complex Chronic Conditions|Individual Characteristic|Not Applicable|CMS90v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists|Individual Characteristic|Not Applicable|CMS74v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients|Individual Characteristic|0389|CMS129v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Pneumonia Vaccination Status for Older Adults|Individual Characteristic|0043|CMS127v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetes: Eye Exam|Individual Characteristic|0055|CMS131v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetes: Foot Exam|Individual Characteristic|0056|CMS123v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Chlamydia Screening for Women|Individual Characteristic|0033|CMS153v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Oncology: Medical and Radiation – Pain Intensity Quantified|Individual Characteristic|0384|CMS157v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Pregnant women that had HBsAg testing|Individual Characteristic|Not Applicable|CMS158v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Individual Characteristic|0712|CMS160v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic|Individual Characteristic|0068|CMS164v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy|Individual Characteristic|0088|CMS167v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Falls: Screening for Future Fall Risk|Individual Characteristic|0101|CMS139v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery|Individual Characteristic|0565|CMS133v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|Individual Characteristic|0385|CMS141v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)|Individual Characteristic|0070|CMS145v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Appropriate Testing for Children with Pharyngitis|Individual Characteristic|0002|CMS146v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening: Influenza Immunization|Individual Characteristic|0041|CMS147v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Hemoglobin A1c Test for Pediatric Patients|Individual Characteristic|0060|CMS148v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Dementia: Cognitive Assessment|Individual Characteristic|Not Applicable|CMS149v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetes: Low Density Lipoprotein (LDL) Management|Individual Characteristic|0064|CMS163v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control|Individual Characteristic|0075|CMS182v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|Individual Characteristic|0405|CMS52v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|HIV/AIDS: RNA Control for Patients with HIV|Individual Characteristic|Not Applicable|CMS77v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan|Individual Characteristic|0418|CMS2v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed|Individual Characteristic|Not Applicable|CMS61v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)|Individual Characteristic|Not Applicable|CMS64v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Documentation of Current Medications in the Medical Record|Individual Characteristic|0419|CMS68v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Childhood Immunization Status|Individual Characteristic|0038|CMS117v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Cervical Cancer Screening|Individual Characteristic|0032|CMS124v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Use of Appropriate Medications for Asthma|Individual Characteristic|0036|CMS126v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Colorectal Cancer Screening|Individual Characteristic|0034|CMS130v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Breast Cancer Screening|Individual Characteristic|Not Applicable|CMS125v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Anti-depressant Medication Management|Individual Characteristic|0105|CMS128v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures|Individual Characteristic|0564|CMS132v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetes: Urine Protein Screening|Individual Characteristic|0062|CMS134v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication|Individual Characteristic|0108|CMS136v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care|Individual Characteristic|0089|CMS142v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation|Individual Characteristic|0086|CMS143v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||CY 2014 EP|Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)|Individual Characteristic|0083|CMS144v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Hearing Screening Prior To Hospital Discharge|Individual Characteristic|1354|CMS31v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival|Individual Characteristic|0164|CMS60v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Aspirin Prescribed at Discharge|Individual Characteristic|0142|CMS100v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Discharged on Antithrombotic Therapy|Individual Characteristic|0435|CMS104v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Statin Prescribed at Discharge|Individual Characteristic|0639|CMS30v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram|Individual Characteristic||CMS109v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Venous Thromboembolism Discharge Instructions|Individual Characteristic||CMS110v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Stroke Education|Individual Characteristic||CMS107v3|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Anticoagulation Therapy for Atrial Fibrillation/Flutter|Individual Characteristic|0436|CMS71v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients|Individual Characteristic|0147|CMS188v4|
2.16.840.1.114222.4.11.837|20140701|Centers for Disease Control National Center for Health Statistics|Extensional||FY 2014 EH|Antithrombotic Therapy By End of Hospital Day 2|Individual Characteristic|0438|CMS72v3|
2.16.840.113883.3.67.1.101.3.2444|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.464.1003.105.11.1018:Major Depression),(2.16.840.1.113883.3.464.1003.105.11.1060:Major Depression In Remission),(2.16.840.1.113883.3.464.1003.105.11.1019:Major Depression),(2.16.840.1.113883.3.464.1003.105.11.1061:Major Depression In Remission),(2.16.840.1.113883.3.464.1003.105.11.1017:Major Depression),(2.16.840.1.113883.3.464.1003.105.11.1062:Major Depression In Remission)|CY 2014 EP|Depression Remission at Twelve Months|Condition/Diagnosis/Problem|0710|CMS159v3|
2.16.840.113883.3.67.1.101.3.2444|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.464.1003.105.11.1018:Major Depression),(2.16.840.1.113883.3.464.1003.105.11.1060:Major Depression In Remission),(2.16.840.1.113883.3.464.1003.105.11.1019:Major Depression),(2.16.840.1.113883.3.464.1003.105.11.1061:Major Depression In Remission),(2.16.840.1.113883.3.464.1003.105.11.1017:Major Depression),(2.16.840.1.113883.3.464.1003.105.11.1062:Major Depression In Remission)|CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Condition/Diagnosis/Problem|0712|CMS160v3|
2.16.840.113883.3.67.1.101.3.2445|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.526.2.1927:Psych Visit - Psychotherapy),(2.16.840.1.113883.3.526.2.1923:Psych Visit - Diagnostic Evaluation)|CY 2014 EP|Depression Remission at Twelve Months|Encounter|0710|CMS159v3|
2.16.840.113883.3.67.1.101.3.2445|20140701|Minnesota Community Measurement|Grouping|(2.16.840.1.113883.3.526.2.1927:Psych Visit - Psychotherapy),(2.16.840.1.113883.3.526.2.1923:Psych Visit - Diagnostic Evaluation)|CY 2014 EP|Depression Utilization of the PHQ-9 Tool|Encounter|0712|CMS160v3|
